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SUMMARY
The aim of this study was to investigate the virus-specific cell-mediated immune 
responses, particularly virus-specific CD4^ T cells, elicited following oronasal 
exposure to feline leukaemia virus (FeLV).
In Chapter 1, the general features of the retroviridae are outlined; current knowledge 
on various aspects of FeLV, including epidemiology, pathogenesis and clinical 
disease is reviewed. General features of the immune responses to retroviridae are 
described; in addition, the virus-specific immune response to FeLV, and other 
retroviridae such as human immunodeficiency virus (HIV), Friend retrovirus 
complex (FV) and bovine leukaemia virus (BLV), is illustrated in detail. The 
technologies currently available to detect virus-specific CD4^ T cell responses are 
described and reviewed. This chapter also outlines the aims of this thesis.
Chapter 2 describes the development and characterisation of monoclonal and 
polyclonal antibodies to feline interferon-y (fIFN-y). These novel reagents were 
generated as tools to detect virus-specific immune responses using intracellular 
cytokine staining (ICS), and flow cytometry. The sensitivity of these novel reagents 
in the detection of both recombinant fIFN-y using an enzyme linked immunosorbent 
assay (ELISA) and Western blots, and the production of intracellular fIFN-y in 
physiologically stimulated cells using flow cytometry, was illustrated.
A longitudinal FeLV immunopathogenesis study was conducted to monitor the 
evolution of virus-specific cell-mediated immune responses, particularly virus- 
specific CD4^ T cells, following oronasal exposure to FeLV. A group of six specific 
pathogen free (SPF) cats was exposed oronasally to 5 x 10  ^ focus forming units (ffu) 
FeLV-A/Glasgow-1 aged sixteen weeks, in the expectation that approximately fifty 
per cent of cats would recover, and fifty per cent would become persistently infected. 
However, all six cats became persistently infected. In an attempt to modify the 
outcome of exposure and improve the chances of recovery, a second group of six 
SPF cats was exposed to a lower dose of FeLV, 5 x 10"^  ffu FeLV-A/Glasgow-1, 
under identical conditions. Five of these cats became persistently infected following
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oronasal exposure to FeLV, and one cat ostensibly recovered. Although virus was 
not detected in the peripheral blood from this cat at any time throughout the study, 
proviral DNA was detected in the bone marrow and lymphoid tissues post mortem, 
as a latent infection. An  account of the virological parameters measured in these cats 
throughout the study is given in Chapter 3. Sensitive and sophisticated assays, such 
as the p27 ELISA, virus isolation (VI), and quantitative reverse transcription- 
polymerase chain reaction (qRT-PCR), were used to detect antigenaemia, viraemia 
and proviral DNA, respectively, in the peripheral blood throughout the study, and in 
the lymphoid tissues post mortem.
Disease outcomes and proviral DNA loads were correlated with virus-specific CD4^ 
T cell responses. In Chapter 4, virus-specific cell-mediated immune responses in 
these cats were investigated using two techniques, the lymphocyte proliferation assay 
(LPA) and ICS, analysed using flow cytometry. Results obtained in either assay did 
not correlate with the proviral DNA load; however, the data generated using ICS 
appeared to be more relevant to the outcome of infection. Latently infected cat E12 
failed to develop virus-specific proliferative responses in the peripheral blood; 
however, the virus-specific upregulation of flFN-y in CD4^ T cells was detected 
using ICS. Conversely, persistently infected cats generated significant virus-specific 
proliferative responses in the peripheral blood, and transient low frequencies of 
virus-specific CD4^ T cell responses were detected using ICS in the critical early 
weeks following exposure.
The bone marrow and lymphoid tissues are important sites of FeLV integration and 
replication. In Chapter 5, FeLV expression in the post mortem bone marrow and 
peripheral lymph node (PLN) tissues of these cats is described. In addition, the 
impact of an active bone marrow infection on haematopoiesis is assessed, using 
concurrent cytological and haematological analyses of bone marrow and peripheral 
blood, respectively. Persistently infected cats expressed FeLV in the bone marrow 
and in PLN tissues; in addition, abnormal haematology and cytology reports were 
recorded for each of these cats. The latently infected cat did not express FeLV in 
either the bone marrow or PLN tissues; furthermore, cytology and haematology 
reports were normal in this cat. In Chapter 6, the results of this thesis are brought
together and discussed in the context of current research.
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CHAPTER 1
GENERAL INTRODUCTION
1.1 Retroviridae
1.1.1 Introduction
Retroviruses comprise a large family of enveloped RNA viruses, defined by common 
morphological and replicative properties. Each family member is equipped with a 
reverse transcriptase (RT) enzyme, which derives double-stranded DNA from the 
genomic dimer RNA. This distinctive feature of retroviral replication facilitates viral 
integration into host chromosomal DNA as provirus. Once integrated, proviral DNA 
is replicated along with the host DNA. The dual processes of reverse transcription 
and integration contribute to the proficiency of retroviruses in establishing lifelong 
infections in their hosts (Vogt, 1997a).
Retroviruses are significant causes of cancer and other serious diseases in humans 
and animals. Since the discovery of the first disease-causing retrovirus, equine 
infectious anaemia virus (EIAV), in 1905 (Vallée and Carré, 1905), investigators 
have strived to understand the pathogenesis of retroviral disease, identify the 
correlates of protective immune responses, and develop novel curative and 
prophylactic therapies. More recently, workers have sought to manipulate the 
retrovirus to advance other areas of medicine and science.
The pathogenesis of retroviral disease is not completely understood, and its 
elucidation remains an important aspect of viral research. Although retroviral 
disease can be investigated most effectively in its natural host, experimental animal 
models have an important role, particularly in investigating human retroviral disease. 
Thus, feline immunodeficiency virus (FIV) infection in the cat is a useful model for 
human immunodeficiency virus (HIV) infection (Willett et ah, 1997; Hosie et a i, 
1998; Flynn et aL, 2000b), while the murine leukaemia virus (MLV) complex 
provides an important model to study genetic resistance to retroviral infection, the 
evolution of oncogenesis and tumour immunity (Adams et aL, 1985; Beaty et aL, 
1999; Dittmer et aL, 2001).
Their unique life cycle and ability to flout antiviral defences make retroviruses
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successful intracellular pathogens. Protective vaccines are proving elusive to 
investigators while treatments for retroviral infection are rarely curative. However, 
while considerable success has been achieved, particularly in regard to vaccination 
against feline leukaemia virus (FeLV) (Marciani et aL, 1991; Hanlon et aL, 2001), 
and FIV (Hosie et aL, 2000; Dunham et aL, 2002), protective regimes have yet to be 
established for many retroviral infections.
Interestingly, the fields of molecular biology and biotechnology have exploited the 
retroviral life cycle in developing novel reagents and techniques. Retroviruses are 
proving to be useful vectors in gene transfer (Rosenberg et aL, 1990), while reverse 
transcriptase enzymes from avian and murine retroviruses are used extensively to 
generate cDNA copies of RNA for molecular cloning and sequencing (Vogt, 1997a).
1.1.2 History
Retroviruses were first discovered because of their ability to cause disease, 
particularly cancer (Temin, 1992). However, the first retrovirus to be described, 
EIAV, was in fact non-oncogenic (Vallée and Carré, 1905). In 1908, a Danish team 
(Ellermann and Bang, 1908) demonstrated that leukosis in chickens was caused by a 
virus now known as the avian leukosis virus (ALV). Shortly afterwards, Rous 
(1911) described the experimental transmission of sarcoma in chickens using cell- 
free material (Rous sarcoma virus, RSV). A further twenty years would elapse 
before viral-induced tumours were described in mammalian species, when a 
filterable agent transmitted in milk was reported to cause murine mammary 
carcinoma (Bittner, 1936). Over the following decades, tumour-causing retroviruses 
were identified in many outbred mammalian species: FeLV (Jarrett et aL, 1964b); 
gibbon ape leukaemia virus (GALV) (Theilen et aL, 1971); bovine leukaemia virus 
(BLV) (van Der Maaten et aL, 1972), and Jaagsiekte sheep retrovirus (JSRV) 
(Verwoerd et aL, 1983). The first oncogenic human retrovirus, human T cell 
leukaemia virus-1 (HTLV-1) was isolated in 1980 (Poiesz et aL, 1980). More 
recently, retroviruses with oncogenic properties that principally cause 
immunodeficiency diseases have been identified: HIV (Barré-Sinoussi et aL, 1983) 
and FIV (Pedersen et aL, 1987).
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Originally, murine and avian RNA leukaemogenic viruses were believed to be 
transmitted solely as Mendelian traits (Aaronson and Todaro, 1968; Huebner and 
Todaro, 1969; Hardy et aL, 1973). The vertical transmission of retroviruses was first 
described in 1951, when MLV was isolated from a strain of mice selected for high 
frequency of leukaemia (Gross, 1951). Citing the results of prior studies using 
murine embryonic cells, Huebner (1969) hypothesised that viral information in the 
form of an oncogene-bearing virogene was present within the genome of most 
vertebrates. Huebner believed that the virogene was transmitted from animal to 
progeny animal, and from cell to progeny cell, and proposed that oncogenic reagents 
and carcinogens precipitated activation of the oncogene. However, the discovery of 
FeLV in 1964, and the subsequent revelation that this retrovirus could be 
horizontally transmitted, proved significant landmarks in the field of retroviral 
research (Jarrett et aL, 1964b; Hardy et aL, 1973). All disease-inducing retroviruses 
are now known to be horizontally transmitted (Hardy, 1993).
1.1.3 Taxonomy
Historically, retroviruses within the retroviral family were divided into types A, B, C 
and D, based on their morphological appearance in cells using electron microscopy 
(EM). Recently, the availability of genomic sequence data has enabled the 
retroviruses to be regrouped according to sequence conservation; however, these 
divisions often reflect the morphological similarities identified earlier. Retroviruses 
are now classified under the following genera: alpha (a), beta (|3), gamma (y), delta 
(Ô) and epsilon (e) retroviruses, lentiviruses and spumaviruses (Mayo and van 
Regenmortel, 2000) (Table 1.1).
1.1.4 Retroviral Genomic Organisation
All retroviral genomes consist of two identical single-stranded positive sense 
molecules of RNA, which are physically linked by hydrogen bonds to form a dimer. 
A third molecule of nucleic acid, a specific type of tRNA used as a primer for reverse 
transcription, is present freely within the nucleocapsid (Vogt, 1997b). The diploid 
genome consists of three principal genes, gag, pol and env. The gene order in all 
retroviruses is 5'-gag-pol-env-3'. Some retroviruses possess additional ‘accessory’
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genes encoding regulatory non-structural proteins, and are described as ‘complex’. 
Accessory genes regulate and co-ordinate retroviral gene expression. The HIV 
genome encompasses a number of accessory genes including tat, rev, vif, vpr and nef. 
The tat gene activates transcription, while rev regulates RNA splicing. The products 
of the nef, vpr and v(f genes facilitate viral infectivity (Vogt, 1997b). The genome of 
retroviruses possessing only the genes required for replication is termed ‘simple’, 
such as in FeLV (Vogt, 1997a) (Fig. 1.1).
Gag proteins, comprising nucleocapsid (NC), capsid (CA) and matrix (MA) proteins, 
form the internal virion structure. The pro gene lies between the gag and pol genes, 
and encodes the viral protease (PR). Po/-encoded proteins, RT and integrase (IN), 
facilitate viral replication. Finally, the surface (SU) and transmembrane (TM) 
components of the outer glycoprotein envelope are products of the env gene (Fig. 
1.2; Table 1.2).
The NC core comprises the RNA genome as well as NC proteins. These proteins are 
closely associated with the genome and are involved with RNA packaging, at least in 
vitro (Coffin, 1992). Surrounding the core lies an internal virion shell made up of the 
CA protein, the exact structural and biological functions of which have yet to be 
identified. The MA protein lines the inside of the viral envelope and may interact 
with the Env proteins in order to facilitate viral budding from the host cell membrane 
(Vogt, 1997b). The pro gene product, PR, generates mature Gag and Pol proteins 
through proteolytic cleavage of the precursor proteins (Vogt, 1996). This process 
occurs either late in assembly or immediately after budding.
The viral RT has RNA and DNA polymerase activity, in addition to RNA 
endonucleolytic activity, and generates double-stranded DNA from the single strand 
of viral RNA. The IN protein demonstrates both nucleolytic and ligation activity and 
is responsible for the integration of proviral DNA into cellular DNA (Katz and 
Skalka, 1994).
The viral envelope is a lipid bilayer, which is derived from the host cell membrane 
during the budding process. The envelope surface contains SU and TM 
glycoproteins, which are derived from a common precursor polypeptide (Vogt,
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Fig. 1,1 Genetic organisation of prototypic retroviruses
A ‘simple’ retroviral genome (A) contains four major coding regions, gag, pro, pol, 
env; a ‘complex’ retroviral genome (B) contains four major coding domains in 
addition to information for six regulatory proteins. Based on Vogt, V. M. 1997. 
Retroviral Virions and Genomes, pp 27-69 in J, M. Coffin, S. H. Hughes, and H. E. 
Varmus, editors. Retroviruses. Cold Spring Harbor Laboratory Press, New York.
A FeLV
LTR
R US
LTR
U3 R
gag pro pol
BHIV
LTR
R US
gag
pro pol
LTR
Vi/I
V
I
tat
U3 R
nef
I
vpu
Fig, 1.2 Schematic cross-section through a retroviral particle
Based on Vogt, P. K. 1997. Historical Introduction to the General Properties of 
Retroviruses, pp 1-25 in J. M. Coffin, S. H. Hughes, and H. E. Varmus, editors. 
Retroviruses. Cold Spring Harbor Laboratory Press, New York.
surface protein (SU)
lipid bilayer
matrix protein (MA)
capsid protein (CA)
%
t
transmembrane protein (TM)
integrase (IN)
protease (PR)
nucleocapsid protein (NC) everse transcriptase (RT)
§
I1I
§IA1
I
II
II
CL,1I
0>t
OhII
8
rCI
ÏII
ÎI
1II
II
'o1
1ÎI
%
I
II1
§
I
II
ê
"oiIa
I I II I Îi
O h1
g u g
1997b). The SU protein mediates virus-host cell attachment via the host cell 
receptor, and thus entry into the host cell. In addition, the SU, due to its external 
location, contains the major antigenic determinants for virus neutralising antibodies 
(VNA). The TM protein anchors the envelope protein complex to the virus envelope 
and mediates envelope fusion with the host cell membrane.
1.2 Feline Leukaemia Virus
1.2.1 Discovery of FeLV
1.2.1.1 Transmission of FeLV
Feline leukaemia virus was first associated with feline leukaemia in 1964 (Jarrett et 
a l, 1964b). Four kittens, injected at birth with cell-free material from a field case of 
thymic lymphosarcoma (USA), died within eighteen months; three of these kittens 
were subsequently diagnosed with USA. This was the first report of the horizontal 
transmission of spontaneous USA. In 1967, a similar experiment was conducted; 
cats were inoculated with cell-free tumour extracts and found to transmit disease. 
The presence of virus within all experimentally induced cases of LSA was confirmed 
using EM techniques (Rickard et a l, 1967). Kawakami et a l  (1967) reported similar 
findings using virus isolated from plasma. In 1969, Rickard et a l  used cellular and 
cell-free thymic tumour extracts derived from a cat with spontaneous lymphocytic 
leukaemia to inoculate newborn kittens. Eighty-two per cent of kittens died from 
leukaemia, seven per cent died from other diseases and ten per cent survived. Two 
uninoculated in-contact controls died from leukaemic lesions and C-shaped 
nucleocapsid cores (type-C particles) were demonstrated in tissues post mortem.
1.2.1.2 Identification o f FeLV in Neoplastic Tissues
Using transmission electron microscopy (TEM), type-C viral particles were
identified within the neoplastic tissue from a kitten in the original transmission study
(Jarrett et a l, 1964b), and purported to be the aetiological agent (Jarrett et a l,
1964a). Furthermore, virus-like particles were demonstrated in three-quarters of
spontaneous feline LSA cases involving spleen, thymus or mesenteric lymph nodes
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(MLN), using EM imaging (Laird et a l, 1967). Type-C particles were apparent 
within extracellular spaces and intracellular vacuoles; in addition, particles were 
observed budding from plasma membranes, which suggested that the tumour cells 
were actively producing virus.
1.2.1.3 Isolation o f FeLVfrom Plasma
In 1967, FeLV was isolated from the plasma of cats, suffering from both naturally 
and experimentally induced leukaemia, using sucrose-density gradients (Kawakami 
et a l, 1967). The isolated virus displayed characteristic of type-C particles, similar 
to MLV, with a buoyant density of 1.15-1.17 g/cm^ (O'Connor et a l, 1964). 
Electron micrograph preparations of the isolated virus showed typical morphological 
features of immature and mature type-C particles. Mature virions measured 
approximately 115 pm in diameter, with an outer envelope and inner dense core. 
The isolated viral particles were effective and rapid inducers of LSA in kittens less 
than four days old.
1.2.1.4 Detection o f Group Specific Antigen
The group specific antigen (GSA) represented the internal component of avian and 
murine leukaemia viruses, which occurred freely in leukaemic and other infected 
cells. The GSA described in the early years of FeLV research corresponds to the 
FeLV CA protein p27. Feline leukaemia virus was recognised as an oncogenic virus 
morphologically similar to MLV and ALV, prompting suggestions that these viruses 
might be related. Using the Ouchterlony immunoprécipitation technique, Geering et 
a l  (1968) demonstrated that FeLV shared the GSA of MLV, but not ALV. Feline 
leukaemia virus GSA was subsequently detected in twenty-five out of thirty-three 
cats with LSA, using precipitating rabbit antiserum raised against purified virus in 
immunodiffusion tests. Electron microscopy was used to verify the presence of 
FeLV in cats considered positive by immunodiffusion (Hardy et a l, 1969).
1.2.1.5 Culture o f FeLV
The virus was initially cultured in spleen, thymus, liver, heart and kidney cells from
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newborn kittens in vitro, as well as in embryonic lung cells. The cells were cultured 
with cell-free homogenates of leukaemic cells and platelets from spontaneous 
leukaemic cases (Jarrett et ah, 1968). In each culture system, virus could be detected 
within most cells after eleven days, and was present until the termination of the 
experiment at day twenty-nine. Virus was observed budding from cell membranes, 
suggesting active replication. Thereafter, a culture system based on feline embryonic 
cells of the FEA strain was used; cells were propagated using Eagles’ minimal 
essential medium (MEM) supplemented with ten per cent foetal calf serum (PCS) 
(Jarrett et al., 1972; Jarrett et al., 1973).
1.2.2 Taxonomy
Feline leukaemia virus is classified as a y-retrovirus. This group includes many 
viruses within the MLV family as well as endogenous retroviral sequences in porcine 
cells (PERV), GALV and the reticuloendotheliosis virus. Feline leukaemia virus 
displays type-C particles on budding from infected cells using EM techniques (Fig. 
1.3). On maturation, the core appears spherical and is centrally located within the 
virion (Coffin, 1992).
1.2.3 Evolution
At least three groups of endogenous FeLV-related cat viruses have been detected in 
the cellular DNA from all domestic cats and some close relatives (Benveniste et al., 
1975; Hardy, 1993). These endogenous viruses are genetically transmitted, do not 
replicate in cats, and cannot cause disease by themselves (Hardy, 1993). However, 
some recombine with exogenous FeLV, giving rise to pathogenic viruses with an 
altered host range (Stewart et al., 1986). Feline endogenous retroviral sequences are 
related to endogenous viruses in other species, such as rodents and primates, from 
which these endogenous sequences, and ultimately the pathogenic and contagious 
exogenous FeLV, are believed to be derived (Benveniste et al., 1975).
Feline leukaemia virus-related gene sequences (enFeLV) have been detected in
cellular DNA of specific pathogen free (SPF) domestic cats (Felis catus) and in DNA
of three other closely related felidae: the jungle cat, sand cat and European wildcat
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Fig. 1.3 TEM demonstrating FeLV budding from membrane of an 
infected cell
Transmission electron micrograph images of FeLV during the final stages of budding 
(A and B). Mature virions are apparent within the extracellular space (B). Images 
prepared by Laird, H.M., University of Glasgow.
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(Benveniste et al., 1975). These species all originated from the Mediterranean basin 
and are closely related genetically. More distantly related felidae, originating from 
the Americas, Sub-Saharan Africa or Southeast Asia, lack these FeLV-related genes. 
Analysis of rodent cellular DNA, particularly from the rat, but also from mouse and 
hamster, revealed that they also contained FeLV-related sequences (Benveniste et al.,
1975). Therefore, it appears that the FeLV-related sequences were acquired by cats 
subsequent to the initial felidae evolutionary divergence, but before the separation of 
the four closely related felidae described above. The source of enFeLV would 
appear to be the rat (Sherr et al., 2002) (Fig. 1.4). The enFeLV exist as full-length 
proviruses; however, they contain many stop codons, which prevent their expression 
as whole infectious viruses. However, the env gene of these viruses may participate 
in recombinational events with exogenous FeLV to produce novel variant viruses 
(Jarrett, 2001).
The endogenous feline RD-114 virus, referred to as feline endogenous virus (FeEV), 
displays a similar viral sequence to an infectious endogenous virus in baboons, 
baboon endogenous virus (BaEV), implying a cross-species infection by an ancestor 
virus of BaEV (McAllister et al., 1972; Hardy, 1993). The FeEV is present in feline 
cellular DNA as a complete pro virus, which produces infectious virus if expressed. 
However, the virus is xenotropic; thus, it cannot reinfect cat cells and is considered 
non-pathogenic (Jarrett, 2001). The existence of a third feline endogenous virus 
distantly related to a primate virus MAC-1, has also been implied, but not 
characterised (Todaro et al., 1978; Bonner and Todaro, 1979). However, the MAC-1 
sequences in feline cells do not give rise to infectious replicating virus particles 
(Hardy, 1993).
1,2,4 Genomic Organisation
The genetic structure of FeLV parallels that of other simple retroviruses, such as the
MLV complex (Hardy, 1993) (Fig. 1.5). Only the genome of an isolate of FeLV
subgroup A, which causes feline acquired immune deficiency syndrome (FeLV-
FAIDS), has been sequenced in its entirety (Donahue et al., 1988) (Accession nos
M l8247 and M l9392). Feline leukaemia virus gene products have yet to be fully
characterised but deficiencies in the knowledge base have been plugged through
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extrapolation from the closely related, and more completely characterised, MLV 
complex (Neil and Onions, 1985).
Feline leukaemia virus gag gene products comprise both glycosylated and non- 
gylocosylated proteins. Approximately half of the principal Gag precursor protein, 
Pr65, remains in the cell cytosol to be assembled into progeny virus, whereas the 
remainder is translocated to the lumen of the endoplasmic reticulum (ER) where it is 
glycosylated and transported to the plasma membrane (Jarrett, 2001). The 
glycosylated Pr65 is cleaved at the cell surface releasing a soluble glycosylated gp40. 
The gp40 protein contains determinants recognised by p27, p l2  and plO antisera and 
thus is likely to contain peptide sequences from p27, p l2  and plO Gag proteins (Neil 
et a i, 1980b). Glycosylated Gag proteins contribute to murine retrovirion assembly 
(H. Fan, personal communication). However, the role of these proteins in FeLV 
infection is yet unclear. It has been suggested that anti-Gag antibodies may 
contribute to the formation of immune complexes, or that the large amounts of 
soluble glycosylated protein released from FeLV-infected cells may trigger anergic 
responses (Jarrett, 1999). Within the cytosol, the non-glycosylated Gag protein, 
Pr65, is further cleaved into plO, pl2, pl5 and p30 proteins (Okasinski and Velicer, 
1976; Khan and Stephenson, 1977). The largest of these mature proteins, p30, forms 
the internal virion shell, or CA. The pl5  entity functions as the MA protein (Hardy, 
1993). While the role of the smaller plO and p l2  proteins has yet to be fully 
elucidated, these may be involved in packaging and binding of the nucleic acid as 
NC proteins (Neil and Onions, 1985).
Feline leukaemia virus pol gene products have not been characterised. However, the 
closely related MLV pol gene encodes PR, RT and IN proteins (Levin et al., 1984). 
The env gene products are derived from a single large precursor protein Pr80, which 
yields a glycosylated SU protein gp70 (Bolognesi, 1974), and a smaller non- 
glycosylated TM protein, pl5  (pl5E). The FeLV TM protein pl5E undergoes further 
processing to yield pl2. These smaller hydrophobic proteins are buried within the 
outer viral membrane and are disulphide-linked to SU protein gp70 (Neil et al., 
1980a), several hundred of which make up the outer virus envelope (Neil and 
Onions, 1985).
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1.2.5 Feline Leukaemia Virus Subgroups
Three subgroups of FeLV have been identified, FeLV-A, -B and -C, based on 
differences in their SU protein gp70 (Jarrett and Russell, 1978). A distinction was 
made based on the results of interference tests (Sarma and Log, 1971; Sarma and 
Log, 1973), neutralisation tests using subgroup-specific antisera (Sarma and Log, 
1973; Russell and Jarrett, 1978b), and viral host cell range (Jarrett et a i,  1973; 
Sarma et al., 1975).
Sarma and Log (1971) reported that when FeLV-infected feline embryonic fibroblast
(FEF) cells were superinfected with a closely related pseudotype virus derived from
an identical FeLV strain, the FEF cells were resistant to viral transformation in a
phenomenon known as viral interference, where both viruses are assumed to use the
same cellular receptor. However, when the FEF cells were superinfected with a
pseudotype virus derived from a different FeLV strain to the original infecting strain,
no interference occurred. From the results of this study, Sarma proposed the
existence of three FeLV subgroups, A, B and C. Virus neutralisation studies were
conducted using subgroup-specific antisera in order to confirm the interference data
(Sarma and Log, 1973). The findings were identical, verifying the existence of three
major FeLV envelope variations corresponding to three FeLV subgroups. In his
original interference study, Sarma and Log (1971) demonstrated that FeLV-A
induced viral interference only when used in conjunction with homologous
pseudotype viruses, whereas FeLV subgroup B and C viruses were able to induce
interference to the pseudo type viruses derived from FeLV-A, in addition to their
homologous pseudotype viruses. These findings suggested that subgroups B and C
might contain FeLV-A sequences. Supporting data were provided from
neutralisation studies testing viral isolates prepared from both lymphomatous cats
and healthy cats in multiple cat households. Subgroup A was identified in every
FeLV isolate, whereas subgroups B and C occurred only in combination with
subgroup A viruses (Jarrett et al., 1978). In a subsequent study, FeLV-B was
reported to occur in approximately forty-two per cent of field isolates in combination
with FeLV-A, while FeLV-C was identified in only one per cent of isolates,
occurring either as FeLV-AC or as FeLV ABC (Jarrett et a l, 1984). Furthermore,
kittens infected with isolates containing FeLV-B alone were unable to transmit the
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virus to contact cats (Jarrett and Russell, 1978), suggesting that horizontal 
transmission could not occur without FeLV-A.
The unexpectedly high distribution of neutralising antibodies to FeLV-C in cats from 
FeLV-infected multiple cat households, FeLV-positive experimentally infected cats 
and lymphomatous cats (Russell and Jarrett, 1978a), compared to the percentage of 
field isolates which contained subgroup C (Jarrett et aL, 1978), raised the possibility 
that these antibodies were evoked by a determinant expressed by an endogenous 
FeLV-like gene present in all cat cells. It was suggested that the rare FeLV-C 
isolates arose de novo as a result of recombination between FeLV-A and these 
endogenous genes (Russell and Jarrett, 1978b). However, further studies disproved 
this conjecture (Rigby et aL, 1992). The phenotypic determinants of subgroup C 
isolates were isolated to a single variable region (Vr) of FeLV SU protein gp70. The 
sequence of this region varied from one naturally occurring isolate to another 
implying that each isolate arose through mutation of FeLV-A (Rigby et aL, 1992).
Neutralisation studies conducted to investigate the antigen specificities of VNA to 
the three FeLV subgroups showed that all FeLV-A viruses used in the experiment 
were neutralised to the same extent by two antisera raised to FeLV-A/Glasgow 1. 
These findings suggested that subgroup A virus was very stable antigenically 
(Russell and Jarrett, 1978b), and supported growing speculation that FeLV-A might 
be the prototype virus from which subgroups B and C were derived (Russell and 
Jarrett, 1978a). It had already been shown that subgroups FeLV-A, B and C were 
very closely related (Levin et aL, 1976), demonstrating eighty-five per cent genetic 
homology. A later study examined the more divergent sequence of the FeLV-A env 
gene and compared the region in two FeLV-B isolates (Stewart et aL, 1986). The 
authors reported that the FeLV-B probes prepared to the region in question 
hybridised only to FeLV-B isolates and endogenous FeLV-related sequences, 
supporting the hypothesis that FeLV-B was derived from recombination between 
FeLV-A and proviral elements within the feline genome.
Data derived from the studies described above and subsequent work (Roy-Burman,
1996; Betchel et aL, 1999) has greatly improved our understanding of the origin of
the three principal FeLV subgroups. From all the available data, it is clear that
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FeLV-A serves as the prototype virus from which other phenotypic variants are 
derived. Feline leukaemia virus-A is the most frequently occurring subtype in 
nature, and is highly conserved antigenically. In addition, FeLV-A is ecotropic, and 
has the most restricted host range, growing almost exclusively in feline cells (Hardy, 
1993). Subgroup FeLV-B is polytropic and arises de novo from recombination 
events between FeLV-A and endogenous env sequences; various recombinant 
genotypes may arise depending on the site of recombination. Feline leukaemia virus- 
C is also poly tropic and is derived from mutational events within FeLV-A.
Certain subgroups have been linked with particular diseases under experimental 
conditions. Aplastic anaemia was shown to be associated with FeLV-C (Mackey et 
aL, 1975; Onions et aL, 1982). Additionally, a higher prevalence of FeLV-AB than 
FeLV-A alone was reportedly associated with LSA (Jarrett et aL, 1978).
1.2.6 Epidemiology
1.2.6.1 Prevalence ofFeLVInfection
In 1989, a study was published reporting the prevalence of FeLV in the U.K. (Hosie 
et aL, 1989). The data were acquired from over two thousand blood samples 
submitted to the University of Glasgow from sick and healthy cats. Samples were 
screened using a commercial capture enzyme linked immunosorbent assay (ELISA) 
that detected the presence of the FeLV CA protein p27 in plasma (Leukassay F 
ELISA, C-Vet Veterinary Products Ltd, Lancashire, U.K.). Positive results were 
confirmed using virus isolation (VI) techniques on FEA cells (Jarrett et aL, 1982a). 
The prevalence of FeLV infection was reported to be eighteen per cent in sick cats, 
and five per cent in healthy cats. The incidence of FeLV was not greater in either 
sex, and the highest probability of infection was among cats aged between one and 
five years. Currently, the prevalence of FeLV infection in healthy cats within the 
U.K. is estimated to be approximately one per cent (Addie, D. and Jarrett, O., 
personal communication, 2002). This dramatic reduction in the prevalence of FeLV 
is associated with the recent availability of several commercial vaccines (Section 
1.3.2.5), and the success of ‘test and removal’ policies in catteries.
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1.2.6.2 Transmission o f FeLV
Following the discovery of FeLV in 1964, epidemiological and experimental data 
rapidly identified FeLV as an exogenous horizontally transmitted virus. In an early 
FeLV transmission experiment, two uninoculated cats housed with FeLV-inoculated 
cats died (Rickard et aL, 1969). Leukaemic lesions were discovered in both cats post 
mortem, in which type-C particles were identified. Type-C particles were also 
identified in plasma pellets and bone marrow samples from a third uninoculated in­
contact cat. Blood from this third cat was injected into an experimental kitten that 
subsequently developed LSA, from which type-C particles were identified. 
Furthermore, spontaneous infections arose in laboratory cat colonies (Jarrett et al., 
1972; Essex et aL, 1977; Hoover et aL, 1977a; Pedersen et aL, 1977). In one 
incident, six out of twenty-five uninoculated controls living in the same isolation 
cage as inoculated littermates, died. Half of these had evidence of FeLV infection 
(Rickard et aL, 1969).
The development of a rapid diagnostic test to determine FeLV status provided 
conclusive proof that FeLV was a horizontally transmitted disease. In 1973, Hardy 
et al. developed a serological test to detect FeLV GSA in blood smears using rabbit 
anti-serum prepared against FeLV GSA (Fig. 1.6). Using this novel indirect 
immunoEuorescent antibody (IFA) test, Hardy et al. (1973) demonstrated that 
normal cats living with two or more cats with LSA, were twice as likely to be FeLV- 
positive than cats living with only one cat with either LSA or an FeLV-associated 
disease. Two thirds of the LSA-positive cats that were living in households with an 
average of 3.1 cats with LSA were unrelated to the other diseased cats. The IFA test 
also demonstrated that apparently normal cats living in households with a known 
history of LSA had a high risk of becoming infected, and that overt FeLV in normal 
cats living under other circumstances was very rare (0.14%). A follow-up study 
investigating the fate of those FeLV-positive cats living under apparently normal 
circumstances discovered that these cats had an eight hundred and eighty-eight times 
greater incidence of developing LSA, compared to normal cats. Sixteen per cent of 
these cats developed LSA and over seven per cent died of non-responsive anaemia.
In utero infections also occur, where infected queens transfer FeLV to their foetuses
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Fig. 1.6 Positive IFA test on PBMC smear
Indirect immunofluorescence test illustrating the presence of the FeLV CA protein 
p27 in neutrophils (white arrow) and platelets (dashed arrow, open head) in the 
peripheral blood, using rabbit antiserum against the FeLV CA protein p27.

(Hardy, 1981a). However, most of these infections will result in foetal or neonatal 
death. A small proportion will survive but remain persistently viraemic (Pedersen, 
1988).
1.2.6.3 Sources ofFeLVInfection
Prolonged intimate contact between a viraemic cat and a normal cat is required for 
horizontal transmission. A number of factors contribute to this requirement: the poor 
environmental stability of the virus (Francis et aL, 1979), the relatively large dose of 
virus required for infection via the oronasal route, and age resistance (Hoover et aL,
1976).
Saliva is considered the most likely vehicle for spreading the virus (Hardy et aL, 
1973; Pedersen, 1988; Hoover and Mullins, 1991; Hardy, 1993; Jarrett, 2001). Cats 
are social animals and spend hours grooming themselves and their companions. 
Large amounts of infectious virus are present in the salivary glands of viraemic cats 
(Francis et aL, 1977; Hoover et aL, 1977b); FeLV has been identified in the parotid 
glands of six FeLV-positive cats with LSA (Hardy et aL, 1969). It was considered 
that aerosols of the virus created from nasal and salivary secretions emitted by 
persistently viraemic cats might also be an important route for dissemination of the 
virus (Hardy et aL, 1973). However, as Francis et aL (1977) observed, persistently 
viraemic cats are usually clinically healthy, and rarely cough and sneeze. 
Furthermore, FeLV-naïve cats housed in the same room, but not in contact with, 
FeLV-viraemic cats, did not become infected (Hoover et aL, 1977a).
Feline leukaemia virus GSA can be detected in the kidneys from seventy per cent of
cats suffering from LSA; GSA has been identified in the infiltrating neoplastic
lymphocytes, and forms discrete deposits on glomerular basement membranes. From
these sites, infectious virus and infected transformed cells can pass into the urine
(Hardy et aL, 1973); however, infectious virus is poorly preserved in urine (Hoover
et aL, 1977a). Feline leukaemia virus is also found free in plasma; therefore, it is
possible that blood-sucking parasites could acquire and transmit FeLV. Bite wounds
are a more efficient means of transmitting the virus than the oronasal route as large
amounts of virus can be injected directly into the bloodstream. However, blood
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transfer does not appear to be an important factor in transmission of FeLV (Hoover 
and Mullins, 1991). Infection can also be transmitted using contaminated surgical 
instruments and infected blood transfusions (Pedersen, 1988).
1.2.7 Pathogenesis of FeLV Infection
The epidemiological data suggest that most cats acquire FeLV via the oronasal route. 
In the acute stage of infection, virus initially replicates in lymphocytes and 
macrophages within the tonsils, before being conveyed via efferent lymphatics to the 
draining lymph nodes of the head and neck (Rojko et aL, 1979). Virus replicates 
extensively within the lymph node; then, after two to twelve days, infected 
lymphocytes and macrophages disseminate the virus via the blood to bone marrow; 
thymus; spleen; intestine; MLN and peripheral lymph nodes (PLN) (Rojko and 
Kociba, 1991). Feline leukaemia virus replicates easily in the actively dividing cells 
of bone marrow precursor cells, gut endothelial crypt cells and germinal centre B 
cells. At this point, unless the immune response has curtailed virus growth, FeLV 
will spread to epithelial and glandular tissues throughout the cat, which usually 
include salivary, tonsillar, pharyngeal, urinary bladder, gastric, intestinal, pancreatic, 
endometrial and endothelial tissues (Hoover et aL, 1977b; Rojko et aL, 1978; Rojko 
et aL, 1979; Rojko and Kociba, 1991).
Immunohistochemical staining of formalin-fixed tissue sections from cats suffering
from an FeLV-associated disease, using anti-FeLV monoclonal antibodies (mAb),
gave a valuable insight into the nature and distribution of FeLV-infected cells
(Kovacevic et aL, 1997). Feline leukaemia virus CA protein p27 and SU protein
gp70 were detected in the bone marrow from some, but not all, FeLV-infected cats in
the same study. Where present, these viral proteins were chiefly associated with
megakaryocytes. In lymph nodes, expression of the FeLV CA protein p27 was
mainly restricted to the follicles, in association with the follicular dendritic cell
(FDC) population, whereas FeLV SU protein gp70 was detected in the lymph node
follicles, paracortex and medulla. In spleen, both FeLV CA protein p27 and SU
protein gp70 expression was confined to the follicles. Where FeLV proteins were
detected in the small intestine, p27-positive cells were found only in crypt epithelial
cells, whereas FeLV SU protein gp70 was detected in virtually all mucosal
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lymphocytes.
In acute infection, FeLV appears to initially replicate in the lymphoreticular 
lymphocyte and macrophage populations (Rojko et a l, 1979). However, in 
persistently viraemic cats, the main source of FeLV appears to be the follicular B cell 
(Rojko et aL, 1979; Rojko et aL, 1981). Peripheral blood mononuclear cells from 
kittens and adult SPF cats were exposed to FeLV in vitro following a two-day pre­
incubation period. Both B and T cells were found to be permissive to FeLV 
infection. However, lymphocytes from SPF kittens replicated fifty times as much 
FeLV as SPF adult cats in vitro (Rojko et aL, 1981). In addition, macrophages from 
kittens are five times more susceptible to FeLV than macrophages from adult cats in 
vitro, and this effect was enhanced one hundred fold by the addition of corticosteroid 
(Hoover et aL, 1981). However, macrophages from recovered cats were not any 
more resistant than those from naïve cats. The inhibition of macrophage function 
through the administration of silica in vivo was associated with the suppression of 
cell-mediated immune responses (Hoover et aL, 1981).
1.2.8 Outcome Following Exposure to FeLV
There are three well-defined outcomes following exposure to FeLV, namely 
spontaneous recovery, persistent viraemia and the development of a latent infection. 
If a virus-specific immune response develops during the acute phase of infection, 
FeLV replication is halted and virus expression abrogated. If sufficiently prompt, the 
antiviral response may prevent virus being borne into the blood from infected lymph 
nodes of the head and neck so that a viraemia does not occur. The immune response 
may emerge later, following a transient viraemia but before widespread 
dissemination of the virus, typically four to eight weeks following exposure (Hoover 
et aL, 1977b; Rojko et aL, 1979). Where the immune response has successfully 
abrogated virus expression, those cats are deemed to have recovered from infection 
(Fig. 1.7).
However, cats that experience a transient viraemia before recovering are highly
likely to retain virus as a latent proviral infection within bone marrow or lymph node
cells for a variable duration (Rojko et aL, 1982b; Madewell and Jarrett, 1983). Most
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Fig. 1.7 Possible outcomes following exposure to FeLV
There are three possible outcomes following exposure to FeLV, namely recovery, 
persistence or latency.
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latently infected cats were observed to eliminate virus within thirty months of 
exposure (Pacitti and Jarrett, 1985). Provirus persists in bone marrow monocytic 
precursor cells and certain T cell populations (Rojko et aL, 1982b). Viral proteins 
are not expressed; therefore, the infection is not detectable unless biopsy or post 
mortem specimens of bone marrow or lymph node are cultured in vitro (Madewell 
and Jarrett, 1983; Pedersen et aL, 1984). It is possible to reactivate latent virus in 
vivo through the administration of pharmacologic doses of corticosteroids (Rojko et 
aL, 1982b; Pedersen et aL, 1984), or through pregnancy (Pacitti et aL, 1986). It has 
been reported that cats with latent infections have an increased incidence of FeLV- 
associated disease and lymphomas, compared to non-infected cats (Lutz et aL, 
1980a; Rojko et aL, 1982b; Lafrado and Olsen, 1986).
A rare outcome following FeLV exposure has been described as an atypical or 
discordant infection (Lutz et aL, 1982). Affected cats give conflicting FeLV status 
results using VI and p27 ELISA diagnostic tests, being typically antigenaemic but 
aviraemic. These discordant cats are most likely latently infected, and occasionally 
express viral proteins that are detected using the p27 ELISA (Kahn et aL, 1980; 
Madewell and Jarrett, 1983). Localised or sequestered infections have also been 
identified using immunofluorescence. An experimentally infected cat in which 
neither antigenaemia or viraemia was detected, expressed FeLV CA protein p27 in 
spleen, but not bone marrow (Hayes et aL, 1989).
Cats that are unable to contain viral replication by sixteen weeks are considered 
persistently viraemic. These cats will die from an FeLV-associated disease within 
two to three years. Persistently viraemic cats secrete contain large amounts of virus 
in saliva and nasal secretions, and are important sources of infection for FeLV-naïve 
cats.
1.2.9 Factors Influencing Outcome Following Exposure to FeLV
Virus isolate, dose, host susceptibility, age at time of exposure and route of exposure 
all interact to influence the outcome following exposure to FeLV (Hoover et aL, 
1976).
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1.2.9.1 Age-Related Resistance
Age at the time of exposure to FeLV is an important factor influencing the outcome 
of FeLV infection in cats. All newborn kittens are susceptible to experimental FeLV 
infection, unless protected by maternal antibodies (Kawakami et at., 1967; Rickard et 
aL, 1969; Hoover et aL, 1976; Jarrett et aL, 1977). Resistance to FeLV increases 
with age. Under experimental conditions when viral dose, isolate and route are 
consistent, only a minority of cats are susceptible to experimental infection by four 
months of age (Jarrett et aL, 1982a). Age-related resistance may reflect the 
susceptibilities of particular cell subsets to FeLV infection; it has been shown in vitro 
that lymphocytes and macrophages from kittens were more susceptible to FeLV 
infection than those from adult cats (Hoover et aL, 1981; Rojko et aL, 1981). 
Furthermore, kittens are born with greater CD4:CD8 ratios (approximately 3.5:1) 
than adults (approximately 1.5:1). Changes in the CD4:CD8 ratio appear to be 
primarily associated with increased CD8^ T cell numbers, which appears to be 
sensitive to antigen exposure. (Sellon et aL, 1996). An adult ratio may not be 
reached until the cat is one year old. Although neonatal kittens have high numbers of 
CD4’*' T cells, kittens less than ten weeks of age produce lower levels of interleukin 
(IL)-2 in response to concanavalin A (Con A), compared to adult cats, indicating that 
these cells are unable to function to capacity (Tompkins, M.B., unpublished data).
1.2.10 Clinical Disease Associated with FeLV
Feline leukaemia virus replicates in all nucleated cells in feline bone marrow (Hardy, 
1981b), and favours other rapidly dividing cells elsewhere, such as lymphoid, 
myeloid, mucosal and epithelial cells (Hardy, 1993). Therefore, the potential for 
degenerative and proliferative disease is great (Fig. 1.8).
1.2.10.1 Oncogenesis
Feline leukaemia virus is a simple retrovirus, bearing only the genes necessary for
replication. As such, the virus is without specific oncogenes. However, FeLV is
responsible for most feline haematopoietic tumours, which accounted for one third of
all feline tumours in the U.S. (Dorn et aL, 1968; Hardy, 1981b). All haematopoietic
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Fig. 1.8 Images illustrating FeLV-associated disease
Fig. 1.8.A and B demonstrate two forms of feline lymphosarcoma, alimentary (A) 
and multicentric (B). Myelogenous leukaemic cells are demonstrated in blood smear 
(C). In Fig. 1.8.D bone marrow from a normal cat (upper) is compared with bone 
marrow from a FeLV-viraemic cat (lower), where a paucity of erythrocytes indicates 
a severe non-regenerative anaemia.
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cell lines, the myeloid, lymphoid, erythroid, and platelet series, are susceptible to 
FeLV transformation (Cotter, 1990). It is still unclear exactly how FeLV contributes 
to the genetic dysregulation that culminates in malignancy. A number of 
mechanisms have been proposed including insertional mutagenesis, whereby 
provirus integrates adjacent to a cellular oncogene, which activates it; and 
transduction, where provirus incorporates cellular oncogenes in a recombination 
event. An investigation into spontaneous FeLV-associated thymic LSA identified 
changes in the cellular myc gene in fifty per cent of cases (six) (Neil et aL, 1984). 
Five genomes had myc-containing proviruses, and one genome demonstrated proviral 
integration adjacent to c-myc. Rearrangement of the c~myc locus was detected in two 
out of four experimentally induced tumours, associated with adjacent proviral 
integration. Therefore, in the field cases, oncogenesis was most often associated 
with recombination between FeLV provirus and c-myc. These findings were similar 
to other reports (Levy et aL, 1984; Mullins et aL, 1984), where naturally-occurring 
FeLV-associated tumours showed evidence of wyc-containing FeLV provirus. 
However, since more than seventy-five per cent of naturally-occurring LSA in cats 
do not have these acute transforming defective FeLV-myc viruses, other mechanisms 
by which FeLV can induce LSA must exist (Hardy, 1993). In mice, polytropic mink 
cell focus-inducing (MCF)-MLV are generated as a result of a recombination event 
between ecotropic MLV and endogenous env sequences; the formation of which 
appears to be the initial step in the induction of lymphomas in AKR mice (Fan, 
1993). The substituted portion of the env gene of a Moloney virus-derived MCF- 
MLV virus was reported to be remarkably similar to the analogous region of FeLV- 
B, prompting suggestions that the recombination event which generated FeLV-B 
may also precipitate oncogenesis in the cat (Hardy, 1993).
1.2.10.2 Lymphosarcoma
The most common FeLV-associated tumour is LSA, a malignant tumour of
lymphocytes (Hardy, 1981b). Lymphosarcoma may originate within any organ and
spread to other sites, but is classified according to the site of primary involvement.
The categories are thymic (mediastinal) LSA, alimentary LSA, multicentric LSA and
unclassified (Hardy, 1981b; Cotter, 1990). Thymic LSA originates from thymic
lymphocytes but can extend throughout the chest cavity. Three-quarters are
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associated with FeLV, and usually occur in cats aged approximately two and a half 
years (Hardy, 1981b). Alimentary LSA is more prevalent in older cats; however, a 
much lower percentage of these, approximately twenty-five per cent, are associated 
with FeLV (Pedersen, 1988). Alimentary LSA was the most commonly diagnosed 
form of LSA in Scotland (Crighton, 1969b; Crighton, 1969a). These tumours may 
arise from any source of lymphocytes along the gastrointestinal tract (GIT) but most 
are derived from B cells within the lamina propria (Hardy, 1981b). Multicentric 
LSA originates from multiple sites, such as the internal organs and lymph nodes. 
Ninety per cent are associated with FeLV and they tend to occur in cats of 
approximately four years of age. Multicentric LSA was the most common LSA form 
identified in the U.S. (Hardy, 1993). Unclassified LSA originates from a single site 
anywhere, apart from the GIT and thymus, such as skin, eyes, or nervous system; this 
is the least common form of LSA (Hardy, 1993).
1.2.103 Leukaemia
Leukaemia without concurrent LSA is rare (Crighton, 1969b; Hardy, 1981b). Where 
leukaemia occurs, it is often associated with multicentric LSA. In fact, 
approximately thirty per cent of cats with LSA have concurrent leukaemia (Hardy, 
1993), the majority of which have multicentric LSA.
1.2.10.4 Feline Leukaemia Virus-Negative Tumours
Approximately thirty per cent of cats with LSA are aviraemic. However, FeLV 
proviral DNA sequences, distinct from endogenous sequences, have been detected in 
virus-negative LSA tissues (Koshy et ah, 1979; Koshy et aL, 1980). In addition, 
proviral DNA has been detected in non-LSA tissues, often bone marrow cells, in 
sixty per cent of these cats (Hardy et aL, 1980; Hardy, 1993). Feline leukaemia virus 
was reactivated from the bone marrow, but not LSA cells, in two aviraemic cats with 
LSA (Rojko et aL, 1982b). These findings suggested that FeLV was able to induce 
transformation but was not required to maintain the transformed state (Hardy, 1993). 
Francis et aL (1979) reported that out of one hundred and eighty-four cats diagnosed 
with either LSA or lymphoblastic leukaemia, sixty-one were aviraemic (thirty-three 
per cent), using the IFA test. He observed a distinct variation in the age distribution
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of viraemic and aviraemic cats at the time of diagnosis; viraemic cats were diagnosed 
with LSA or lymphoblastic leukaemia at a significantly lower age (3.5 years), than 
aviraemic cats (4.9 years). Another study reported that in old cats, a higher 
proportion of tumours occurred in aviraemic animals (Gardner et al., 1974). 
However, in Francis’ study (1979), the actual number of tumour s in young aviraemic 
cats was equivalent to those in older aviraemic cats, but tumours were rarely 
associated with viraemia in old cats.
1.2.10.5 Myeloproliferative Disease
Primary bone marrow neoplastic disorders are referred to as myeloproliferative 
diseases (MPD), which may involve any one or a combination of cells that originate 
in the bone marrow. Twenty per cent of FeLV-infected cats were reported to suffer 
from MPD, such as reticuloendotheliosis, erythemic myelosis, erythroleukaemia, 
myelogenous leukaemia, megakaryocytic leukaemia and myelofibrosis (Hardy, 
1981b).
1.2.10.6 Anaemia
The incidence of anaemia is high among FeLV-viraemic cats (Mackey et al., 1975). 
Secondary anaemia associated with concurrent FeLV disease, such as LSA, MPD or 
immunosuppressive disease, is common. Fifty-four per cent of LSA-positive cats 
with no accompanying bone marrow infiltration, suffered concurrent anaemia, which 
was suggested to be of haemolytic origin (Mackey et al., 1975). In addition, 
transient regenerative anaemia was reported to occur following the experimental 
infection of kittens with FeLV-A and FeLV-B, prior to the development of 
haematopoietic neoplastic lesions (Mackey et al., 1975). This form of anaemia was 
accompanied by increased bone marrow erythropoiesis and extramedullary 
haematopoiesis in the spleen, consistent with haemolytic anaemia.
However, primary non-regenerative anaemia without concurrent FeLV disease is an 
important syndrome in viraemic cats and is particularly associated with subgroup C. 
Kittens inoculated neonatally with FeLV-C died within sixteen weeks of infection, 
typically of congestive heart failure (Mackey et aL, 1975). Bone marrow was
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severely depleted of erythropoietic tissue consistent with aplastic anaemia (Fig. 
1.8.D). Similar results were reported by Hoover et aL (1974); neonatal kittens were 
inoculated with a KT-FeLV isolate containing subgroups A-C, which was donated by 
a cat suffering from progressive non-regenerative anaemia three months prior to 
death. Thirteen out of fifteen inoculated kittens demonstrated a severe progressive 
non-regenerative anaemia, presumably due to the FeLV-C component. Microscopic 
examinations of the bone marrow revealed a marked paucity of erythroid cell 
precursors. The pathogenesis of FeLV-C associated anaemia is yet unresolved. 
Research is currently focused on establishing the target cells for FeLV-C and 
identifying the pathogenic viral genetic determinants. Previous studies have 
indicated that FeLV-C greatly impairs the differentiation of early erythroid 
progenitor cells (burst-forming units, BFU) within the bone marrow, inhibiting 
erythrocyte production (Onions et aL, 1982; Hoover and Mullins, 1991).
1,2.10,7 Other FeL V-Associated Diseases
(i) Immune Complex Disease
Immune complexes form in situations of soluble antigen excess, rendering 
persistently viraemic cats susceptible to the development of immune complex 
disease. Many immune complexes deposit in the renal glomeruli (Weksler, 1975), 
although very few cats develop associated signs.
(ii) Reproductive Abnormalities
A  variety of reproductive abnormalities has been associated with FeLV. Abortion, 
foetal resorption, infertility, stillbirths and neonatal deaths are reported to occur in 
over eighty per cent of FeLV-positive cats (Pedersen, 1988).
(Hi) Enteritis
Feline leukaemia virus has a predilection for the rapidly dividing intestinal crypt 
cells. Feline leukaemia virus-associated enteritis (FAE) is a non-neoplastic condition 
associated with persistent FeLV infection, which is characterised by diarrhoea,
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haematemesis and anaemia (Hardy, 1993). Viral proteins can be detected 
immunohistochemically in the small intestines of FeLV-positive cats; although only 
FeLV SU protein gp70 and TM protein pl5E  proteins are strongly expressed in 
regions of pathological change associated with FAE (Kipar et aL, 2000).
1.3 Immune Responses to Retroviral Infections
1.3.1 General Introduction
Retroviruses are obligate intracellular pathogens; therefore, to survive, they must 
establish a productive infection within a host cell. The immune system has evolved 
to resist such a scenario, and if successful, the animal recovers and is immune to 
subsequent exposure. However, if the host fails to mount an effective immune 
response, or if the retrovirus itself has evolved escape mechanisms, a persistent 
retroviral infection usually results. Persistent infections may be latent or productive, 
depending on whether the virus is actively replicating. If provirus remains in the 
host cell genome and fails to express viral proteins, the immune system cannot be 
alerted to its presence; thus, provirus persists in a latent state, such as often occurs 
following FeLV viraemia (Madewell and Jarrett, 1983). Alternatively, failure of the 
immune system to clear actively replicating virus may lead to a productive persistent 
infection, as transpires in most cases of HIV, FV and lymphocytic choriomeningitis 
virus (LCMV) infections.
Many retroviruses successfully establish either latent or productive persistent 
infections in host cells. Several viral factors contributing to the failure of the 
immune response have been identified. Some retroviruses, such as HIV-1, are 
specifically cytotoxic to key elements of the specific immune response, such as the 
CD4^ T cell. In addition, HIV-1 is an effective immune escape artist: heavy 
glycosylation of the gpl20 protein, a key VNA epitope, masks other potential 
immunogenic sites (Haseltine et aL, 1989). The HIV genome is also highly variable 
(Hu and Temin, 1990), so that mutations of key epitopes may arise within an 
individual at a sufficiently high frequency to escape VNA or cytotoxic T lymphocyte 
(CTL) recognition (Phillips et aL, 1991; Couillin et aL, 1994; Borrow et aL, 1997).
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Escape mutants appear to have a survival advantage, as they persist (Borrow et aL, 
1997). Furthermore, some retroviruses may contain immunosuppressive elements, 
such as the FeLV TM protein pl5E, which has been reported to selectively inhibit 
cells within the immune system (Mathes et aL, 1979). The FlIV-1 Nef protein causes 
the downregulation of major histocompatibility complex (MHC) class I molecules, 
effectively protecting infected cells against CTL killing (Collins et aL, 1998).
1.3.1.1 Humoral Immune Response
Virus neutralising antibodies have a critical role in inhibiting viral infectivity and 
cell-to-cell transmission. Secreted immunoglobulins bind free virus particles in 
mucosal secretions, serum, lymph and bone marrow. The exposed envelope and 
capsid proteins are bound by the immunoglobulin, sterically inhibiting viral 
attachment to cellular receptors; therefore, any potential viral effect on the cell is 
neutralised. Although most retroviruses induce VNA, in many instances they are 
either not protective (Bex et aL, 1979; Essex, 1982), or require other elements of 
cellular immunity in order to elicit a protective immune response (Hasenkrug and 
Chesebro, 1997; Dittmer et aL, 1999).
1.3.1.2 Cell-mediated Immune Response
(i)C D 4^T cells
In humans and mice, CD4^ T cells can be divided into two subtypes, T helper (Th)l 
and Th2, according to their pattern of cytokine secretion (Mosmann et aL, 1986; 
Fiorentino et aL, 1989; Mosmann and Coffman, 1989; Abbas et aL, 1996). 
However, the distinction is not as complete as originally proposed; many cells have 
been identified which produce an array of cytokines that is not consistent with either 
Thl or Th2 subsets. These cells are termed ThO cells, and are more numerous in the 
early stages of lymphocyte activation (Kelso, 1995). However, both experimental 
and natural conditions have been identified, which induce clearly polarised immune 
responses, such as persistent infection with parasites such as Leishmania major, and 
bacteria such as Listeria monocytogenes and Mycobacteria spp. (Abbas et aL, 1996). 
In fact, chronic conditions of antigen persistence provide the most obvious examples
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of CD4^ T cell polarisation (Sher and Coffman, 1992).
The key Thl cytokine, interferon (IFN)-y, is a critical element of the host immune 
response, activating macrophages and enhancing their microbicidal activity, 
promoting the production of opsonising antibodies, immunoglobulin (Ig)G2a and 
IgG3, and activating CTL (Farrar and Schreiber, 1993; Boehm et aL, 1997) (Fig. 
1.9). Therefore, the principal function of Thl cells lies in their ability to activate the 
phagocytic and CTL-mediated destruction of intracellular microbes (Abbas et aL,
1996). Th2 cells are characterised by their production of IL-4 and IL-5. Interleukin-
4 elicits the isotype switching of B cells to IgE, which activates mast cells, while IL-
5 activates eosinophils. Therefore, Th2 responses are the dominant responses in 
helminth infections and allergic phenomena, which are characterised by the 
activation of both mast cells and eosinophils (Abbas et aL, 1996).
Mature naïve CD4^ T cells are non-polarised, and division into subtypes is a product 
of the cytokine microenviroment in which they first encounter an antigenic stimulus 
(Abbas et aL, 1996; Swain, 1999). Interleukin-12, IL-18 and IFN-y, are all involved 
in eliciting Thl responses, whereas IL-4 drives Th2 polarisation (Trinchieri, 1995; 
Tominaga et aL, 2000). Recently, it has been shown that human dendritic cell (DC) 
subsets can be defined according to whether they promote differentiation of Th cells 
into Thl or Th2 subsets (Rissoan et aL, 1999). Dendritic cell subset-1 (DCl) 
produced IL-12 shortly after CD40L activation; conversely, DC2 produced neither 
IL-12 nor IL-4. The type I IFNs, IFN-a and IFN-(3, are also significant products of 
uninfected precursor DC2 subset (pDC2) (Siegal et aL, 1999), and have a 
controversial role in directing human CD4^ T cells into Thl cells (O'Shea and 
Visconti, 2000).
CD4^ T cells are important in the priming, maturation and maintenance of CD8^ T 
cell responses through mechanisms as yet unexplained. However, the role of CD4^ T 
cells in the activation of DC and secretion of key cytokines such as IFN-y, both 
involved in the initiation and regulation of cellular and humoral immune responses, 
is likely to be relevant.
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Dendritic cells are activated through interactions between the CD40 molecule 
expressed on DC, and the CD40L molecule expressed on CD4^ T cells (Ridge et al., 
1998; Schoenberger et al., 1998). Activated DC are critically important in the 
priming of naïve CD8  ^ T cells (Ridge et al., 1998; Schoenberger et al., 1998). 
Therefore, DC activation by CD4^ T cells is an integral part of CD8^ T cell priming 
(Zajac et al., 1998b). CD4'*' T cells may also be important in maturing CD8^ T cell 
function (Zajac et al., 1998a; Appay et al., 2000).
CD4^ T cells are involved in the maintenance of CD8* T cell effector functions, 
particularly during chronic viral infections. Studies investigating chronic LCMV 
infection in mice have indicated that CD8^ T cell responses cannot be maintained in 
the absence of CD4^ T cell help (Battegay et al., 1994; Matloubian et al., 1994). In 
CD4-depleted mice, LCMV-specific CTL responses remain normal during the acute 
stage of infection, but are not maintained during the chronic phase of disease. As a 
result, these mice become persistently infected with the virus. Furthermore, LCMV- 
specific T cells in chronically infected mice are functionally inept, an effect 
exacerbated in a state of CD4'*' T cell deficiency (Zajac et al., 1998b).
Virus-specific CD4^ T cells are also required to maintain CD8^ memory T cells in 
chronic human viral infections. The effectiveness of CD8^ T cell clones infused into 
cytomegalovirus (CMV)-infected patients depended on the availability of specific 
CD4^ T cell help (Walter et al., 1995). In addition, poor CD4^ T cell responses in 
HIV infection correlate with higher viral RNA loads (Rosenberg et al., 1997).
(ii) CD8^ T cells
CD8^ T cells are the principal mediators of retroviral clearance. Cytotoxic T 
lymphocytes are activated CD8^ T cells, and function as potent killers of virally 
infected cells via perforin-dependent or Fas-mediated mechanisms. In addition, CTL 
secrete inhibitory antiviral cytokines such as IFN-y and tumour necrosis factor 
(TNF)-a, as well as chemokines. ‘Regulated on activation, normal T cell expressed 
and secreted’ (RANTES), macrophage inflammatory protein (M lP)-la and M lP-lp 
competitively inhibit binding of HIV to the CCR5 chemokine receptor in vitro,
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effectively suppressing replication (Cocchi et al., 1995). The relative importance of 
lytic and inhibitory functions varies with individual viruses (McMichael and 
Rowland-Jones, 2001).
(Hi) Interferon-y
Interferon-y is recognised as a critical component of the innate and adaptive host 
immune response to viral, bacterial and parasitic pathogens of man and animals 
(Kemp et al., 1999; Shankar et al., 2000; Dittmer et al., 2001; Bourreau et al., 2002). 
Mutant mice with genetic deficiencies in IFN-y, the receptor for IFN-y (IFN-yR), or 
the Stat-1 transcription factor, were unable to generate an effective immune response 
against microbial infections (Shtrichman and Samuel, 2001).
Interferon-y was, until recently, believed to be the product solely of natural killer 
(NK) cells (Carnaud et al., 1999) and particular T cell subsets (Farrar and Schreiber, 
1993), i.e. CD4'*' Thl (Kohno et al., 1997; Robinson et al., 1997) and CD8^ T cells 
(Consens et al., 1999). However, other sources of IFN-y have since been identified, 
such as the B cell (Yoshimoto et a i, 1997); macrophage (Munder et al., 1998; 
Schindler et al., 2001); DC (Ohteki et al., 1999; Hochrein et al., 2001); the 
regulatory T cell (Tr) (Trinchieri, 2001), and the NKT cell (Carnaud et a l, 1999).
Interferon-y interacts with the ubiquitously and almost universally expressed IFN-yR, 
launching a diverse series of events that directly and indirectly serve to contain 
microbial invasion. The induction of apoptosis and the inhibition of viral replication 
are antimicrobial events directly mediated by IFN-y. Additionally, the role of IFN- 
y in the upregulation of MHC class I and 11, the activation of antigen presenting cells 
(APC) and the induction of Thl responses, contributes indirectly but powerfully to 
antimicrobial resistance (Farrar and Schreiber, 1993; Young and Hardy, 1995; 
Boehm et al., 1997). Interferon-y acts directly to antagonise viral growth and 
replication through the induction of three genes encoding dsRNA activated protein 
kinase (PKR), 2’-5’-oligoadenylate synthestase (2-5A synthetase) and dsRNA 
specific adenosine deaminase (dsRAD) (Boehm et al., 1997). Protein kinase is 
activated by binding to dsRNA intermediates produced by RNA viruses, thus
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interfering with protein synthesis. Activation of 2-5A synthetase ultimately leads to 
activation of ribonuclease (RNAse)L that degrades single-stranded viral and cellular 
RNAs, inhibiting protein synthesis and viral growth. The dsRAD enzyme utilises 
dsRNA as a substrate in the deamination of adenosine, damaging mRNA resulting in 
the translation of a non-functional protein.
Interferon-y promotes Thl development by enhancing lL-12 secretion by 
macrophages, and by maintaining 1L-12R expression on CD4^ T cells, rendering 
them more responsive to IL-12 (Trinchieri, 1995). The addition of IFN-y during Th 
priming in vitro accelerated and enhanced the effect of lL-12 on Thl differentiation 
(Wenner et aL, 1996). Interferon-y exerted an anti-proliferative effect on murine Th2 
cells but not on murine Thl cells in vitro (Maggi et aL, 1992), suggesting that the 
role for IFN-y in T hl differentiation lies in its ability to prevent the outgrowth of Th2 
cells (Constant and Bottomly, 1997).
Major histocompatibility complex class I molecules are constitutively expressed on 
most nucleated cell types, with greatest expression on lymphomyeloid cells, whereas 
only professional APC, such as B lymphocytes, macrophages and dendritic cells, 
constitutively express MHC class II molecules in humans and mice (Boehm et aL, 
1997). Interestingly, both resting and activated feline lymphocytes constitutively 
express MHC class 11 molecules (Willett and Callanan, 1995). Nonetheless, IFN-y 
can induce MHC class 11 expression, as well as augmenting MHC class I molecule 
expression on virtually all cells, strongly promoting antigen presentation (Lapierre et 
aL, 1988; Boehm et aL, 1997). Interferon-y promotes isotype switching from IgM by 
acting directly on the B cell (Snapper and Paul, 1985). Antibodies of isotype lgG2a 
and IgG3 are opsonising antibodies, binding to high affinity Fc receptors on 
macrophages and complement proteins in order to enhance phagocytosis.
Nitric oxide (NO), an unstable radical gas, is derived from L-arginine and molecular 
oxygen. The catalyst for this reaction comprises a series of enzymes termed nitric 
oxide synthase (NOS), an intermediate of which is inducible by IFN-y acting with a 
second signal, such as TNF-a or lipopolysaccharide (LPS). In mice, IFN-y- 
dependent NO formation appears to have a major role in the killing of intracellular
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pathogens such as Leishmania major and Listeria monocytogenes (Green et aL, 
1990). Interferon-y also enhances the ability of macrophages to participate in other 
immune effector responses through the induction of high affinity Fc receptors and by 
boosting antibody dependent cell-mediated cytotoxicity (ADCC), and promoting 
complement protein synthesis (Farrar and Schreiber, 1993). Interferon-y promotes 
the development of immature myeloid precursors into mature monocytes, and 
enhances antigen presentation through increased MHC class 11 expression and 
accelerated formation of intracellular and cells surface proteins, such as intracellular 
adhesion molecule (ICAM)-l (Farrar and Schreiber, 1993).
1.3.2 Immune Response to FeLV 
1.3.2.1 Introduction
The immune mechanisms that determine the outcome following exposure to FeLV 
have yet to be fully resolved. Both VNA and complement-dependent antibodies 
(CDA) have been detected in the peripheral blood from FeLV exposed cats 
(Charreyre and Pedersen, 1991). In some circumstances, VNA can confer protection 
(Jarrett et aL, 1977). Recently, the role of CTL in mediating both vaccinal protection 
and recovery has been investigated (Flynn et aL, 2000a; Flynn et aL, 2002a).
1.3.2.2 Humoral Immunity
Cats exposed to FeLV under experimental and natural conditions produce a wide 
range of virus-specific antibodies (Lutz et aL, 1980; Charreyre and Pedersen, 1991; 
Hawks et aL, 1991), regardless of whether they recover or remain persistently 
viraemic. Antibodies were detected to viral proteins gp70, p27, pl5, p l2  and plO, as 
well as to eight additional antigenic components of 58, 47, 36, 24, 17, 15.7, 12 and
8.5 kDa, in both recovered and persistently viraemic cats (Lutz et aL, 1980b) using a 
GEDELISA assay. This assay combines two techniques, polyacrylamide gel 
electrophoresis (PAGE) and ELISA; purified FeLV was electrophoresed on a 
polyacrylamide gel and molecular weight markers were used to detect the position of 
protein bands, which were cut out and used to coat polystyrene tubes. Antibodies to 
each of the FeLV proteins could then be detected using an ELISA.
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Similarly, in a second study, both recovered and viraemic cats generated antibodies 
to viral proteins pl5, pl2, plO, p27 and gp70, detected using Western blots 
(Charreyre and Pedersen, 1991; Hawks et aL, 1991). In general, a negative Western 
blot pattern was consistent with persistent viraemia (Charreyre and Pedersen, 1991). 
Hawks et al. (1991) found that differences in anti-p27 antibody responses alone were 
statistically significant between persistently viraemic kittens and transiently viraemic 
or aviraemic kittens.
However, other authors reported that neither recovered nor viraemic cats produce 
anti-Gag antibodies, although anti-p27 antibodies can be induced in recovered cats 
(Jarrett, 1999). This might imply that the FeLV CA protein p27 either induces an 
anergic immune response, or absorbs circulating anti-p27 antibody (Neil et aL, 
1980b; Hawks et al., 1991).
(i) Virus Neutralising Antibodies
Virus neutralising antibodies may be of any isotype, although IgA antibodies may 
have an important role in the sites of early viral infection, such as in the oropharynx 
of cats infected with FeLV (Abbas et al., 1997a). Virus neutralising antibodies 
predominately target epitopes located on the FeLV SU protein gp70 and TM protein 
pl5E (Russell and Jarrett, 1978a; Elder et al., 1987). Nick et al. (1990) mapped two 
epitopes on SU protein gp70, and one epitope on TM protein pl5E, capable of 
inducing powerful cross-neutralising antibodies against all FeLV subgroups. Grant 
et al. (1983) demonstrated virus neutralising activity using mAbs directed against a 
number of FeLV Env glycoproteins. Epitope expression appeared to vary with the 
virus isolate under study, demonstrating antigenic polymorphism within FeLV 
subgroups and between isolates (Russell and Jarrett, 1978a; Grant et al., 1983).
Neonatal kittens born to FeLV-immune queens may be protected by passively
transferred maternal antibodies. Two queens exposed to FeLV-A/Glasgow-1
developed FeLV-specific VNA and remained clinically healthy (Jarrett et al., 1973).
Kittens born to each queen were allowed to suckle for two days before being
challenged subcutaneously with FeLV. Kittens that received passively transferred
VNA were protected from challenge, whereas kittens born to a naïve queen became
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viraemic. The VNA titres from the passively protected kittens decayed 
exponentially, and were completely absent by sixteen weeks. In this study, 
maternally derived antibody protected kittens from postnatal challenge, and the 
authors predicted that suckling kittens are likely to be protected in the same way 
under natural conditions (Jarrett et al., 1977).
In general, recovered cats produce higher antibody titres, which peak earlier, than 
persistently viraemic cats (Lutz et al., 1980b; Charreyre and Pedersen, 1991). Using 
the data from their study. Lutz et al. (1980b), concluded that extreme levels of virus- 
specific antibody correlated with the clinical outcome of infection. Lower antibody 
levels were detected in cats that became persistently viraemic following experimental 
exposure to FeLV, compared to cats that recovered without becoming viraemic. 
Transiently viraemic cats produced levels of antibody that overlapped with those 
produced by aviraemic and persistently viraemic cats.
Although VNA appeared to be protective in Jarrett’s study (1977), and are often 
present at higher levels in recovered cats, VNA do not necessarily mediate recovery. 
In a recent longitudinal FeLV immunopathogenesis study, all cats that recovered 
from experimental challenge developed significant VNA titres. However, the 
appearance of VNA followed, or was concurrent with, clearance of infectious virus 
(Flynn et al., 2002b). Similar findings have been reported in other studies where a 
small proportion of cats recovering from experimental challenge with FeLV do not 
have detectable VNA (Hoover et al., 1976; Russell and Jarrett, 1978b; Charreyre and 
Pedersen, 1991). Moreover, VNA were present in the serum of some cats that 
eventually became persistently viraemic (Charreyre and Pedersen, 1991).
Virus neutralising antibodies are unlikely to be involved in eliciting protective 
immunity following vaccination. Specific pathogen free kittens were vaccinated 
with one of three commercially available vaccines, and were exposed to FeLV 
viraemic cats. Significant differences in antibody responses were not detected 
between kittens that developed persistent viraemia, and either those that became 
transiently viraemic, or those that recovered without becoming viraemic (Hawks et 
al., 1991). Furthermore, in a recent FeLV DNA experimental vaccine study (Hanlon 
et a l, 2001), protection was conferred in the absence of VNA. Moreover, infectious
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virus was cleared from the blood before virus-specific VNA were generated post­
challenge, indicating that VNA were not involved in recovery.
(ii) Complement-Dependent Antibodies
Complement-dependent antibody interacts with antigen, bound in an immune 
complex or attached to a cell surface, and mediates viral or cell lysis (Abbas et al., 
1997b). Complement-dependent antibodies are not present in unexposed SPF cats 
but appear following exposure to FeLV, and are present in both recovered and 
persistently viraemic cats (Grant et a i, 1978; Grant et al., 1979). These antibodies 
are directed to neither Env nor Gag proteins (Grant et al., 1978), and can be 
demonstrated in vitro using immune cat sera and feline complement to lyse FeLV 
antigen-expressing FL74 cells (Grant et al., 1977). Complement-dependent antibody 
is typically of isotype IgGl, lgG3 or IgM. Grant et al. (1979) observed that in FeLV 
immune cats, CDA levels declined over time, whereas persistently viraemic cats 
experienced cyclical fluctuations in CDA levels. The author also considered whether 
CDA might be directed against tumour antigens rather than viral antigens as 
demonstrated by a significant correlation between the presence of CDA and the 
presence of lymphoma.
1.3.2.3 Cell-mediated Immune Response
The importance of CTL as mediators of protective immunity and effectors of 
recovery in retroviral infections such as FIV and HIV, has been established (Flynn et 
al., 1996; Kaul et al., 2000). The ability of CTL to control FeLV replication and 
mediate recovery has recently been delineated; cats that recovered following 
experimental exposure to FeLV developed early virus-specific CTL responses, which 
were maintained until infectious virus was cleared from the blood (Flynn et al., 
2002b). All FeLV-exposed cats demonstrated two peaks in CTL activity, at weeks 
four to seven, and subsequently at weeks ten to thirteen, which coincided with two 
peaks in proviral DNA load (at weeks four and ten). The early CTL response was 
Gag/Pro-Specific, while the second peak was Env-specific. Cats that failed to 
recover from FeLV infection following experimental challenge exhibited delayed 
and short-lived virus-specific CTL. In addition, the adoptive transfer of a single
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infusion of mixed virus-specific CD4^ and CD8^ T cells significantly reduced the 
proviral DNA burdens in persistently infected cats, indicating a direct role for virus- 
specific T cells in the control of FeLV viraemia (Flynn et al., 2002b).
Virus-specific CTL are also important in protective vaccinal immunity. High levels 
of FeLV-specific CTL were detected in the blood and lymphoid tissues from FeLV 
DNA-vaccinated protected cats (Flynn et al., 2000a; Hanlon et al., 2001). Virus- 
specific CTL were detected at significantly higher levels in both protected and 
recovered cats, compared to persistently viraemic cats. Furthermore, significantly 
higher levels of Gag/Pro-specific CTL were detected in transiently viraemic cats that 
recovered, compared to persistently viraemic cats. However, differences in Env- 
specific CTL responses between the same groups were not significant (Flynn et al., 
2000a), indicating that the predominant CTL response in protected and recovered 
cats is Gag/Pro-specific. The authors suggested that the CTL responses of 
persistently viraemic cats may be directed to viral proteins other than Gag, Pro or 
Env, such as the Pol proteins RT and IN.
1.3,2,4 Immunosuppression
Early studies indicated that both cell-mediated and humoral immune responses were 
suppressed in FeLV-exposed cats (Perryman et al., 1972; Cockerell et a l, 1976; 
Hebebrand et al., 1977; Mathes et al., 1978; Hebebrand et al., 1979; Mathes et al., 
1979). At that time, it was not clear whether lymphopenia caused by thymic atrophy 
and viral infection of lymphoid tissues could account for the ensuing 
immunosuppression (Perryman et al., 1972), or whether other, as yet undefined, 
immuosuppressive factors were involved. An emerging consideration was the status 
of the CD4^T cell, known to be important in the regulation of both cell-mediated and 
humoral immune responses as well as innate non-specific immune responses.
In 1976, Cockerell et al. examined the response of lymphocytes from FeLV-infected 
kittens to mitogen-induced activation using the lymphocyte blast transformation 
(LET) assay. He discovered that, compared to uninfected controls, infected kittens 
had a greatly reduced ability to respond to Con A, and to a lesser extent, pokeweed
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mitogen (PWM). Disease progression was characterised by an early decline in B cell 
numbers, which subsequently returned to normal levels. In humans and mice. Con A 
is known to be T cell selective, whereas PWM stimulates both T and B cells. If these 
mitogens exerted similar selective effects on feline cells, the findings from this study 
would indicate that FeLV exerts a greater suppressive effect on T cells, compared to 
B cells. The author also suggested that the early decline in B cell numbers might 
reflect early defective CD4^ T cell function.
Eight clinically healthy but persistently viraemic cats were inoculated with (l - 
tyrosine-L-glutamic acid)-poly-DL-alanine-poly-L-lysine, ((T,G)AL) antigen, a T cell- 
dependent antigen in the rat. Subsequent blood sampling revealed that six out of 
eight cats showed a delayed and reduced (T,G)AL-specific antibody response 
compared to an uninfected control group (Trainin et a l, 1983), prompting the author 
to suggest that a CD4^ T cell malfunction in the persistently viraemic cats might 
have contributed to the diminished humoral response.
The immunosuppressive effect of FeLV did not appear to be restricted to B and T 
cells. Persistently viraemic cats are highly susceptible to opportunistic bacterial and 
fungal infections, which might indicate impaired innate immunity. Indeed, 
polymorphonuclear (PMN) cells from FeLV-infected cats were shown to be 
functionally impaired in vitro as determined by the chemiluminescent (CL) response. 
Depressed PMN function first became evident during early viraemia and continued 
to decline throughout the course of the experiment, even though all cats had 
succeeded in eliminating virus and were clinically healthy (Lafrado and Olsen, 
1986). In 1987, Lafrado et al. investigated the effect of FeLV on the functional 
capacity of PMN cells from healthy cats. Inactivated virus added to latex bead- 
stimulated PMN suppressed CL activity by fifty per cent, compared to controls.
The suppressive effect of UV-inactivated FeLV on lymphocyte function had 
previously been reported. The response of PBMC from SPF cats to the mitogen Con 
A in a LBT assay, was suppressed twenty to sixty-five per cent in the presence of 
inactivated FeLV (Hebebrand et al., 1977). The inactivated virus was not cytotoxic, 
as determined using Trypan Blue exclusion to assess the viability of cultured cells. 
Similarly, UV-inactivated FeLV significantly suppressed cat lymphocyte recognition
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of allogenic cells using the mixed leukocyte reaction (MLR) (Stiff and Olsen, 1983).
It is apparent from these studies that FeLV in vivo, and inactivated FeLV in vitro, can 
suppress T, and to a lesser extent B, cell function, as well as PMN function. 
Evidence exists to suggest that the FeLV TM protein pl5E may be partly responsible 
for the immunosuppressive effects of FeLV. Mathes et al, (1979) added purified 
FeLV TM protein pl5E to Con A-stimulated lymphocytes from SPF cats, and found 
a markedly reduced responsiveness in the LBT, compared to an identical incubation 
with purified FeLV CA protein p27. Inhibition was shown to be independent of 
competition for Con A binding sites and FeLV TM protein pl5E  toxicity. Lafrado et 
al. (1987) also observed a suppression of chemiluminescent activity when latex- 
stimulated PMN from healthy cats were incubated with FeLV TM protein pl5E. The 
ability of FeLV TM protein pl5E  to suppress human lymphocyte mitogenic and 
antigen-specific responses was illustrated using the LBT (Hebebrand et al., 1979); 
proliferative responses to the mitogens Con A and phytohaemagglutinin (PHA) were 
reduced by up to ninety-six per cent, in four out of six humans tested.
The mechanisms through which inactivated FeLV and/or pl5E might exert an 
immunosuppressive effect have been investigated. Copelan et al. (1983) reported 
that purified FeLV TM protein pl5E inhibited the proliferative responses of human 
lymphocytes to Con A when the cells were co-cultured with IL-1, and suggested that 
FeLV TM protein pl5E  interfered with IL-2 production by T cells. Shortly 
afterwards, UV-inactivated FeLV was shown to depress the accumulation of IL-2 
and macrophage activating factor (MAF) in Con A-stimulated murine T cells (Orosz 
et al., 1985). Both IL-2 and MAF production by CD4^ T cell and CTL populations, 
respectively, were blocked. It was concluded that FeLV acted directly to exert a 
general but temporary impairment on the ability of the T cell to produce, and respond 
to, cytokines.
Further evidence that FeLV impairs cytokine production has been documented.
Peripheral blood mononuclear cells and splenic lymphocytes from FeLV-infected
cats could not be induced to produce significant levels of feline IFN-y (fIFN-y) in
response to Staphylococcus aureus protein A (SPA) (Liu et al., 1984). Similar
findings were recorded in vitro, where PMBC from SPF cats were co-cultured with
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inactivated FeLV and Staphylococcus aureus enterotoxin A (SEA) in LBT assays. 
Supernatants were collected and assayed for flEN-y activity using a plaque reduction 
assay. Levels of flFN-y were markedly reduced where inactivated FeLV was 
included in the culture system, compared to activity detected using the mitogen alone 
(Engelman et al., 1984). The effect was dose dependent, with increased antiviral 
activity detected at lower concentrations of inactivated FeLV.
Nonetheless, no differences in protection afforded by a canarypox virus recombinant 
FeLV vaccine (ALVAC-FL) expressing either intact Env, or Env in which 
‘immunosuppressive’ sequences were eliminated, were detected (Tartaglia et al., 
1993).
1.3.2.5 Vaccination
Currently, three FeLV vaccines are commercially available in the U.K. (Sparkes,
1997). The first of these is an adjuvanted form of whole inactivated FeLV 
(‘Fevaxyn’, Fort Dodge Animal Health, Wyeth, New Jersey, U.S.); the second is an 
adjuvanted mixed subunit from FeLV-infected tissue culture filtrate (‘Leukocell 2 \  
Pfizer Ltd, Kent, U.K.). Finally, a vaccine based on a purified, adjuvanted, 
recombinant non-glycosylated form of FeLV SU protein gp70 (p45), is available 
(‘Leucogen’, Virbac S.A. Garros cedex, France). Ideally, an effective vaccine should 
protect FeLV exposed cats from both viraemia and latent infection. However, none 
of these vaccines fully protect exposed cats against the development of viraemia or 
latent infection (Jarrett and Ganière, 1996; Sparkes, 1997).
Few independent vaccine efficacy studies are available; many efficacy studies have 
either been conducted or supported by the manufacturer, and results are often 
conflicting. The preventable fraction (PF) figures (Sparkes, 1997), which represent 
the proportion of cats protected by vaccination in excess of that protected by natural 
resistance, reveal variations between studies testing the same vaccine. For instance, 
the ‘Leukocell 2’ vaccine has a reported PF which varies between 4.8 per cent 
(Jarrett and Ganière, 1996), and one hundred per cent (Lafrado, 1984). However, 
vaccine efficacy cannot truly be compared without considering other factors such as 
the number of cats used in the study, the number of cats that developed persistent
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viraemia, the route of challenge and the age of cats at the time of challenge. 
Nonetheless, however these vaccines are compared, none have successfully managed 
to prevent transient viraemia when challenged in a controlled study (Sparkes, 1997). 
In fact, none of these vaccines consistently protected against the development of 
persistent viraemia (Sparkes, 1997).
The search for more effective vaccines has precipitated experimentation with novel 
adjuvants (Osterhaus et al., 1985), live viral vectors (Willemse et al., 1996) and 
DNA vaccination (Hanlon et al., 2001). An experimental FeLV DNA vaccine 
containing gag, pol and env genes, as well as IL-12 and IL-18 DNA, was shown to 
be an effective vaccine, in that all cats receiving this construct were protected from 
persistent and transient viraemia (Hanlon et a l, 2001). However, protection from 
latent infection was not complete.
The mode of protection conferred by the commercially available vaccines has not 
been investigated. It was believed that VNA were critical mediators of protection 
(Loar, 1993; Sparkes, 1997), although significant VNA titres were not observed 
using some vaccine preparations until after challenge (Pedersen, 1993). Indeed, 
inoculation with the FeLV DNA vaccine described above did not elicit any anti- 
FeLV antibody response before challenge. After challenge, strong VNA responses 
were elicited in the majority of recovered and protected cats. These antibodies did 
not appear any earlier, or at any greater titre, in vaccinated protected cats, compared 
to recovered control cats; these data suggest that the VNA were not induced by the 
vaccine (Hanlon et al., 2001). In contrast, high levels of FeLV-specific CTL were 
detected in the blood and lymphoid tissues from vaccinated protected cats (Flynn et 
al., 2000a). In both protected and recovered cats, FeLV-specific CTL were detected 
at significantly higher levels than in persistently viraemic cats, indicating that 
protection was conferred by CTL. The inclusion of DNA encoding cytokines IL-12 
and IL-18 in the vaccine construct would have enhanced the generation of CTL 
effector cells; these cytokines are known to drive Thl immune responses (Trinchieri, 
1995; Tominaga et al., 2000). Therefore, for FeLV, vaccine strategies favouring Thl 
responses that generate virus-specific CTL should prove the most successful in 
eliciting protective immunity.
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1.3.3 Immune Response to Other Retroviruses
What information regarding antiretroviral immunity can be gleaned from other 
systems, and applied to FeLV?
1.3.3.1 Role o f CD4^ T Cells in Antiretroviral Immunity
Cytotoxic T lymphocyte responses, T cell proliferative responses and VNA are all 
required elements in a protective immune response against FV (Hasenkrug and 
Chesebro, 1997). Virus-specific CD4^ T cells provide help for both CTL 
(Hasenkrug and Chesebro, 1995) and B cells (Perry et al., 1994; Super et al., 1998). 
The rapid development of CD4^ T cell proliferative responses is associated with 
recovery from a high dose challenge of FV (Miyazawa et al., 1988). Depletion of 
CD4^ T cells in vivo had little effect in the early stages of recovery but did lead to a 
marked reduction in recovery in the final stages, suggesting that CD4^ T cells were 
less important in the early stages of recovery but were required to maintain the 
recovered status (Robertson et al., 1992). The CD4^ T cell response is specific for 
determinants in the FV Env protein, and two epitopes have been characterised within 
the SU protein gp70.
In HIV-1 infected humans and non-human primates, CD8^ T cells are central to anti- 
HIV-1 immune responses (Schmitz et al., 1999; McMichael and Rowland-Jones,
2001). An additional role for VNA in the suppression of primate lentiviral infections 
has also been postulated (Shibata et al., 1999). Since CD4^ T cells have a 
fundamental role in the promotion and regulation of these two arms of the immune 
response, the capacity of these cells to function normally during primate lentiviral 
infections is of critical importance. Human immunodeficiency virus-1 infection is 
characterised by a steady decline in CD4^ T cell numbers, presumably lost through 
infection and virus-induced apoptosis (Rosenberg and Walker, 1998; Altfield and 
Rosenberg, 2000). The number of virus-specific CD4^ T cells is also low (Pitcher et 
al., 1999). HIV preferentially infects virus-specific CD4^ T cells (Douek et al.,
2002), which may be particularly vulnerable to HIV infection because of their 
association with HIV-bearing dendritic cells within lymph nodes. However, a 
functional defect in CD4'*' T cells is apparent early in the asymptomatic phase, before
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the dramatic drop in CD4^ T cell numbers occurs (Miedema et al., 1988; Clerici et 
al., 1989; McMichael and Rowland-Jones, 2001). Nonetheless, in both humans and 
rhesus macaques, early virus-specific CD4"^  T cell responses can be restored using 
antiretroviral therapy. The application of such therapy in rhesus macaques during 
primary infection with simian immunodeficiency virus (SÏV) replication led to the 
rapid suppression of viral replication in some animals, together with the development 
of strong SIV-specific CD4^ T cell responses. Furthermore, these animals were 
resistant to re-challenge. Simian immunodeficiency virus-specific CD4^ T cell 
responses inversely correlated with viral RNA load, implicating CD4’*' T cells in 
resistance to infection (Lifson et a l, 2000). Early antiretroviral therapy can also 
‘rescue’ this HIV Gag-specific CD4"^  T cell response in humans (Rosenberg et al., 
1997; McMichael and Rowland-Jones, 2001).
However, in the absence of treatment, the majority of patients infected with HIV-1 
experience a progressive and irreversible loss of CD4^ T cell function, characterised 
by a deterioration of delayed type hypersensitivity (DTH) responses to common 
recall antigens (Dolan et al., 1995); a loss of in vitro responsiveness to mitogenic and 
antigenic stimulation (Clerici et al., 1989), and a switching from Thl to Th2 cytokine 
profiles (Maggi et al., 1994). Human immunodeficiency virus-1-specific CD4^ T 
cell responses have been measured in patients throughout the course of infection 
using lymphocyte proliferation assays (LPAs). Only the long-term non-progressor 
(LTNP) patients consistently demonstrated significant levels of proliferation to viral 
antigens (Rosenberg et a l, 1997; Picker and Maino, 2000). This cohort of HIV- 
infected individuals maintain normal CD4^ T cell numbers and low to undetectable 
viral RNA loads, exhibit no signs of HIV-1-related disease and consistently 
demonstrate vigorous cellular and humoral responses to HIV (Rosenberg et al., 
1997). However, AIDS patients with lower viral RNA loads did show some HIV- 
specific CD4^ T cell responses (Musey et al., 1999). Responses were predominately 
directed towards Gag proteins; occasionally, responses towards Env and Pol proteins 
were detected (Rosenberg et a l, 1997; Musey et a l, 1999).
Intracellular cytokine staining (ICS) using flow cytometry to detect IFN-y expression
provides a means of MHC-independent quantification of antigen-specific CD4^ T
cell frequencies (Pitcher et al., 1999), and is more reflective of the true frequency of
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antigen-specific CD4^ T cells (Picker and Maino, 2000). Using this method, HIV-1- 
specific CD4^ T cells were detected in all LTNP and recently infected (less than three 
years) patients, and surprisingly, in over half of the chronically infected patients with 
progressive disease. The response was primarily against Gag proteins, and the 
cytokine profile characteristic of Thl cells (IFN-y and IL-2). In the proliferation 
studies, an inverse correlation was detected between plasma viral RNA loads and 
CD4^ proliferative responses (Rosenberg et al., 1997; Musey et al., 1999); however, 
using ICS, there was no statistically significant correlation between HIV-1-specific 
CD4^ T cell frequencies and viral RNA load, although the median frequencies were 
higher in LTNPs than in the progresser group (Pitcher et al., 1999). A second study 
using similar ICS techniques to detect IFN-y expression in recognition of cognate 
antigen, concurred; the difference in Gag-specific CD4^ T cell frequencies between 
LTNPs and the slow progressors (SPs) was not statistically significant (Boaz et ah,
2002). However, Gag-specific CD4^ T cells that produced both IFN-y and IL-2 were 
associated with a good clinical outcome in HIV infection, in that LTNPs had higher 
frequencies of such cells in the peripheral blood, compared to slow progressors (SPs) 
(Boaz et al., 2002). Furthermore, the frequency of the IFN-y^ IL-2^ CD4‘^ T cell 
population correlated inversely with viral RNA load, but not CD4 count. Gag- 
specific IFN-yCD 8^ T cell frequency did not differ between the two groups; and 
only Gag-specific IFN-yIL-2^ CD4’*' T cell frequency correlated with the Gag- 
specific IFN-yCDS^ T cell frequency.
Bovine leukaemia virus-specific cellular immune responses have been investigated 
using the LPA. The core antigen, p24, was prepared from a cell line constitutively 
producing BLV antigens, and incubated with T cells isolated from the serum of 
asymptomatic, seropositive animals. CD4^ T cells from seropositive animals 
proliferated in response to p24, whereas CD8^ T cells did not show any significant 
proliferation (Mager et al., 1994). These findings suggested that the p24 responder 
population resided in the CD4^ T cell subset.
1,33.2 Role of CTL in Antiretroviral Immunity
The presence of FV-specific CTL correlates with recovery from splenomegaly in
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FV-infected mice (Robertson et al., 1992). Depletion of CDS'*' T cells in vivo 
dramatically reduced the incidence of recovery. Friend virus complex-specific CTL 
recognise viral antigens in the context of H-2D molecules (Chesebro, 1990). The 
major CTL epitope is present within the FV Env protein but has yet to be identified 
(Hasenkrug and Chesebro, 1997).
Cytotoxic T lymphocytes are important in the control of viraemia in the initial acute 
phase of HIV and SIV infection, and during the asymptomatic period (Koup et al., 
1994; Borrow et a l, 1997; Ogg et al., 1998; Wilson et al., 1998; Jin et al., 1999). 
However, virus-specific CTL are unable to control virus spread, despite the presence 
of high frequencies of virus-specific CD8^ T cells, (Ogg et al., 1998; Wilson et al., 
1998; Kuroda et al., 1999; Lieberman et al., 2001). These data suggest that the 
virus-specific CTL may not be functioning optimally. In one study, less than fifteen 
per cent of HIV-specific CTL contained perforin, which resulted in the poor killing 
of target cells ex vivo (Appay et al., 2000). Low levels of perforin expression may 
correlate with immaturity, and might reflect inadequate CD4^ T cell function 
(Champagne et al., 2001; McMichael and Rowland-Jones, 2001). The majority of 
HIV-specific memory T cells detected in HIV-infected individuals resided in a pre- 
terminally differentiated subset, whereas most CMV-specific cells were terminally 
differentiated (Champagne et al., 2001). Assessment of the capacity of SIV and 
HIV-epitope-specific CD8  ^T cells to produce IFN-y has been made possible through 
the development of tetramer technology and ICS. These highly sensitive techniques 
permit the enumeration of individual epitope-specific cells (Section 1.4). In rhesus 
monkeys chronically infected with SIV, CD8^ T cells were unable to secrete IFN-y in 
response to their specific peptide epitope (Vogel et al., 2001), but could in response 
to the mitogens phorbol myristate acetate (PMA) and ionomycin. Similar findings 
were reported for humans infected with HIV. In most patients, less than twenty-five 
per cent of tetramer-positive cells produced IFN-y in response to their cognate HIV 
peptide epitope (Shankar et al., 2000). Short-term culture with IL-2 restored the 
capacity of CD8^ T cells to produce IFN-y and lyse HIV-infected CD4^ target cells; 
however, these cells could not be rescued in more advanced patients, suggesting 
progressive CD8^ T cell dysfunction with disease advancement. Where the anti-HIV 
CTL response is restricted to just a few immunodominant epitopes (Phillips et a l, 
1991; Couillin et al., 1994; Borrow et al., 1997), virus escape mutants can develop
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and persist. In fact, HIV-specific CTL responses directed against a limited number 
of viral epitopes will drive the selection of escape mutants (Borrow et al., 1997), and 
may contribute to the failure of the early CTL response to control viral replication.
1 .3 3 3  Role o f Humorallmmunity
Virus neutralising antibodies are an important correlate of protection against FV. A 
non-MHC gene, Rjv-3, influences the production of VNA. Mortality is increased by 
up to ninety per cent in mice unable to elicit VNA (Hasenkrug and Chesebro, 1995). 
In addition, B cell-depleted mice have reduced tumour-specific CD4^ and CDS’*" T 
cell responses, indicating a role for B cells in antigen presentation and the induction 
of T cell responses in vivo (Schultz et al., 1990).
Anti-HIV antibodies are primarily directed against the Env glycoproteins gpl20 and 
gp41, and against the Gag proteins p l7  (Barker et a l, 1995) and p24 (Weber et a l, 
1987). Viruses isolated from an infected individual over time have shown variable 
levels of sensitivity to VNA, suggesting the development of virus escape mutants 
(McKeating et a l, 1989; Bourreau et a l, 2002). The Env protein is subject to greater 
selection pressure than Gag and Pol proteins, which tend to be more conserved; anti- 
Gag antibodies do not neutralise virus so no effect of antibody selection occurs. 
Despite the fact that high anti-Env titres can be detected in the sera of most HIV- 
infected individuals, the key events of CD4 binding and fusion are not inhibited, 
indicating that humoral immune responses are not protective (Matthews et a l, 1986). 
However, recent studies in pig-tailed macaques with chimeric simian-human 
immunodeficiency virus (SHIV) have demonstrated passive protection conferred by 
anti-HIV-1 Env neutralising antibodies alone in vivo (Shibata et a l, 1999). The env 
gene was derived from HIV-1dhi2, a dual-tropic primary virus isolate.
Bovine leukaemia virus induces antibodies to the Env protein gp51 and to the Gag 
protein p24 (Bex et a l, 1979; Bruck et a l, 1984). However, these antibodies, which 
may persist throughout the life of infected animals, are not effective in eliminating 
virus or in preventing disease progression. Furthermore, antibody titres may even 
increase as disease progresses to persistent lymphocytosis or tumour development 
(Mager et a l, 1994).
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1.3.3 A  Role o f Cytokines in Antiretroviral Immunity
Whether Thl or Th2 responses predominate in recovering FV-exposed mice is not 
yet unknown. However, the importance of CTL in recovery suggests that Thl 
responses are likely to be important. The role of IFN-y, as well as ÏL-4 and IL-12, in 
the pathogenesis and control of a primary FV infection was determined using mice 
with genetic inactivations in each of the cytokine genes (Dittmer et at., 2001). High 
levels of viraemia were detected in IFN-y-deficient mice; furthermore, one-third 
developed gross splenomegaly by week ten. The remaining IFN-y-deficient mice 
appeared to be able to compensate for the lack of IFN-y. Interleukin-4 and IL-12- 
deficient mice behaved as normal wild-type mice. Vaccinated challenged mice did 
not require IFN-y to control FV infection.
1.3.3.5 Immunosuppression
Friend retrovirus complex can suppress both cellular and humoral immune responses 
in certain mouse strains. In H-2D^^  ^ mice (mice with the lowest incidence of 
recovery), humoral immune responses were suppressed, including antibody 
responses to T cell independent antigens, indicating that defective CD4^ T cell 
function was not the cause (Morrison et al., 1986). Susceptible mice also experience 
FV-mediated impaired NK activity (Lu et a l, 1992); in addition, antigen presentation 
by macrophages is compromised (Jones et al., 1992).
The majority of sera from BLV-infected cattle inhibited mitogen-induced 
lymphocyte blastogenesis in a dose-dependent manner (Takamatsu et al., 1988), and 
impaired PMN cell activity. Sera from cattle with persistent lymphocytosis were 
added to an IL-2-dependent T cell line, and caused growth suppression. However, 
cellular viability was not impaired, suggesting the existence of an 
immunosuppressive factor in the serum of diseased animals.
1.3.3.6 Vaccination
Protection of susceptible mouse strains against FV can be achieved using a range of
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vaccine types, such as killed or attenuated viruses, viral proteins, viral peptides or 
recombinant vaccinia virus (rVV) vectors expressing FV genes (Hasenkrug and 
Chesebro, 1997). Protective responses must include CD4^ T cell proliferation and 
CTL activity, as well as VNA. The env gene within the rVV vectors appears to elicit 
better protective responses than the gag gene (Miyazawa et a i, 1992). However, 
seventy per cent of H-2^^ mice that were immunised with xW -gag  recovered after 
sixty days post challenge. The protective mechanism has not been delineated; 
however, co-operation between Gag-specific CD4^ T cells and Env-specific effector 
cells was considered to be involved e.g. class switching of VNA to IgG following 
challenge with FV in Gag-immune mice. One CTL, three Th and two VNA epitopes 
have been identified within the SU protein gp70. The number of CD4^ T cell 
epitopes available within the vaccine appears to be a critical factor in determining the 
requirement for CTL (Hasenkrug et al., 1996).
With an estimated fifteen thousand new infections each day, the development of an 
effective therapeutic and prophylactic vaccine against HIV is critical. Researchers 
are striving to target virus-specific CD8^ T cells in order to evoke protective immune 
responses. Experimental studies have shown that antibodies failed to neutralise wild- 
type virus in vitro, and neutralisation, where it occurred, was largely strain-specific. 
Ideally, a vaccine against HIV would deliver sterilising immunity. However, 
realistically, an HIV-vaccine might only offer partial protection against infection. 
CD8^ T cells cannot prevent infection of cells by HIV, but could abort an infection 
before it became established, or if the virus is not eliminated, contain the virus at a 
significantly lower level (McMichael and Rowland-Jones, 2001), which might 
reduce the severity of infection, create more LTNP and, in addition, reduce the 
transmissibility of the virus.
Various prime and boost vaccine combinations can also be used to enhance immune
responses. Prime-boost HIV vaccines are currently undergoing phase I and II
clinical trials; an epitope-based DNA vaccine is administered followed by a modified
vaccinia virus Ankara (MVA) vaccine incorporating a CTL multi-epitope
immunogen. This combination induced good virus-specific CTL responses in rhesus
macaques, detected using ^^Cr release assays, enzyme linked immunospot (ELISpot)
assays and tetramer staining (Hanke et a l, 1999; Allen et a l, 2000). However, this
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regimen failed to protect two out of three challenged animals.
Since BLV is more pathogenic in sheep than in cattle, with a shorter latent period, 
sheep have often been used in experimental BLV studies. Sheep vaccinated with 
rVV expressing the BLV glycosylated Env protein generated partially protective 
immune responses against BLV (Ohishi et al., 1991). Vaccinated animals were not 
completely protected from challenge but BLV proliferation was suppressed in both 
healthy challenged animals and in carrier animals. Antibodies were not induced 
before challenge, suggesting that cell-mediated immunity was important. In fact, 
vaccination elicited strong DTH responses, implicating CD8^ T cell activity. 
Antibody titres post-challenge were similar in both the control infected and 
vaccinated protected populations, and did not correlate with the degree of BLV 
proliferation. Vaccination using a rVV vector containing the complete BLV env 
gene protected sheep against challenge with BLV, and protection was shown to 
correlate with the activity of Env-specific CD4^ T cells (Gatei et al., 1993). 
However this response was absent four months post challenge.
1.4 Technologies Detecting Antigen-Specific CD4^ T Cells
1.4.1 Lymphocyte Proliferation Assay
In this assay, specialised plates are coated overnight with mitogen or specific antigen 
in the form of peptides or proteins. Cells isolated from peripheral blood or lymphoid 
tissues are seeded into the coated wells and incubated for three days at 37°C. During 
the final five hours of incubation, tritiated thymidine (^H-thymidine) is added, which 
becomes incorporated into the DNA of proliferating cells. The DNA is harvested 
onto filter plates and radioactivity measured using a liquid scintillation counter. The 
amount of radioactivity detected is proportional to the number of proliferating cells, 
which corresponds with the number of antigen-specific lymphocytes.
The LPA is designed to measure the ability of lymphocytes to proliferate clonally in 
vitro, in response to mitogenic or specific antigenic stimulation. Antigen-specific T 
cell proliferation assays are used to assess the functional capacity of CD4'*' T cells to 
respond to their cognate antigen. The assay has been used in AIDS clinical trials in
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order to assess improvements in CD4^ T cell function following antiretroviral 
therapy; to measure the development of HIV-specific responses following the 
administration of HIV vaccines (Lederman et al., 1998), and to determine the 
immunopathogenesis of HIV infection (Rosenberg etal., 1997; Musey et al., 1999).
1.4.2 Cytokine Technologies
The analysis of cytokine production patterns is important in the elucidation of the 
immunopathogenesis of disease processes, and in the evaluation of novel 
immunotherapies and the monitoring of disease progress. Cytokine expression can 
be detected as mRNA using quantitative reverse transcriptase-polymerase chain 
reaction (qRT-PCR) techniques (Dean et al., 1998), or as secreted soluble proteins 
within body fluids using ELISA (Mateu de Antonio et al., 1998). However, the 
detection of expressed cytokines using sensitive and quantitative technologies, such 
as ELISpot assays and ICS using flow cytometry, is preferable. These highly 
sensitive assays detect cytokine expression at the single cell level and facilitate the 
quantification of antigen-specific cells.
1.4.2.1 Enzyme Linked Immunospot Assay
Specialised filter plates are coated overnight with cytokine-specific antibodies before 
being seeded with cells isolated from PBMC or lymphoid tissues. The cells are 
stimulated with antigen, in the form of peptide or whole protein, for up to twenty- 
four hours. Cytokine expression can be detected using a second specific monoclonal 
or polyclonal antibody labelled with biotin or directly labelled with enzyme. An 
additional streptavidin-enzyme conjugate step enhances sensitivity. Colour is 
developed using a substrate-chromogen mixture, which reveals spots of expressed 
cytokine on the plate. Spots can be counted manually or by using sophisticated 
image analysis equipment.
The ELISpot is a highly sensitive and quantitative assay designed to detect antigen- 
specificity at a single cell level; this technique is very useful for evaluating the 
quantity and quality of T cell responses induced by immunotherapies (Czerkinsky et 
al., 1983; Favre et al., 1997; Schmittel et al., 1997; Yang et al., 2000). It is also
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possible to dual-stain; thus, the simultaneous expression of two cytokines can be 
detected (Okamoto et al., 1998).
1.4.2.2 Intracellular Cytokine Staining
Target cells are cultured with their specific antigen in the form of peptides, proteins 
or MHC-tetramers, over a short time course of four to six hours. Protein transport 
inhibitors are present throughout the period of cell stimulation. Cells are stained 
with fluorochrome-labelled antibodies to cell surface molecules in order to identify 
specific cell populations, then fixed and permeabilised before staining with a 
cytokine-specific antibody labelled with a second fluorochrome. Two-colour flow 
cytometry is used to simultaneously detect cell surface molecules and intracellular 
cytokines. Antigen-specific cells can thus be identified and quantified.
The detection of intracellular cytokines has been facilitated through the identification 
of reagents such as brefeldin A (BFA) and monensin, which inhibit protein secretion 
and allow expressed cytokines to accumulate within the cell (Fujiwara et al., 1988; 
Nylander and Kalies, 1999). Intracellular cytokines are detected using 
fluorochrome-labelled cytokine-specific antibodies, and visualised using flow 
cytometry (Jung et al., 1993). This highly sensitive and antigen-specific technique 
permits the enumeration of individual antigen-specific cells and the characterisation 
of antigen-specific cell phenotype using antibodies to cell surface molecules.
1.4.2.3 Tetramer Staining
Knowledge of MHC and immunodominant epitopes is required to quantify antigen- 
specific cellular immune responses using tetramer technology, rendering these assays 
technically complex. T cells recognise antigen in the form of an MHC-peptide 
complex. An MHC-tetramer complex comprises four complexes of antigenic peptide 
molecules, (J2 microglobulin and a biotinylated MHC class I molecule, bound to 
fluorochrome-labelled streptavidin. This technology is currently being used to 
investigate virus-specific T cell responses in man and mouse to HIV, SIV, LCMV 
and Epstein-Barr virus (EBV), as well as to investigate immune responses in 
parasitic infections, cancer and autoimmune conditions (Gallimore et al., 1998;
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Kuroda et al., 1998; Wilson et al., 1998). The MHC tetramer staining technique is 
highly sensitive, antigen-specific, and can detect rare cells (McMichael and 
OCallaghan, 1998). Flow cytometry is used to detect T cell receptors (TCRs) that 
recognise and bind their cognate antigen. This technique can be used to identify and 
sort specific T cell populations, and to detect antigen-specific responses at single cell 
level. Alternatively, unconjugated bound tetramers can be detected using ELISpot 
assays (Kaul et al., 2000).
1.4.2.4 Summary
These assays vary in their sensitivity and technical requirements. The quantification 
of antigen-specific cells using tetramer technology is technically complex; the MHC 
must be defined and immunodominant epitopes characterised. Furthermore, the 
identification of non-functional populations of antigen-specific T cells in certain 
chronic disease states in mice and humans (Zajac et al., 1998a) imply that functional 
studies are also important. Lymphocyte proliferation assays are technically 
straightforward and reflect the functional ability of target cells. Peptides and whole 
proteins can be used in antigen-specific assays, and knowledge of the MHC is not 
required. Furthermore, specific anti-cytokine antibodies are not needed. However, 
these assays require a long period of in vitro restimulation of cells, are often subject 
to high background readings and are not quantitative at the single cell level. 
Intracellular cytokine staining using flow cytometry, and ELISpot assays, are rapid, 
highly sensitive antigen-specific assays that facilitate the enumeration of IFN-y 
expressing cells at the single cell level, without requiring MHC definition and 
knowledge of immunodominant epitopes.
1,5 Aims of Thesis
Feline leukaemia virus is a naturally occurring y-retrovirus of domestic cats
worldwide. Following exposure, most FeLV-naïve cats successfully eliminate the
virus and recover; however, a number of exposed cats become persistently viraemic
and die within two to three years from an FeLV-associated disease. Furthermore, an
unknown proportion of recovered cats retain a latent proviral infection within their
bone marrow cells. The immune mechanisms that determine the fate of the exposed
70
cats are unknown. Early studies showed that the elicitation of VNA correlated with 
recovery. However, more recently, the importance of virus-specific CTL in recovery 
from FeLV and in the protection of vaccinates has been described. Studies of murine 
and human retroviral infections illustrate that CTL are important in the elimination of 
virus and the elicitation of protective immune responses; inadequate CD8  ^ T cell 
function culminates in viral persistence. The importance of humoral immunity in the 
control of retroviral disease is controversial and may vary among individual viruses.
The aim of this thesis was to identify and compare FeLV-specific cell-mediated 
immune responses, particularly virus-specific CD4^ T cells, in recovered, latently 
infected, and persistently infected cats following experimental exposure to FeLV. 
CD4^ T cells have a critical role in regulating the humoral and cell-mediated arms of 
the immune response through the activation of DC and the elaboration of cytokines, 
particularly IFN-y. Failure of the CD4^ T cell response in HIV and FV infection has 
been shown to result in inadequate priming, maturation and maintenance of the CTL 
response. Sophisticated technologies identifying virus-specific CD4‘*‘ T cells were 
combined with highly sensitive assays to quantify viral burdens, in an attempt to 
correlate virus-specific immune responses with viral burdens in vivo.
To achieve these goals, a group of sixteen-week old SPF cats were exposed 
oronasally to a dose of infectious FeLV expected to result in fifty per cent recovery, 
and fifty per cent persistent infection. In addition, an unknown proportion of 
recovered cats were expected to retain a latent proviral infection. Peripheral blood 
was sampled at frequent intervals following exposure; bone marrow and lymphoid 
tissues were harvested post mortem. Virus-specific immune responses were 
evaluated in the peripheral blood and in the lymphoid tissues, using two techniques, 
the LPA, and ICS analysed using flow cytometry.
It was first necessary to develop reagents to measure fIFN-y. Anti-flFN-y antibodies 
were generated as tools to detect and quantify virus-specific cells using ICS analysed 
using flow cytometry. Intracellular fIFN-y expressed by virus-specific mononuclear 
cells in the peripheral blood and lymphoid tissues was detected using these novel 
anti-flFN-y antibodies; fIFN-y-expressing cells were simultaneously characterised
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using cell surface staining. Proliferative responses were measured using a liquid 
scintillation spectrophotometer to calculate the uptake of ^H-thymidine by cellular 
DNA. Cells in the peripheral blood, which significantly proliferate in response to 
specific virus-specific stimulation, were phenotyped using flow cytometry.
Second, the specificity of the immune response was determined by assessing the 
ability of mononuclear cells in the peripheral blood, and in the lymphoid tissues, to 
proliferate, and to express flFN-y, in response to specific stimulation with either 
recombinant p27or p45 proteins, or inactivated FeLV particles.
Finally, immunohistochemistry and immunofluorescence were used to identify FeLV 
CA protein p27 in the bone marrow and lymphoid tissues, harvested post mortem. 
The bone marrow and lymphoid tissues are important sites of viral replication and 
expression; consequently, these are important sources of FeLV-associated disease 
and act as foci for the antiviral immune response. The impact of active virus 
replication and expression in these tissues was assessed through the haematological 
and cytological analysis of peripheral blood and bone marrow samples, respectively, 
post mortem.
The contribution of humoral immunity in the immune response to FeLV was 
assessed by monitoring the development of VNA throughout the study, using a focus 
reduction assay.
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CHAPTER 2
GENERATION AND CHARACTERISATION OF 
MONOCLONAL AND POLYCLONAL ANTIBODIES TO 
FELINE INTERFERON  ^(HFN-y)
2.1 Introduction
The nature, specificity and efficacy of the immune response can be characterised 
using assays to detect IFN-y expression and secretion. Thus, the ELISA can detect 
soluble IFN-y in plasma or culture supernatants; and ELISpots, or ICS analysed 
using flow cytometry, can be used to enumerate cells that express and/or secrete 
IFN-y in response to mitogenic or antigenic stimuli. However, these techniques 
require specific and sensitive anti-IFN-y antibodies. To date, antibodies to bovine, 
canine, human and porcine IFN-y, amongst others, have been generated and 
characterised (Novick et aL, 1983; Wood et aL, 1990; Fuller et al., 1994; Mateu de 
Antonio et al., 1998). However, at the commencement of these studies, reagents to 
detect fIFN-y were not available.
It has recently been demonstrated that early FeLV Gag/Pro-specific CD8^ CTL 
effector responses are associated with recovery from experimental FeLV infection 
(Flynn et aL, 2002b). Furthermore, high levels of FeLV Gag-specific CTL were 
detected in the blood and lymphoid tissues from cats protected from FeLV challenge 
following inoculation with an FeLV DNA vaccine containing gag, pol and env genes 
(Flynn et al., 2000a; Hanlon et al., 2001). Therefore, the capacity of virus-specific 
CD4^ T cells to activate CD8^ T cells through the elaboration of cytokines such as 
IFN-y, could be a key factor in the control of viraemia (Rosenberg et al., 1997).
This chapter describes the generation and characterisation of monoclonal and 
polyclonal antibodies to fIFN-y as tools to investigate the evolution of the immune 
response in cats experimentally exposed to FeLV. The sensitivity of the generated 
antibodies was determined using an anti-flFN-y indirect ELISA and Western blots. 
In addition, these novel reagents were assessed for their ability to detect the 
upregulation of fIFN-y by specific feline T cell populations ex vivo, following co- 
culture with mitogen for four hours in the presence of protein secretion inhibitor 
BFA (Sigma-AIdrich Company Ltd, Dorset, U.K.). Feline IFN-y expression was 
evaluated using flow cytometry to simultaneously detect phycoerythrin (PE)-labelled 
surface markers and fluorescein isothiocyanate (FITC)-labelled intracellular fIFN-y.
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2.2. Materials and Methods
2.2.1 Production of Recombinant HFN-y
2.2.1.1 Expression offlFN-yGene
Th& flFN-y gene encodes a 167 amino-acid polypeptide with a predicted molecular 
weight of 19.6 kDa. The gene sequence shares seventy-eight per cent and sixty-three 
per cent homology with the human and murine genes respectively (Argyle et aL, 
1995). Human and murine gene sequences share only sixty per cent homology 
(Farrar and Schreiber, 1993). In humans and mice, the biologically active IFN-y 
molecule has been identified as a noncovalent homodimer, 34 kDa in size, formed 
from two 17 kDa polypeptides (Farrar and Schreiber, 1993; Boehm et aL, 1997).
The gene encoding flFN-y was cloned and sequenced in 1995 (Argyle et aL, 1995). 
The gene sequence was inserted into a glutathione S-transferase (GST) gene fusion 
vector (pGEX-4T-l, Amersham Biosciences U.K. Ltd, Buckinghamshire, U.K.) and 
expressed in bacterial cells (BL21(DE3), Stratagene Europe, Amsterdam, The 
Netherlands).
2.2.1.2 Preparation of the Bacterial Lysate
Forty ml L-broth medium\ containing ampicillin (0.2 mg/ml, Sigma-Aldrich, U.K.), 
was inoculated with bacterial expression vectors from glycerol stocks. The bacteria 
were grown overnight at 3>TC in an orbital incubator (Sanyo Gallenkamp PLC, 
Loughborough, U.K.) rotating at approximately 200rpm. The cultured cells were 
subsequently diluted by a factor of ten in fresh culture medium, and incubated further 
as above until the optical density reading at 600 nm (O.D.eoo) reached 0.6-0.8 
(‘Spectrophotometer DU® 640’, Beckman-Coulter Inc., California, U.S.). At this 
point, the bacterial vectors were induced to express the recombinant protein by 
adding 0.4 mM isopropylthio-j3-D-galactoside (IPTG, Gibco, Invitrogen Corporation, 
California, U.S.) to the culture medium for a final four-hour incubation.
* L-broth, pH 7.4: 3% (w/v) tryptone; 1.5% (w/v) yeast extract; 1.5% (w/v) NaCl
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Subsequently, the bacterial culture was transferred into a JA-10 rotor (Beckman- 
Coulter, U.S.), and centrifuged in a J2-21 centrifuge (Beckman-Coulter, U.S.) for 
fifteen minutes at 6000rpm. The supernatants were decanted and the cell pellets 
were either frozen at -20°C, or resuspended in 20 ml phosphate buffered saline^ 
(PBS), containing the protease inhibitors 4-(2-aminoethyl) benzenesulfonyl fluoride 
hydrochloride (0.2 mg/ml, AEBSF, Sigma-Aldrich, U.K.) and aprotinin (2 [ig/ml, 
Sigma-Aldrich, U.K.). The cells were then lysed by sonicating on ice for three, 
thirty-second cycles separated by intervals of one minute (‘Sonicator'^^ XL’, Heat 
Systems-Ultrasonics Inc., New York, U.S.), followed by shaking on ice in a solution 
of 1% Triton X-100 (BDH Laboratory Supplies, Poole, U.K.) for thirty minutes. To 
remove the insoluble debris, the bacterial lysate was transferred to a JA-20 rotor 
(Beckman-Coulter, U.S.), and centrifuged in a J2-21 centrifuge at SOOOrpm for 
fifteen minutes; the supernatant containing the recombinant protein was stored at - 
20°C until further use.
2.2.1.3 Affinity Chromatography
The recombinant flFN-y protein was purified from the bacterial lysate using affinity 
chromatography. Glutathione coupled to Sepharose 4B via a 10-carbon linker arm 
can be used for the purification of fusion proteins containing the carboxyl terminus 
of GST. Glutathione sepharose 4B slurry (1.33 ml of 75% solution, Amersham 
Biosciences, U.K.) was added to an empty polypropylene column (Amersham 
Biosciences, U.K.). The column was centrifuged at SOOrpm for three minutes using a 
bench-top centrifuge (Beckman-Coulter GS-6 centrifuge, U.S.) to sediment the 
slurry, which was then washed twice using 5 ml cold PBS. One ml PBS was then 
added to provide a 50% slurry.
Five ml of bacterial lysate containing the GST fusion protein was added to the slurry. 
The mixture was agitated at room temperature (RT) for thirty minutes, before 
centrifugation and the addition of a further 5 ml lysate. This was continued until all 
the bacterial lysate had been added to the column. The column was then washed five
 ^ PBS, pH 7.2: lOx concentrated: 8% (w/v) NaCl; 0.2% (w/v) KCl; 1.15% (w/v) Na2HP0 4 ; 0.2% 
(w/v) KH2PO4
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times with 5 ml PBS using centrifugation as described above. Subsequently, 25 units 
of thrombin protease (Amersham Biosciences, U.K.) in PBS was added to the 
column in order to cleave the recombinant protein from the glutathione sepharose 
gel. The column was shaken gently overnight at RT; the eluted protein within the 
supernatant was then decanted following sedimentation of the gel matrix. The 
protein was subsequently electrophoresed on a 12% polyacrylamide gel (SDS- 
PAGE), and stained using Coomassie Brilliant Blue R250 to assess the purity of the 
eluted protein (Sections 2.2.1.4 and 2.2.1.5). The recombinant protein was 
quantified using the BCA protein assay (Perbio Science U.K. Ltd., Cheshire, U.K.), 
and then frozen in aliquots at -20°C.
2.2.1,4 Detection o f Recombinant Proteins using SDS-PAGE
This method is based on the original description of polyacrylamide gels containing 
sodium dodecyl sulphate (SDS) in gel electrophoresis (Laemmli, 1970). A 12% 
polyacrylamide separating gel^ was prepared and cast in a vertical slab gel system 
(‘Mini-protean IP, Bio-Rad Laboratories, Hemel Hempstead, Hertfordshire, U.K.). 
A 5% stacking g ef was layered above the separating gel. The recombinant protein 
was diluted 1:1 in SDS loading dye^, containing bromophenol blue. Ten \xl of each 
sample was placed in the sample wells prepared in the stacking gel. Prestained 
standard samples comprising proteins of known molecular weights were used as size 
markers (Precision protein standards, Bio-Rad, U.K.). The gel was run in a tris- 
glycine running buffer‘d at 200 volts for approximately thirty minutes, or until the dye 
front reached the bottom of the gel. The gels were either stained with Coomassie 
Brilliant Blue R250, or transferred electrophoretically onto nitrocellulose, as 
described below.
 ^ 12% separating gel: 32.6% (v/v) dH^O; 12 % (v/v) acrylamide mix; 25.3% (v/v) 1.5 M tris, pH 8.8; 
0.1% (w/v) SDS; 0.1% (w/v) ammonium persulphate; 0.026% (v/v) TEMED
5% stacking gel: 67.5% (v/v) dHiO; 5% acrylamide mix (v/v); 12.5% (v/v) 1 M tris, pH 6.8; 0.1% 
(w/v) SDS; 0.1% (w/v) ammonium persulphate; 0.1% (v/v) TEMED
 ^SDS-Ioading dye (2x): 4% (w/v) SDS; 20% (v/v) glycerol; 12% (v/v) 1 M tris, pH 6.8; 28% (v/v) 
dHzO; 0.01% (w/v) bromophenol blue
® Running buffer: 25 mM (w/v) tris; 250 mM (w/v) glycine; 0.1% (w/v) SDS in dHaO
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2.2,1.5 Coomassie Brilliant Blue Staining o f SDS-PAGE Gels
The SDS-PAGE gel was immersed in a Coomassie Brilliant Blue solution^ for a 
minimum of four to sixteen hours. The gel was subsequently destained by soaking in 
a methanol-acetic acid solution® on a slowly rotating platform for four to eight hours. 
During this time, the destaining solution was changed several times. After 
destaining, the gels were immersed in distilled water and dried using a gel drier 
(‘Easy Breeze Gel Dryer’, Hoefer Scientific Instruments, San Francisco, U.S.). The 
gel image was recorded using a scanner (TmageScamier’, Amersham Biosciences, 
U.K.) and the software package ‘LabScan’ (Amersham Biosciences, U.K.).
2.2.2 Generation of Anti-flFN-y Antibodies
2.2.2.1 Animal Inoculations
Immunisation of mice and sheep was carried out by Diagnostics Scotland 
(Edinburgh, U.K.). Three female Balb/c mice were inoculated with 20 jxg of 
recombinant protein flFN-y in complete Freund's adjuvant. Each mouse received a 
total volume of 200 \xl, injected in equal volumes at two separate intraperitoneal (IP) 
sites. Two booster injections, each containing 10 pig recombinant protein in 100 pil 
incomplete Freund’s adjuvant, were given at twenty-eight day intervals. Seven days 
after the second booster, sera were recovered and the antibody titres measured by 
ELISA (Section 2.2.2.S). After a further eight days, the mice received a final 
intravenous (IV) booster inoculation of 10 pig fIFN-y in 100 pil PBS; their spleens 
were harvested four days later.
Polyclonal antiserum to fIFN-y was prepared by the inoculation of a sheep 
subcutaneously (SC) and intramuscularly (IM) with 200 pig BFN-y in complete 
Freund’s adjuvant, in a total volume of 5 ml. Three booster inoculations of 200 pig 
fIFN-y in 5 ml incomplete Freund’s adjuvant were given SC and IM at four-week
 ^ Coomassie Brilliant Blue solution: 0.05% (w/v) Coomassie Brilliant Blue R250 in 50% (v/v) 
methanol; 40% (v/v) dH20; 10% (v/v) glacial acetic acid
 ^Destain solution: 45% (v/v) methanol; 45% (v/v) dH20; 10% (v/v) glacial acetic acid
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intervals; serum was harvested seven days after each booster injection. Antibody 
titres were determined by ELISA (Section 2.2.2.5).
2.2.22 Generation o f Murine Anti-JIFN-y Monoclonal Antibodies
Harvested spleen cells were fused with mouse myeloma cells according to the 
method originally described by Kohler and Milstein (1975). The NSO myeloma cells 
were grown in RPMI 1640 medium supplemented with 10% heat-inactivated PCS; 
100 U/ml penicillin; 10 pig/ml streptomycin and 2 mM glutamine (complete RPMI 
1640 medium; GibcoBRL, Paisley, U.K.), supplemented with 5x10^ M 2- 
mercaptoethanol (ME, Gibco, U.K.). Adherent NSO cells in the log phase of growth 
were harvested using 0.02% EDTA (Sigma-Aldrich, U.K.) in complete RPMI 1640 
medium, and used in the production of the hybridomas.
The murine spleens were gently teased using sterile instruments in a microbiological 
safety cabinet (‘BioMat’, Medical Air Technology, Manchester, U.K.), to generate 
single cell suspensions. Murine splenic lymphocytes (5.3 x 10^) were collected over 
Ficoll-Paque (Amersham Biosciences, U.K.), washed and resuspended in complete 
RPMI 1640 medium, containing ME. The murine lymphocytes were then added to 
NSO cells in a 2:1 ratio, and pelleted by centrifugation in a benchtop centrifuge at 
1200rpm for five minutes. One ml PEG-1500 (polyethylene glycol-1500, BDH, 
U.K.), heated to 37°C, was added drop-wise to the cell pellet over thirty seconds. 
The mixture was then gently agitated for five minutes in a water bath (Grant 
Instruments Ltd., Cambridge, U.K.), which had been pre-heated to 37°C. 
Subsequently, 5 ml complete RPMI 1640 medium containing ME, was added drop- 
wise to the cell pellet over ninety seconds, followed immediately by a further 20 ml. 
The fused cells were pelleted and resuspended in complete RPMI 1640 containing 
ME. Each well of 96-well U-bottom culture plates (Becton Dickinson Labware 
Europe, Le Pont de Claix, France) was seeded with 1x10^ fused cells in a final 
volume of 200 |il complete RPMI 1640 medium supplemented with ME and HAT 
medium (5 mM sodium hypoxanthine, 20 p,M aminopterin and 0.8 mM thymidine, 
Gibco, U.K.). A total of nine plates were set up, placed in polythene bags and 
incubated at 37°C in a humidified atmosphere containing 5% CO2 . After fourteen
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days, supernatants from visible cell colonies were collected and screened for the 
presence of anti-flFN-y antibodies using ELISA, as described in Section 2.2.2.5. 
Hybridomas secreting the highest levels of detectable mAbs were cloned by limiting 
dilution in 96-well plates at dilutions of 0.3, 3 and 10 cells/well. After two further 
subclonings, positive clones were finally transferred into compartmentalised flasks 
for expansion in vitro (‘Cl-1000’, Integra Biosciences Ltd, Hertfordshire, U.K.).
2.2,23 Affinity Purification o f Anti-flFN-yAntibodies
Monoclonal antibodies were affinity purified using a 1 ml protein G affinity column 
(‘HiTrap’ protein G affinity column, Amersham Biosciences, U.K.). Protein G, a 
cell surface protein of Group G streptococci, is a type III Fc receptor that binds to the 
Fc region of IgG by a non-immune mechanism.
The column was equilibrated with ten column volumes of binding buffer^, applied 
using a peristaltic pump (‘P-1’, Amersham Biosciences, U.K.). Culture supernatant 
containing the mAbs was passed through a 0.45 jrm filter (Sartorius Ltd., Surrey, 
U.K.), and pumped through the column at a rate of approximately 1 ml per minute. 
The column was subsequently washed with ten column volumes of binding buffer; 
the purified fractions were then eluted using an elution buffer^^. The pH of the 
eluted fractions was adjusted immediately to pH 7.0 using 1 M tris-HCl buffer, pH 
9.0. The fractions were tested by ELISA to ensure sensitivity (Section 2.2.2.5); 
positive fractions were then pooled into a glass universal container. To precipitate 
antibody from the eluted fractions, an equal volume of saturated ammonium sulphate 
(Sigma-Aldrich, U.K.) was added, and the solution placed at 4°C for one hour. To 
collect the precipitated mAbs, the solution was placed in a JA-20 rotor and 
centrifuged at 10,000rpm for thirty minutes. Monoclonal antibodies were then 
transferred to a storage buffer^^ using a PD-10 column containing sephadex G-25 
medium (Amersham Biosciences, U.K.). The PD-10 column was equilibrated using
® Binding buffer, pH 7.0: 20 mM (w/v) sodium phosphate 
Elution buffer, pH 2.7: 0.1 M (w/v) glycine-HCl 
Storage buffer, pH 7.0: 0.05 M (w/v) Na2HP0 4 ; 0.1% (w/v) NaNa
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25 ml equilibration buffer^^. Next, 2.5 ml of purified antibody in PBS was loaded 
onto the column and allowed to run through. 3.5 ml of storage buffer was then added 
to the column. This final run-through, which contained the purified mAb in storage 
buffer, was collected, quantified using a spectrophotometer, and tested for sensitivity 
using ELISA (Section 2.2.2.5) and Western blots (Section 2.2.2.6).
Polyclonal antiserum was affinity purified using a 1 ml N-hydroxysuccinimide 
(NHS)-activated affinity column (‘HiTrap’ NHS-activated affinity column, 
Amersham Biosciences, U.K.), coated with recombinant flFN-y. To coat the 
column, the recombinant protein flFN-y was transferred into coupling buffer^^ using 
a PD-10 column as described above, and used at a concentration of approximately 1 
mg/ml. The coupling buffer containing the protein was then injected onto the 
column using a syringe, and recirculated back and forth across the column for 
approximately thirty minutes per mg of protein. Affinity columns were coated with 
up to 4 mg of flFN-y. The column was then washed a total of six times with 
alternate solutions of 3 x 2 ml Buffer A^“^ and 3 x 2 ml Buffer B^  ^ to eliminate non- 
specifically bound ligands, and to inactivate excess NHS active groups. The column 
was then equilibrated with 5 ml start buffer^^ using a peristaltic pump, after which 
the polyclonal antiserum was applied to the column. The column was washed with 
10-15 ml start buffer and the purified fractions eluted using an elution buffer^^. The 
pH of the eluted fractions was adjusted to pH 7.0 using IN  NaOH. Positive fractions 
were detected using an ELISA (Section 2.2.2.S), before transfer into a storage buffer 
using a PD-10 column, as described above.
PD-10 equilibration buffer, pH 7.0: 0.1 M (w/v) NaH2? 0 4 ; 0.15 M (w/v) NaCl
Coupling buffer, pH 8.3: 0.2 M (w/v) NaHCO^; 0.5 M (w/v) NaCl
Buffer A, pH 8.3: 0.5 M (w/v) ethanolamine; 0.5 M (w/v) NaCl
Buffer B, pH 4.0: 0.1 M (w/v) acetate, 0.5 M (w/v) NaCl
Start buffer, pH 9.4: 0.1% (v/v) tween-20 in TBS
Elution buffer (pAb), pH 2.5: 0.1 M (w/v) glycine; 0.15 M (w/v) NaCl
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2.2.2 A  Isotyping of Murine Anti- fIFN-y Antibodies
Antibody isotyping was performed using a commercially available kit (‘Sigma 
Immunotype Kit’ Sigma-Aldrich, U.K.). All reagents used to isotype the mAb were 
provided in the kit. The precoated nitrocellulose strip captured Ig within the 
hybridoma supernatant following a thirty-minute incubation. The strip was washed 
in PBS, containing 0.05% tween-20 (BDH, U.K.), and 1% bovine serum albumin 
(BSA, Sigma-Aldrich, U.K.) for five minutes, before a thirty-minute incubation with 
biotinylated anti-mouse Ig pAb. After a single wash in PBS-T-BSA, ‘ExtrAvidin- 
peroxidase’ was added for a fifteen-minute incubation. Colour was developed after 
the final washing step using the chromogen 3-amino-9-ethyl-carbazole (AEG), and 
substrate hydrogen peroxide (H2O2 ).
2.2.2.5 Detection o f Anti-flFN-y Antibodies using ELISA
The wells of 96-well high-binding plates (Greiner Laboratechnik Ltd., 
Gloucestershire, U.K.) were coated overnight at RT with 100 ng recombinant flEN-y 
in 100 \i\ coupling buffer^® per well. The plates were washed three times with tris 
buffered saline^^ (TBS) containing 0.05% tween-20 (TBS-T); any unreacted sites 
were subsequently blocked by incubation for thirty minutes at RT with 2% dried 
skimmed milk powder (‘Marvel’, Premier Brands U.K. Ltd, Merseyside, U.K.) in 
TBS-T. After three washes in TBS-T, 100 p,l of culture supernatant was added to 
each well and incubated for two hours at RT. After a further six washes in TBS-T, 
the wells were incubated with alkaline phosphatase (AP)-conjugated goat anti-mouse 
Ig pAb (Bio-Rad Laboratories, U.K.) diluted 1:1000 in TBS-T, for one hour at RT. 
Bound antibodies were visualised using p-nitrophenyl phosphate disodium tablets 
(‘Sigma 104^’, Sigma-Aldrich, U.K.), dissolved in AP buffer^^. Absorbance was 
read at 405 nm after incubating for one hour in the dark (‘Labsystems Multiskan 
Ascent’, Process Analysis and Automation Ltd, Hampshire, U.K.). The same 
protocol was used when titrating the mAb, except that doubling dilutions of purified
18
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ELISA coupling buffer: 100 mM (w/v) NaHCOs; 1 mM (w/v) EGTA
TBS, pH 7.8: lOx concentrated: 6.06% (w/v) tris and 9% (w/v) NaCl
AP buffer, pH 9.5; 100 mM (w/v) NaCl; 100 mM (w/v) diethanolamine; 5 mM (w/v) MgCL
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mAb were made in 20% normal goat serum (NGS, Diagnostics Scotland, U.K.). 
Normal mouse serum (NMS), diluted in the same way as the primary mAb, was used 
to determine the end point of the ELISA.
To detect sheep pAbs, unreacted sites on the ELISA plates were blocked for thirty 
minutes with 200 \xl 20% normal rabbit serum (NRS, Diagnostics Scotland, U.K.) in 
TBS-T. Polyclonal antibodies were diluted in 20% NRS and an AP-conjugated 
rabbit anti-sheep Ig pAb (Southern Biotechnology Associates, Inc., Alabama, U.S.), 
diluted 1:2000 in 20% NRS in TBS-T, was used to detect bound sheep antibodies. 
Normal goat serum, diluted in the same way as the primary pAb, was used to 
determine the end point of the ELISA.
22.2.6 Detection o f Anti-flFN-y Antibodies using Western Blots
The transfer of proteins from a polyacrylamide gel onto nitrocellulose was originally 
described by Towbin et al. (1979). The prepared gel (Section 2.2.1.4) was blotted 
onto a nitrocellulose membrane (Bio-Rad Laboratories, U.K.) using a semi-dry 
technique (‘Trans-Blot Semi-Dry Transfer Cell’, Bio-Rad Laboratories, U.K.). The 
gel was placed over the nitrocellulose membrane and between four sheets of blotting 
paper (Sigma-Aldrich, U.K.), which had been pre-soaked in transfer buffer^\ Fifteen 
volts of electricity was applied for forty-five minutes. The membrane was then 
transferred to 4% Marvel in TBS-T overnight to block any unreacted sites, or dried 
and stored at 4°C.
The nitrocellulose membrane was cut longitudinally into strips and inserted into the 
wells of a blotting trough. All washes were conducted in duplicate at five-minute 
intervals using TBS-T, and all incubations proceeded at RT on a slowly rotating 
platform. Monoclonal and polyclonal antibodies were diluted in 20% NGS and 20% 
NRS in TBS-T, respectively; subsequent reagents were diluted similarly. Two 
hundred p,l of diluted antibody solution was added to each well and incubated for two 
hours. Alternatively, the blots were probed with NMS (mAb) or NGS (pAb), which 
acted as negative controls. The blots were then washed, and incubated with AP-
Transfer buffer: 25 mM (w/v) tris; 0.2 M (w/v) glycine; 20% (v/v) methanol
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conjugated goat anti-mouse Ig pAb, or AP-conjugated rabbit anti-sheep Ig pAb, 
diluted 1:1000 and 1:2000, respectively, for one hour at RT. Following three further 
washes, bound antibodies were visualised using Fast 5-bromo-4-chloro-3-indoyl 
phosphate/nitro blue tétrazolium tablets (BCIP/NBT AP substrate, Sigma-Aldrich, 
U.K.), dissolved in 10 ml distilled water. The blots were rinsed with distilled water 
and dried overnight. The images were subsequently recorded as previously 
described (Section 2.2.1.5).
2.2.2.7 FITC Conjugation o f Anti-JIFN-y Antibodies
Prior to coupling, mouse and sheep antibodies were first transferred into 0.5 M 
carbonate buffer^^ by overnight dialysis, using either conventional dialysis tubing 
(Sigma-Aldrich, U.K.), or dialysis cassettes (Perbio Science, U.K.). A FITC (Sigma- 
Aldrich, U.K.)-dimethyIsuIphoxide (DMSO, Sigma-Aldrich, U.K.) solution was 
prepared (1 mg/ml), added to antibody (45 p-g/mg) and the solution stirred for one 
hour at RT in the dark. Unconjugated FITC was removed using a PD-10 column 
equilibrated using PBS (Section 2.2.2.3); FITC-conjugated antibody was collected in 
PBS and stored at 4°C in the dark until used in the assays.
2.2.2.8 Intracellular Cytokine Staining and Analysis using Flow Cytometry
Each well of a 24-well tissue culture plate (Costar U.K. Ltd., Buckinghamshire, 
U.K.) was coated with 500-1000 pi of complete RPMI 1640 medium containing Con 
A (Sigma-Aldrich, U.K.); Con A is a lectin, which exhibits non-specific mitogenic 
activity with lymphocytes (Ruscetti and Chervenick, 1975). The plates were 
incubated overnight at 37°C in a humidified atmosphere containing 5% CO2 . This 
was done to ensure that the medium was at the correct pH and temperature before the 
addition of cells. The amount of mitogen added was calculated so a concentration of 
5 pg Con A ! \ ( f  cells would be obtained following the addition of cells. Wells that 
did not contain mitogen acted as negative controls.
Expression of intracellular fIFN-y was evaluated in mononuclear cells prepared from
Carbonate buffer, pH 9.5: 0.16 M (w/v) Na^COa, 0.33 M (w/v) NaHCOg
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the peripheral blood from SPF cats. Cryopreserved PBMC and lymphoid tissue 
samples were also available from a previous FeLV immunopathogenesis study 
(Flynn et aL, 2002b). All cats described were housed in groups in custom-built 
accommodation at the University of Glasgow. The cats were fed proprietary cat food 
twice daily, and had access to water ad libitum in accordance with Home Office 
guidelines. Whole blood samples from SPF cats were collected in a 1:1 ratio with 
Alsevers’ solution (Diagnostics Scotland, U.K.). The blood-Alsevers’ solution was 
gently layered over an equivalent volume of Ficoll-Paque, and centrifuged at 
ISOOrpm for fifteen minutes. Peripheral blood mononuclear cells were removed 
from the interface and washed in complete RPMI 1640 medium. Once thawed, 
cryopreserved cells were purified on a Ficoll-Paque gradient and washed before use 
in this assay.
Cells were resuspended in complete RPMI 1640 medium (2 x 10  ^ cells/ml) and 
added to the pre-incubated plates to give a final concentration of 1 x 10  ^cells/ml in a 
total volume of 1-2 ml/well. The plated cells were subsequently incubated for two or 
four hours at 37°C in a humidified atmosphere containing 5% CO2 . Brefeldin A (10 
p.g/10^ cells) was present in all wells throughout the period of stimulation. Brefeldin 
A is a fungal metabolite that specifically and reversibly blocks protein transport from 
the ER to the Golgi apparatus in many cell types and species (Fujiwara et aL, 1988). 
In this way, BFA interferes with the transport of IFN-y from the ER, allowing any 
expressed protein to accumulate within the cell to levels sufficient for detection 
(Nylander and Kalies, 1999).
Subsequent to the in vitro period of stimulation, the cells were aspirated, placed into 
polypropylene tubes (0.5-1 x 10  ^cells/tube, Falcon 2054, Becton Dickinson, France) 
and pelleted by centrifugation for five minutes at lOOOrpm in a bench-top centrifuge. 
Following a five-minute wash using PBS, the cell pellets were stained with a PE- 
labelled mAb to the cell surface molecule feline CD4 (2.5 p,g/10^cells, Southern 
Biotechnology, U.S.), at RT for thirty minutes in the dark. After two further washes 
in PBS, the cells were fixed with 2% formaldehyde (Sigma-Aldrich, U.K.) in PBS 
for twenty minutes at RT. After washing in PBS, the cells were permeabilised using
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1% saponin (Sigma-Aldrich, U.K.) in fluorescence buffer^^. The cells were 
subsequently incubated for thirty minutes at RT in the dark with the anti-flFN-y- 
FITC mAb (1-2 p.g/10  ^ cells) or an isotype-matched control mAb against T-2 
mycotoxin (2 p-g/lO  ^ cells, Southern Biotechnology, U.S.), Alternatively, the cells 
were stained with the sheep anti-flFN-y-FITC pAb (2 jig/10^ cells), while control 
cells remained unstained. The cells were washed twice in permeabilisation buffer, 
and once in fluorescence buffer, before storage in fluorescence buffer at 4°C. Cells 
were then analysed on a flow cytometer (‘EPICS XL-MCL™’, Beckman-Coulter, 
U.S.) using ‘Expo 32 ADC’ software (Beckman-Coulter, U.S.). For each sample, 
10,000 events were recorded. The small lymphocyte and the lymphoblast 
populations were gated based on cell size and granularity, and the percentage of 
fIFN-y-expressing CD4^ T cells within the lymphoblast population was enumerated. 
The gates for fIFN-y expression were determined by the reactivity of the FITC- 
conjugated isotype control mAb.
2.22.9 Immunohistochemical Detection of flFN -y Expressing Cells
Peripheral lymph node tissues from FeLV-recovered cats were harvested post 
mortem (Flynn et aL, 2002b), embedded in tissue freezing medium (‘O.C.T.’, Leica 
Instruments, Nussloch, Germany), then immediately snap frozen in liquid nitrogen 
and stored at -70°C. Cryostat sections of PLN tissues were prepared by the 
Histopathology Laboratory, Department of Veterinary Pathology, University of 
Glasgow. Air-dried sections were fixed in ice-cold acetone for ten minutes before 
being wrapped in ‘Parafilm’ (BDH, U.K.) and aluminium foil, and stored at -70°C.
Frozen slides were brought to RT while still wrapped in ‘Parafilm’. All incubations 
were carried out at RT in a humidified chamber and were followed by two, five- 
minute washes in TBS to remove unbound reagents. Sections were encircled using a 
hydrophobic marker pen to minimise reagent wastage (‘Pap pen’, Sigma-Aldrich, 
U.K.), and gently agitated in TBS for five minutes. The sections were initially 
incubated with 0.3% H2O2 (BDH, U.K.), and 0.1% NaNg (BDH, U.K.), in TBS for 
twenty minutes, to block endogenous peroxidase activity. To minimise non-specific
Fluorescence buffer: 1 mM (w/v) NaN ;^ 0.5% (w/v) BSA in PBS
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binding, sections were incubated for twenty minutes with 10% NRS. Excess serum 
was shaken from the sections, which were subsequently incubated with the sheep 
anti-fTFN-y pAb, diluted 1:5 in 1% NRS in TBS, for one hour. The secondary 
reagent, biotinylated rabbit anti-sheep Ig pAb (Southern Biotechnology, U.S.), was 
diluted 1:1000 in TBS containing 1% NRS, and added to the sections for thirty 
minutes. A final thirty-minute incubation with streptavidin-peroxidase (Diagnostics 
Scotland, U.K.), diluted 1:500 in TBS, preceded the development of colour using a 
diaminobenzidine (DAB) kit (Vector Laboratories, Ltd., Peterborough, U.K.). The 
slides were washed in running tap water, counterstained using Gills’ haematoxylin 
(BDH, U.K.); then dehydrated in graded alcohols, cleared (‘Histoclear’, National 
Diagnostics, Georgia, U.S.), and mounted in DPX (BDH, U.K.). Negative control 
slides were prepared; in these slides, the primary mAb was omitted and replaced with 
10% NRS.
2.3. Results
2.3.1 Production of Recombinant flFN-y
Approximately 1 mg recombinant fIFN-y was purified per 400 ml bacterial culture. 
The protein was electrophoresed on a 12% SDS-PAGE to assess the purity of the 
recombinant protein. Two distinctive bands, 15-25 kDa in size, were evident on the 
Coomassie Blue-stained gel, illustrating two fIFN-y polypeptides. A considerably 
fainter pair of bands, approximately 25-37 kDa in size, may represent the 
homodimeric proteins (Fig. 2.1, lane B).
2.3.2 Generation of Anti-flFN-y Antibodies
2.3.2.1 Generation o f Murine Anti-flFN-y Antibodies
Two hundred and sixty-five hybridomas were visible microscopically at twenty-one 
days post fusion, out of five hundred and twenty wells seeded. Subsequently, ELISA 
screening revealed that thirty-one were secreting anti-flFN-y mAbs. The five 
hybridoma cells secreting the highest levels of anti-flFN-y antibodies were selected
86
for cloning and subcloning. Two hybridoma clones were then selected for further 
expansion and affinity purification. The selected hybrids, 5B5.C5.D9 (D9) and 
2C7.B7.B3 (B3), originated from different primary clones and proliferated well in 
tissue culture. Both clones were shown to secrete IgGl antibodies using the 
commercial isotyping kit. The experiments described in this thesis are based on the 
D9 mAb.
23.2.2 Titration o f Anti-flFN-y Antibodies using ELISA
The sensitivity of the affinity purified D9 mAb and sheep anti-flFN-y pAb, and their 
respective FITC conjugates, in the detection of recombinant fIFN-y, were determined 
using fIFN-y specific ELISA assays. The antibodies were titrated against 
recombinant fIFN-y in an indirect ELISA. The affinity purified sheep anti-flFN-y 
pAb detected 100 ng fIFN-y at a titre of 1:1638400 (Fig. 2.2.A), while its conjugate 
recorded a titre of 1:819200. The D9 mAb demonstrated lower titres in ELISA, 
1:5120 (Fig. 2.2.B); these values were largely unaffected by conjugation with FITC.
2.3.2.3 Detection o f Anti-flFN-y Antibodies using Western Blots
Western blots provide an additional means of assessing antibody sensitivity. The 
recombinant protein fIFN-y characteristically displays polypeptide bands, 15-25 kDa 
in size, in Coomassie Brilliant Blue-stained SDS-PAGE gels (Fig. 2.1, lane B). 
These distinctive double bands were again in evidence when nitrocellulose-blotted 
fIFN-y was probed with the D9 mAb and sheep anti-flFN-y pAb, generated in this 
study (Fig. 2.1, lanes C and E). The sheep anti-flFN-y pAb detected 14 [ig fIFN-y 
diluted to a factor of 1:100,000 (Fig. 2.1, lane E); the D9 mAb detected 14 |ig flFN- 
y diluted 1:1000 (Fig. 2.1, lane C). No specific staining was visible on the negative 
control blots (Fig. 2.1, lanes D and F).
2.3.2.4 Detection o f fIFN-y using ICS and Flow Cytometry
Both the D9 mAb and the sheep anti-flFN-y pAb were assessed for their ability to
detect the production of fIFN-y by CD4^ T cell populations using ICS, analysed by
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flow cytometry.
Mononuclear cells prepared from the peripheral blood from an SPF cat and the 
lymphoid tissues from an FeLV recovered cat were co-cultured with the mitogen 
Con A for four hours in the presence of BFA. Production of flFN-y was compared in 
unstimulated and stimulated cells using flow cytometry. Both the D9-FITC mAb and 
sheep anti-flFN-Y-FITC pAb detected a surge in flFN-y production by Con A- 
stimulated lymphoblasts within the PLN tissues from an FeLV recovered cat and the 
peripheral blood from an SPF cat respectively, compared to unstimulated cells (Fig. 
2.3).
To determine an optimal duration of mitogenic stimulation, the sheep anti-flFN-y- 
FITC pAb was used to detect flFN-y expression in CD4^ lymphoblast cells from an 
SPF cat, following either a two or four-hour in vitro stimulation with Con A in the 
presence of BFA. Mitogenic stimulation for four hours yielded maximal flFN-y 
production (1.8%), compared to two hours (0.8%) (Fig. 2.4).
The ability of the D9-FITC mAb to detect flFN-y expression by CD4’*' T cells? was 
assessed ICS, analysed using flow cytometry. Mononuclear cells in the peripheral 
blood from an SPF cat were stimulated for four hours with Con A in the presence of 
BFA, dual-stained with anti-fCD4-PE mAb and D9-FITC mAb and analysed using 
flow cytometry. The D9-FITC mAb detected fIFN-y at higher levels in Con A- 
stimulated CD4^ T cells (4.7%), compared to unstimulated cells (0.7%); no double 
staining was detected using a FITC-labelled isotype-matched control mAb (Fig. 2.5). 
The D9-FITC mAb was also used to detect fIFN-y production in the PLN tissues 
from an FeLV recovered cat following mitogenic stimulation. Increased flFN-y 
production was detected in CD4^ T cells stimulated for four hours (5.8%), compared 
to unstimulated cells (2.1%) (Fig. 2.6).
In each stimulation assay, feline mononuclear cells were cultured with the mitogen 
Con A in the presence of BFA. Brefeldin A was not observed to interfere with CD4 
expression; in a separate experiment, CD4 expression was not affected by the 
presence of BFA during a four-hour stimulation with Con A (Fig. 2.7).
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23.2.5 Immunohistochemical Detection o f flF N -y Expressing Cells
The sheep anti-flFN-y pAb was used to detect fIFN-y expression in the PLN tissues 
from an FeLV recovered cat. Cryostat sections were prepared from PLN tissues 
harvested post mortem, and probed for fIFN-y in an immunoperoxidase technique. 
The results are presented in Fig. 2.8. Negative control slides did not demonstrate any 
specific staining.
Positive fIFN-y expressing cells were distinctly concentrated in clusters at the 
cortico-medullary junction (Fig. 2.8.A and B). Only a few scattered individual cells 
were found within the lymph node cortex, and virtually no fIFN-y expressing cells 
were associated with the lymph node follicles. Conversely, many positive cells were 
found within the medullary zone. Here, fIFN-y expressing cells were widely 
distributed; some positive cells were also evident within the efferent lymphatic 
vessels (Fig. 2.8.C). It was not possible to characterise the fIFN-y expressing cells 
based on morphological appearance alone. To achieve this, it would be necessary to 
conduct double immunoenzyme staining techniques.
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2,4 Discussion
In this thesis, the evolution of the virus-specific cellular immune response was 
characterised following the experimental exposure of cats E1-E12 cxto FeLV. 
Virus-specific CD4^ and CD8^ T cells were enumerated ex vivo using ICS, analysed 
by flow cytometry, to detect flFN-y expression. However, due to a lack of reagents 
to detect flFN-y at the commencement of these studies, it was necessary to raise 
murine monoclonal and sheep polyclonal antibodies to recombinant flFN-y.
Intracellular cytokine staining, analysed using flow cytometry, is a highly sensitive 
technique used to detect cytokine expression at the single cell level (Jung et al., 
1993; Pitcher et al., 1999). In this chapter, this technique was used to demonstrate 
flFN-y expression by mononuclear cells following a four-hour mitogenic stimulation 
with Con A in the presence of BFA. In cats, the mitogenic activity of Con A is 
principally directed towards T, rather than B, cells (J.N. Flynn, personal 
communication); stimulation of feline PBMC for three days with Con A in the LPA 
resulted in a reduction of CD21 expression, whereas CD4 and CD8 expression were 
markedly upregulated (Chapter 4). Downregulation of CD4 expression has been 
observed to occur following stimulation of murine and rat splenic lymphocytes with 
the mitogens phorbol 12-myristate 13-acetate (PMA) and ionomycin (Nylander and 
Kalies, 1999; Caraher et al., 2000), independently of BFA (Nylander and Kalies, 
1999). In this thesis. Con A was observed to upregulate CD4 expression in both 
small lymphocyte and lymphoblast populations in the peripheral blood and PEN 
tissues, even after a short four-hour incubation with mitogen (Figs. 2.4-2.6). 
Concanavalin A mediates its activity through terminal sugar residues contained 
within cell surface MHC-antigen complexes (Kimura and Ersson, 1981). Brefeldin 
A has been reported to block the export of, and antigen presentation by, MHC class I 
and II molecules (Yewdell and Bennick, 1989; St.Pierre and Watts, 1990). In this 
thesis. Con A exhibited mitogenic activity in the presence of BFA (Figs. 2.3-2.6), 
suggesting that sufficient MHC complexes were present.
In human, murine and rat studies, short four-to-eight hour mitogenic and antigenic 
stimulations have been described for the detection of IFN-y expression (Jung et al.,
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1993; Nylander and Kalies, 1999; Pitcher et al., 1999; Appay et al., 2000; Caraher et 
al., 2000). In this thesis, flFN-y expression by CD4^ T cells was detectable after two 
hours of mitogenic stimulation (Fig. 2.4), and had increased again after a further two 
hours. Based on these and other preliminary data, a four-hour stimulation period was 
used throughout this thesis. However, it may be valuable to conduct a more detailed 
time course to ascertain whether a four-hour period of mitogenic or antigenic 
stimulation was optimal for flFN-y expression. Alternatively, assays to detect flFN-y 
mRNA have been developed (Dean et al., 1998; Liang et al., 2000). This technique 
may be useful in predicting an optimal time for flFN-y protein expression following 
mitogenic or antigenic stimulation. A longer duration of mitogenic stimulation may 
have enhanced flFN-y expression. Some workers use protracted periods of 
mitogenic and antigenic stimulation to elicit maximal IFN-y expression (Boaz et al., 
2002; Palmer et al., 2002). However, it has been reported that prolonged periods of 
antigenic stimulation (>10-16 hours) may also reduce the intensity of IFN-y 
expression (Nomura et al., 2000).
In Figs. 2.S-2.6, a greater proportion of unstimulated lymphoblasts expressed flFN-y 
when stained with the D9-F1TC mAb, compared to the mitogen-stimulated 
lymphoblasts stained with the isotype control-FITC mAb. These findings were 
representative of the assays presented in this thesis, and may be attributed to any of 
the following factors. First, the D9-F1TC mAb may have been non-specifically 
bound by FcR-bearing cells, such as monocytes and granulocytes. Although the 
analysis was conducted on the gated small lymphocyte and the large lymphoblast 
populations, low numbers of monocytes and granulocytes may have been 
unintentionally included. Activated platelets that stick to lymphocytes are also 
recognised as significant contributors to non-specific background staining (Nomura 
et al., 2000). Second, unstimulated mononuclear cells were cultured in vitro for four 
hours before staining for flFN-y expression; cells activated in vivo may have 
expressed flFN-y ex vivo in the absence of antigenic or mitogenic stimulation, 
causing true biological background. In addition, APCs loaded with antigen in vivo 
may have activated co-cultured cells ex vivo. Since the unstimulated cells from an 
SPF cat and an FeLV recovered cat both expressed flFN-y (Figs. 2.5 and 2.6), this 
explanation may not fully account for these findings. However, cells may become
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non-specifically activated in vitro by elements within the culture medium, such as 
FCS, which can be mitogenic for B cells. Thus, non-specific flFN-y staining may be 
a problem when the cells are not fractionated.
In Figs. 2.5 and 2.6, the majority of mitogen-activated cells that expressed fIFN-y 
were not CD4^ T cells. Non-specific or biological background staining, described 
above, may have contributed to this result. However, other cell types such as CD8^ 
T cells, B cells, plasmacytoid DC, NKT cells, Tr cells and NK cells are all capable of 
secreting IFN-y upon activation (Section 1.3.1.2). In particular, NK cells are major 
producers of IFN-y. Since these assays were conducted using unfractionated 
mononuclear cells, all lymphoblast cell subsets, as well as other cell types of similar 
size and granularity, were included in the gated lymphoblast population.
The sheep anti-flFN-y pAb was used to identify fIFN-y-expressing cells in PLN 
tissue sections from an FeLV recovered cat using immunohistochemistry, illustrated 
in Fig. 2.8. The demonstration of IFN-y within tissues in situ may aid in the 
characterisation of the immune response during disease processes (Kakazu et aL, 
1999). Double immunoenzyme techniques could be used to characterise the fIFN-y 
expressing population. In addition, flFN-y expression could be correlated with the 
presence of infectious FeLV or FeLV proteins. However, it was difficult to achieve 
consistency in the detection of fIFN-y expression using immunohistochemistry. It 
has been reported that IFN-y expression in cryostat tissue sections is difficult to 
accurately detect using immunohistochemistry; discrepancies occurred between 
results obtained using intact in vitro stimulated T cells and cryosections prepared 
from the same T cells (van Der Loos et al., 2001). Multiple reasons were cited to 
explain the discrepancies; acetone fixation may result in antigen extraction; non­
specific staining of various cellular constituents and plasma cells occurred 
frequently, and immunohistochemistry is less sensitive than flow cytometry. It has 
been suggested that IFN-y expressing cells should be characterised using double 
immunoenzyme techniques to minimise spurious results (van Der Loos et al., 2001). 
Furthermore, prefixation of tissues with paraformaldehyde (PFA) prior to freezing 
may eliminate leaching of cytokines.
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The anti-flFN-y antibodies have additional applications in the field of feline research. 
In addition to FeLV, the domestic cat is the natural host for a number of significant 
pathogens including FIV (Pedersen et a l, 1987) and feline coronavirus virus (FCoV) 
(Pedersen et a l, 1987; Addie et a l, 1995). Currently, effective vaccines are not 
available for the majority of these feline infections, and curative treatment is often 
not possible. Although the immune mechanisms determining the disease outcome 
following exposure to these pathogens are becoming clearer (Pedersen, 1987; Olsen, 
1993; Beatty et a l, 1996; Willett et a l, 1997; Flynn et a l, 1999), progress in this 
area is slow. This is partly due to the lack of sensitive, species-specific reagents to 
allow the quantitative definition of the important immune control mechanisms. The 
anti-flFN-y antibodies described in this study have the potential to facilitate the 
quantitative analysis of antigen-specific T cells ex vivo using either ICS techniques 
analysed using flow cytometry, or ELISpot assays. These highly sensitive assays 
will enable the evolution of the immune response to be monitored following 
infection or vaccination, or in tumour development. A second important use of these 
novel reagents is to detect circulating flFN-y in plasma using a capture ELISA. Such 
an approach may also be a useful prognostic indicator when evaluating novel 
immunotherapies. Recent studies in domestic cats have attempted to evaluate the 
potential of feline cytokines, for example IFN-y, lL-12 and IL-18, as genetic vaccine 
adjuvants in vivo (Hosie et a l, 1998; Flynn et a l, 2000b; Hanlon et a l, 2001). An 
adjuvant effect has been demonstrated in certain studies as assessed by increases in 
virus-specific cell-mediated immune responses, or by improved vaccine efficacy 
following challenge.
In this thesis, these novel reagents were used to detect and quantify the evolution of 
virus-specific immune responses ex vivo following experimental exposure of cats to 
FeLV. The specificity of the antiviral immune response can be determined through 
the enumeration of flFN-y expressing cells following stimulation with viral antigens. 
To this end, recombinant p27 and p45 proteins and inactivated FeLV particles were 
generated and used in this thesis. Cell surface molecules, such as CD4 and CDS, 
were simultaneously detected, to ensure that the cytokine-positive cells were indeed 
the cells of interest.
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2.5 Summary and Conclusions
Prior to this thesis, no antibody reagents were available to detect flFN-y in the cat. 
The sensitivity of the D9 mAb and sheep anti-flFN-y pAb, in the detection of fIFN-y, 
was determined using an indirect IFN-y ELISA and Western blots. In addition, these 
antibodies were assessed for their ability to detect the production of fIFN-y by 
specific feline T cell populations ex vivo, following co-culture with mitogen for four 
hours in the presence of protein secretion inhibitor BFA. Flow cytometry was used 
to simultaneously detect PE-labelled cell surface molecules, and FITC-labelled 
intracellular flFN-y. Finally, expression of fIFN-y in cryostat sections of PLN tissues 
was detected using the sheep anti-flFN-y pAb in an immunoperoxidase technique.
Using these assays, these novel reagents were shown to be highly sensitive in the 
detection of both recombinant feline IFN-y and the production of intracellular fIFN-y 
in physiologically stimulated cells. In this thesis, these reagents will be employed to 
detect fIFN-y expression by virus-specific CD4^ T cells following recognition of 
their cognate antigen, using ICS analysed using flow cytometry.
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CHAPTER 3
LONGITUDINAL IMMUNOPATHOGENESIS STUDY
I. VIROLOGY
3.1 Introduction
A longitudinal FeLV immunopathogenesis study was conducted to investigate the 
role of FeLV-specific CD4^ T cells in the control of FeLV infection. CD4^ T cells 
have a critical role in regulating the humoral and cell-mediated arms of the immune 
response through the activation of DC and the elaboration of cytokines.
Six SPF cats, E1-E6, were exposed oronasally to FeLV-A aged sixteen weeks, in the 
expectation that each of three well-defined outcomes of infection would result, 
recovery, latency and persistence. To define the outcome of FeLV exposure in each 
cat, and correlate the virus-specific immune response with the viral status of exposed 
cats, a series of virus parameters was monitored throughout the study, and post 
mortem. Peripheral blood samples were taken at regular intervals following oronasal 
exposure to FeLV, and post mortem. In each sample, proviral DNA loads were 
quantified using qRT-PCR; the emergence of p27 antigenaemia was monitored using 
a double antibody sandwich ELISA, and the presence of infectious virus was 
determined using VI techniques. Samples from PLN, MLN, spleen and thymus were 
harvested post mortem, from which proviral DNA loads were quantified using qRT- 
PCR. These data indicated that all cats, E1-E6, became persistently infected with 
FeLV. In this thesis, it was intended to examine and compare FeLV-specific CD4^ T 
cell responses among persistently infected, recovered and latently infected cats. 
Therefore, in order to enhance the probability of recovery, a second group of six SPF 
cats, E7-E12, was exposed to a reduced dose of FeLV-A under identical conditions 
as cats E1-E6. Each group of cats, E1-E6 and E7-E12, underwent the same series of 
assays at comparable time intervals. However, cats E1-E6 were euthanased nineteen 
weeks post exposure while cats E7-E12 were euthanased after thirteen weeks. 
Throughout this thesis, these two groups of cats are frequently referred to as cats E l- 
E12.
This chapter describes the experimental exposure of cats E1-E12 to FeLV, the 
preparation of samples and the evolution of the viral status of cats E1-E12. Virus- 
specific cellular immune responses will be described in Chapter 4. In Chapter 5,
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expression of the FeLV CA protein p27 in the bone marrow and PLN tissues will be 
illustrated.
3.2 Materials and Methods
3.2.1 Experimental Animals
In total, two groups of six 8-9 week old outbred SPF domestic shorthair (DSH) 
kittens were procured from a commercial source and housed in a purpose built 
isolation unit at the University of Glasgow. The first group of six cats (E1-E6) 
occupied two adjoining rooms, each 9.36 m^ and 2.36 m high; the second group (E7- 
E12) shared a single large room. The cats were fed proprietary dry and wet food 
twice daily and received water ad libitum. Male cats within each group were 
castrated at approximately eleven weeks of age under isofluorane gaseous 
anaesthesia (1.5% Isoflo, Schering-Plough, Uxbridge, U.K.).
3.2.2 Exposure to FeLV
Cats E1-E12 were exposed oronasally to a molecular clone of FeLV-A Glasgow-1 
(Jarrett et al., 1972; Jarrett et al., 1973; Stewart et al., 1986), when aged sixteen 
weeks. The virus used was taken from titrated stock prepared by the Companion 
Animal Diagnostic Laboratory (CADL) (Batch 53; 6 x 10  ^ focus-forming units 
(ffu)/ml), and stored at -70°C. Immediately before use, the virus was thawed and 
diluted in sterile PBS to give a final volume of 1 ml/cat; 0.5 ml was administered 
orally and 0.25 ml applied in each nostril. Six cats (E1-E6) received 5 x 10  ^ ffu 
FeLV-A; the remaining six (E7-E12) each received 5 x 10"^  ffu FeLV-A.
3.2.3 Blood Sampling
Blood was collected from conscious animals using jugular venepuncture. Rarely, 
sedation using xylazine (0.5 mg/kg, Rompun, Bayer PLC, Berkshire, U.K.) and 
ketamine (5 mg/kg, Ketaset, Fort Dodge Animal Health, Hampshire, U.K.) was 
required. The maximum volume of blood permitted by U.K. Home Office guidelines
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per sampling was calculated according to the weight of the cats. The first sample 
was taken six weeks prior to FeLV exposure, and sampling continued at intervals of 
three weeks thereafter until the end of the study. An additional sample was taken 
one week following FeLV exposure. Whole blood was collected into lithium heparin 
and sodium citrate blood tubes (Dunwood Ltd., Aberdeen, U.K.), and into Alsevers’ 
solution (1:1).
3.2,3.1 Lithium Heparin Samples
To separate the blood fractions, blood collected in lithium heparin sample tubes was
centrifuged at ISOOrpm for twelve minutes using a bench-top centrifuge. At least
300 fxl plasma was submitted to the CADL to conduct VI, p27 ELISA and virus
neutralisation assays. Virus isolation was performed by infecting QNIOS cells with
plasma samples from exposed cats (Jarrett and Ganière, 1996). QNIOS cells were
derived from a clone of feline fibroblasts, into which had been introduced the
Moloney murine sarcoma virus (MoMSV) (Jarrett and Ganière, 1996). A
subconfluent layer of QNIOS cells, plated in wells of a 24-well tissue culture plate,
was inoculated with 100 p.1 plasma; any virus present was absorbed for two hours,
then replaced with fresh culture medium. The cells were examined for
morphological changes that would indicate the presence of infectious virus. Cells
were initially cultured for six days, negative cells were further subcultured for five
days. The presence of VNA was determined using a focus reduction assay on
QNIOS cells (Jarrett and Ganière, 1996). Dilutions of plasma were incubated with
an equal volume of an appropriate concentration of FeLV - A/Gl asgo w-1, for six
hours at 37°C. Any residual infectivity was determined by VI performed on QNIOS
cells, described above. If virus is used at an appropriate concentration, foci of
transformation are obtained and the infectious virus may be quantified. The VNA
titre was calculated as the reciprocal of the plasma dilution that reduced the focus
count by 75%, compared with a virus control incubated without plasma (Jarrett and
Ganière, 1996). The presence of p27 antigenaemia was determined using a double
antibody sandwich ELISA (Lutz et al., 1983). Micro-ELISA plates were coated with
a combination of two anti-p27 mAbs, which recognised distinct epitopes. Plasma
samples were mixed with a biotinylated anti-p27 pAb, then added to the micro-
ELISA plates, and incubated for thirty minutes at 37°C. A final thirty-minute
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incubation with peroxidase-labelled strepatavidin preceeded the development of 
peroxidase activity. Absorbance was measured in a micro-ELISA plate reader. 
Positive and negative samples were included as controls; a sample was considered 
positive when the absorbance was equal to, or exceeded, 150% of the negative 
control value.
Mononuclear cells were isolated from the buffy coat as described in Section 2.2.2.S, 
prior to being resuspended in 200 pi freeze-mix^"^ and dispensed in cryotubes (Nalge 
Nunc International, Assi Doman, Kolding, Denmark). The cells were stored 
overnight at -70°C in sealed polystyrene containers before transfer to liquid nitrogen 
the following day.
3.23.2 Sodium Citrate Samples
Blood collected in sodium citrate sample tubes was centrifuged at 1500rpm for 
twelve minutes using a bench-top centrifuge. The plasma was removed and 
centrifuged again at 3000rpm for ten minutes in a microluge (‘Micro Centaur’, 
Sanyo Gallenkamp, U.K.) to pellet any remaining red blood cells (RBC). Two 180 
pi plasma samples were aliquoted to determine plasma FeLV RNA loads using qRT- 
PCR analysis. Proviral DNA loads were quantified from the buffy coat layer using 
qRT-PCR. A volume of 200 pi buffy coat was placed in 20 pi protease (Qiagen 
U.K. Ltd, West Sussex, U.K.), to which 200 pi ‘AL Buffer’ (Qiagen, U.K.) was 
added. The reagents were thoroughly mixed prior to a ten-minute incubation at 56°C 
in a water bath. Plasma and buffy coat samples were subsequently stored at -70‘’C 
until submission to Dr Regina Hofmann, Faculty of Veterinary Medicine, University 
of Zurich, for qRT-PCR analysis. The primers and probes used recognised the U3 
long terminal repeat (LTR) of exogenous FeLV-A. The primer sequences were 5' 
ACCTGGGCCCCGGCT 3" (15 bases; nt 2174-2188) for the sense primer, and 5' 
GCGGCCTTGAAACTTCTGCT 3 ' (20 bases; nt 2228-2247) for the antisense 
primer.
The TaqMan FeLV probe was, 5 ' AGGCCAAGAACAGTTAAACCCCGGAT 3'(26 
bases; nt 2191-2216) (Hofmann-Lehmann et al., 2001).
Freeze-mix: 10% (v/v) DMSO in FCS
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3,2,33 Alsevers ’  Samples
Mononuclear cells were harvested from peripheral blood collected in Alsevers’ 
solution, as described in Section 2.2.2.8. In most cases, fresh mononuclear cells 
were used in the LPA, and ICS analysed using flow cytometry (Chapter 4). Any 
remaining cells were frozen and stored in liquid nitrogen.
3,2.4 Post Mortem Sampling
All cats in the study were euthanased using pentobarbital sodium (120 mg/kg, 
Euthatal, Merial U.K., Harlow, U.K.) under sedation 13-19 weeks following FeLV 
exposure. Between 80 and 120 ml blood was withdrawn by cardiac puncture under 
terminal anaesthesia. Samples to determine proviral DNA loads using qRT-PCR 
analysis were collected from the PLN and MLN tissues, spleen and thymus, and snap 
frozen in liquid nitrogen. Samples from PLN, MLN, spleen and thymus were also 
collected in ‘O.C.T.’, and snap frozen in liquid nitrogen for immunohistochemical 
analysis. Remaining PLN, MLN and splenic tissue was collected into RPMI 1640 
medium containing penicillin and streptomycin, for use as single cell suspensions in 
the LPA. Femoral bone marrow was harvested and distributed among sterile 
containers containing 5% BSA in PBS, 10% formalin and bone marrow transport 
medium^^ (BMTM), for cytological analysis and immunofluorescence, 
immunohistochemistry and VI, respectively.
Bone marrow cells within the BMTM were pelleted. To determine whether 
infectious virus was present within the bone marrow, the supernatant, or cell free 
suspension (CFS), was added to QNIOS cells for VI. The presence of a latent 
infection was established by culturing the bone marrow cells in vitro. The cells were 
cultured until confluent in MEM-alpha medium containing 10% FCS, 100 U/ml 
penicillin, 10 pg/ml streptomycin and 2 mM glutamine (complete MEM-alpha 
medium), and passaged once. To determine whether latent provirus had become 
reactivated, tissue culture fluid (TCF) was then added to QNIOS cells for VI.
BMTM: MEM-alpha medium containing 10% (v/v) FCS, 100 U/ml (v/v) penicillin, 100 pg/ml (v/v) 
streptomycin, 2 mM (v/v) glutamine; 50 U (v/v) heparin/ml
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3.2.4.1 Preparation o f  Single Cell Suspensions
Post mortem tissue samples were emptied into plastic Petri dishes (Bibby Sterilin 
Ltd., Staffordshire, U.K.) within a microbiological safety cabinet and washed using 
20-30 ml RPMI 1640 medium containing antibiotics, as described above. Sterile 
instruments were used to remove excess fat from the specimens before the lymphoid 
tissue was gently teased out beneath the fibrous capsules. Lymphoid cells were 
collected into universal containers at regular intervals and aspirated when fibrous 
material had settled to the bottom, and fat had floated to the top. Aspirated material 
was centrifuged in a bench-top centrifuge at lOOOrpm for ten minutes, washed in 
RPMI 1640 medium, frozen in freeze-mix, and stored in liquid nitrogen. Splenic 
cells were additionally layered over Ficoll-Paque in order to minimise RBC 
contamination.
3.2.5.Statistics
Statistical analysis was conducted using ‘GraphPad InStat’ (GraphPad Software, San 
Diego California U.S.). Non-parametric tests were used throughout. The Mann- 
Whitney test was applied to compare results from two groups, using a two-tail P 
value. Where three or more groups were compared, the Kiuskall-Wallis test was 
used. The Spearman rank correlation test (Spearman r-Test) was conducted to 
analyse the association between proviral DNA loads in the peripheral blood and s:p 
values calculated from the p27 ELISA data. The Spearman r-Test is a non- 
parametric test.
3.3 Results
3.3.1 Viral Status of Cats E1-E12
Prior to experimental FeLV exposure at week 0, blood samples from cats E1-E12 
were tested for the presence of FeLV p27 antigenaemia, infectious virus, buffy coat 
proviral DNA, and VNA, and were found to be negative for all of these parameters.
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33.1.1 p27 ELISA
Following the experimental exposure of cats E1-E12 to FeLV at week 0, the 
presence of p27 antigenaemia was determined at regular intervals using a double 
antibody sandwich ELISA. The results are shown in Fig. 3.1 and summarised in 
Table 3.1. Cats were considered positive when the O.D .405 sample value was equal 
to, or greater than, 150% of the negative control value. The sample:positive (s:p) 
ratio was calculated from the O.D .405 value of each sample, using results from the 
positive and negative controls:
sample O.D .405 - negative control O.D .405
positive control O.D .405 - negative control O.D .405
This was done to correct for day-to-day variations in ELISA readings, allowing 
results to be more accurately compared over a time course (Fig. 3.1).
p27 antigenaemia was not detected in the plasma from any cat one week following 
FeLV exposure. By week 4, ten cats were p27-positive, with only cats ElO and E12 
remaining negative. However, cat ElO became p27 antigenaemic at the next sample 
date (week 7), and cats E l-E ll  remained p27-positive for the duration of the study. 
No p27 antigenaemia was detected in the plasma from cat E12 at any time (Table 
3.1). While cats E1-E6 received a higher exposure dose of FeLV by a factor of one 
log, compared to cats E7-E12, significant differences in the s;p values between the 
two groups of cats were not observed until week 13, when cats E1-E6 demonstrated 
significantly higher s:p values (Mann-Whitney Statistic, P=0.0022).
The pattern of s:p results generally conformed to two principal peaks in values, at 
week 4 and/or weeks 10-13, although s:p results from three cats, E l, E2 and E3, 
displayed an additional low peak at week 19. Results from only three cats, E2, E7 
and E8 , demonstrated a biphasic pattern, peaking at both week 4 and weeks 10-13; 
s:p results from the remaining cats peaked at either week 4 or weeks 10-13.
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33.1.2 Virus Isolation
The presence of infectious FeLV in the plasma was determined using VI techniques 
at regular intervals following experimental exposure of cats E1-E12 to FeLV at week 
0. Isolation was initially attempted over a six-day culture period; any remaining 
negative samples were sub cultured for a further five days (Jarrett and Ganière, 1996). 
The results are shown in Table 3.1. Virus was not isolated from the plasma of any 
cat one week following experimental exposure to FeLV. However, infectious virus 
was isolated from the plasma of cats E l-E ll  at each sampling from week 4 until the 
end of the study, signifying that these cats became persistently viraemic following 
oronasal exposure to FeLV. Conversely, infectious FeLV was not isolated from the 
plasma of cat E12 at any time throughout the study, suggesting that cat E12 had 
recovered following oronasal exposure to FeLV.
Since all cats E1-E6 were persistently viraemic by week 19, it was considered not 
necessary to perform VI using the bone marrow from these cats; however, VI was 
conducted on the bone marrow samples collected from cats E7-E12 post mortem. 
Infectious virus was present in the bone marrow CFS from cats E7-E11, but not cat 
E12. However, following a short culture in vitro, infectious virus was isolated from 
the bone marrow cells from cat E12, indicating the presence of a latent bone marrow 
infection in this cat. Thus, while virus could not be detected in the peripheral blood 
from cat E12 throughout the study, which suggested that this cat had eliminated virus 
and spontaneously recovered, virus was still present within the bone marrow, as a 
latent proviral infection.
3.3.1.3 FeLV Proviral DNA Loads
The analytical sensitivity of the qRT-PCR assay was calculated by amplifying a 
tenfold serial dilution of the cloned standard DNA template; the qRT-PCR detected 
between 0.36 and 3.6 copies of the DNA template (Hofmann-Lehmann et al., 2001).
(i) Buffy Coats
Feline leukaemia virus proviral DNA levels in buffy coat samples were measured
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using qRT-PCR at regular intervals following experimental exposure of cats E1-E12 
to FeLV at week 0 (Hofmann-Lehmann et al., 2001). The results are shown in Fig.
3.2 and Table 3.1. The raw qRT-PCR data (proviral DNA per PCR reaction) 
comprises the number of copies of the FeLV U3 LTR in each sample. To calculate 
proviral copy numbers per cell, these figures were divided by two (number of LTR 
copies), and then by the number of buffy coat cells. These were determined from the 
quantity of DNA used in each PCR reaction, which was 1 pg.
The qRT-PCR data showed that proviral DNA was present in the peripheral blood 
from all cats E1-E12 at week 1, except cats E7 and E12 (Table 3.1). Proviral DNA 
was detected in the peripheral blood from cat E7 by week 4, and in cat E l2 by week 
7. Thereafter, proviral DNA continued to be detected in each cat until the 
termination of the study at week 13 (E7-E12) and week 19 (E1-E6).
Latently infected cat E12 displayed low mean levels of proviral DNA over weeks 0- 
13 (0.0093 ± 0.0099 copies per cell), compared to persistently viraemic cats that 
received an equivalent exposure dose of infectious FeLV (0.53 ± 0.46 copies per 
cell). The difference is statistically significant (Mann-Whitney Statistic, P=0.0173). 
Cats E1-E6, which received a greater exposure dose of FeLV, had greater mean 
levels of proviral DNA in buffy coat samples over weeks 0-19 (4.5 ±1 .2  copies per 
cell), compared to cats E7-E12 over weeks 0-13 (0.44 ± 0.42 copies per cell). 
Statistically, significantly higher proviral DNA loads were quantified in cats E1-E6 
at week 1 (P=0.0260), week 4 (P=0.0411), week 10 (P=0.0022) and week 13 
(P=0.0087), compared to cats E7-E12, according to the Mann-Whitney Statistic.
Fluctuations in proviral DNA copy numbers were recorded for each cat E1-E12 over 
the length of the study. Generally, two peaks in proviral DNA load were observed, 
at weeks 4-7 and/or weeks 10-16. Proviral DNA loads in cats E2, E3, E4, E5, E7 
and E9 all displayed a biphasic pattern, peaking at weeks 4-7 and again at weeks 10- 
16. Cat E2 demonstrated a third small peak at week 19. Proviral DNA loads in cats 
E8, ElO and E l l  peaked only at weeks 4-7, while those in cat E6 peaked at weeks 13 
and 19. Cat E12 demonstrated a minor peak in proviral DNA load at week 10.
A direct correlation was detected between the proviral DNA load data measured
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using qRT-PCR, and the s:p figures calculated from the p27 ELISA (Spearman r- 
Test, r=0.5235), over the entire study for cats E1-E16 (weeks 0-19), and cats E7-E12 
(weeks 0-13) (Fig. 3.4). These results were extremely statistically significant 
(P=0.0001 and P<0.0001, respectively). However, no statistically significant 
correlation was detected between the proviral DNA data and the s:p results in either 
groups of cats at any single sample date throughout the study.
(ii) Lymphoid Tissues
Feline leukaemia virus proviral DNA loads in PLN, MLN, thymus and spleen from 
cats E1-E12 post mortem are shown in Fig. 3.3. Proviral DNA was detected in each 
sampled tissue from every cat. Thus, although infectious virus was not detected in 
the peripheral blood from cat E12 at any time throughout the study, proviral DNA 
was detected in the lymphoid tissues and in the bone marrow. Statistically, cats E l- 
E6 demonstrated significantly higher levels of proviral DNA in all tissues, compared 
to cats E7-E12, according to the Mann-Whitney Statistic (PLN, P=0.0043; MLN, 
P=0.0152; thymus, P=0.0260; spleen, P=0.0022). However, no statistically 
significant difference in proviral DNA loads between each tissue type was found, in 
either group of cats, using the Kruskall-Wallis Statistic. However, it is clear from 
Fig. 3.3 that the spleen contained the highest mean levels of proviral DNA (cats E l- 
E6, 1.035 ± 0.2 copies per cell; cats E7-E12, 0.209 ± 0.12 copies per cell), compared 
to all other tissues (cats E1-E6, 0.436 ± 0.31 copies per cell; cats E7-E12, 0.151 ± 
0.018 copies per cell). Latently infected cat E12 displayed low mean levels of 
proviral copy numbers in all tissues (0.000396 ± 0.0001 copies per cell), compared to 
persistently viraemic cats that received a comparable dose of infectious FeLV (0.18 ± 
0.07 copies per cell). The difference is statistically significant (Mann-Whitney 
Statistic, P=0.0159).
3.3.2. Humoral Immunity
3.3.2.1 Virus Neutralising Antibodies
The development of VNA was monitored using a focus reduction assay at three- 
week inteiwals following experimental exposure to FeLV. Throughout the course of
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the study, cats E l-E ll  failed to develop VNA to FeLV. However, a low VNA titre 
was recorded for cat E12 at week 13 (1:16).
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Fig. 3.4 Correlation between s:p values and p27 ELISA data
Correlation of s:p values calculated from p27 ELISA data, and buffy coat proviral 
copy numbers measured using qRT-PCR in cats E1-E6 (A) and cats E7-E12 (B). 
The data was determined at regular intervals following experimental exposure of cats 
B1-E12 to FeLV at week 0, until the end of the study at weeks 13 (E7-E12) and 19 
(E1-E6). Using the Spearman r-Test, r=0.5235 (cats E1-E6) and r=0.7666 (cats E7- 
E12). Both values are extremely significant ( f =0.0001 and f  <0.0001, respectively).
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Table 3.1 Detection of FeLV CA protein, proviral DNA and 
infectious FeLV in cats E1-E12
Plot summarising detection of FeLV proviral DNA, FeLV CA protein p27 and 
infectious FeLV, using qRT-PCR, p27 ELISA and VI respectively, in peripheral 
blood samples taken at regular intervals from weeks 0-19 (E1-E6) and weeks 0-13 
(E7-E12).
z  E6
10 13 16 19
Weeks Post Exposure
#  p27 ELISA positive e Virus isolation positive m PCR positive
O p27 ELISA negative o Virus isolation negative □PCR negative
3.4 Discussion
The aim of the FeLV immunopathogenesis study was to examine and compare 
FeLV-specific CD4^ T cell responses in recovered, latently infected and persistently 
viraemic cats following exposure to FeLV. It was essential to monitor the FeLV 
status of exposed cats through the detection of viraemia, p27 antigenaemia and 
proviral burdens to define the disease outcome for each cat, and to ascertain whether 
the development of FeLV-specific immune responses could be correlated with the 
viral status of the exposed cats. To achieve these aims, cats were exposed at 16 
weeks with a dose of virus previously shown to be associated with recovery in a 
significant proportion of animals (Hoover et al., 1976; Jarrett et al., 1982a; Flynn et 
al., 2002b). However, in the present study, eleven cats became persistently viraemic 
and one cat retained a latent proviral infection in the bone marrow and lymphoid 
tissues.
Cats were dosed oronasally to mimic the natural route of exposure (Hardy et al., 
1973; Francis et al., 1977; Hoover et al., 1977a; Hoover et al., 1977b; Jarrett et al., 
1982a; Pedersen, 1988; Hoover and Mullins, 1991; Hardy, 1993; Jarrett, 2001). 
Additionally, oronasal challenge avoids unsuccessful infections, where virus 
intended for the peritoneal cavity may instead be injected into the abdominal wall 
tissues. Furthermore, it was useful to compare the data collected from this study 
with data acquired from recent studies conducted in our laboratory, which used an 
identical route of exposure.
The FeLV CA protein p27 was not detected in the plasma from any cat E1-E12 at 
week 1; eleven of which subsequently became persistently infected. This is 
consistent with the findings of a previous study, where an early peak in p27 
antigenaemia was absent in all persistently viraemic cats (Flynn et al., 2002b). Only 
three persistently infected cats followed a biphasic pattern in p27 antigenaemia based 
on the s:p values from the p27 ELISA, peaking at weeks 4 and weeks 10-13. 
However, s:p values from all other persistently infected cats demonstrated single 
peaks in p27 antigenaemia at either week 4 or weeks 10-13.
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The p27 ELISA detects FeLV CA protein p27, released free into the plasma by 
virally infected cells or disrupted viral particles; therefore, the presence of FeLV CA 
protein p27 is not necessarily indicative of an active infection. In contrast, VI from 
plasma samples detects the presence of infectious virus. The absence of p27 
antigenaemia in the presence of viraemia in cat ElO at week 4 is a rare, discordant 
result. In other experimental studies, FeLV viraemia consistently occurred in the 
presence of p27 antigenaemia (Jarrett and Ganière, 1996; Flynn et al., 2002b). 
However, one study describing the experimental infection of eight-week old kittens 
reported that although VI was successful on day 10 in two kittens, no kitten was 
positive in the p27 ELISA until day 14 (Jarrett et a l, 1982a), implying that viraemia 
can occur in the absence of a concurrent antigenaemia. More recently, the 
identification of false-negative p27 ELISA results in cats that presented with an 
FeLV-associated disease, and a positive IFA test, was reported (Kerr and Smith, 
1995; Lutz et a l, 1982; Madewell and Jarrett, 1983). Nonetheless, it is considered 
unusual to detect viraemia in the absence of antigenaemia, as dissemination of 
soluble viral polypeptides by FeLV-infected cells occurs widely in vitro (Neil et a l, 
1980b) and in vivo (Jarrett, 1999). Furthermore, viral antigens have been detected in 
plasma from FeLV infected cats for a short period before, and after, virus is detected 
in cells (Lutz et a l, 1980a; Pedersen, 1988). However, the presence of viraemia in 
cat ElO without concurrent p27 antigenaemia may not actually be a true result. The 
s:p values show that cat E4 (0.1) has a lower value than cat ElO (0.11) at week 4, and 
yet cat E4 was considered positive, and ElO negative, suggesting that the discordant 
result may have arisen from the interpretation of the O.D .405 ELISA figures. In this 
study, a cat was considered positive when the sample value is equal to, or greater 
than, 150% of the negative control value. In this instance, the plasma sample from 
cat ElO had an O.D.405 value of 0.26, whereas the negative control had an O.D .405  
value of 0.18, which meant that cats with an O.D .405 value of 0.27 or greater were 
considered positive. Using those criteria, cat ElO was clearly only marginally 
negative. Others, using a similar p27 ELISA assay, have defined cats as positive 
when the s:p value is equal to, or greater than, 0.1 (Miyazawa and Jarrett, 1997). If 
the same criteria had been applied in this study, cat ElO would have been considered 
positive.
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Quantitative RT-PCR is a sensitive and specific method of detecting and quantifying 
FeLV proviral DNA in blood and tissues (Hofinann-Lehmann et al., 2001). The 
primers and probe used in this study were designed to detect exogenous FeLV-A 
sequences so that endogenous FeLV-related sequences were not amplified. Proviral 
DNA was detected in all cats one week following exposure to FeLV, except cats E7 
and E12. An absence of proviral DNA in cats E7 and E12 until week 4 and week 7 
respectively, suggests that the immune response may have been actively restricting 
FeLV integration and replication; possible immune mechanisms include IFN-y and 
the type I IFNs. Interferon-y acts directly to antagonise viral growth and replication 
through the induction of three genes encoding PKR, 2-5A synthetase and dsRAD 
(Section 1.3.1.2). Additionally, type I IFNs secreted by IFN-producing cells (IPCs) 
and virally-infected cells (Rissoan et al., 1999; Siegal et al., 1999) have an antiviral 
role (Levy, 2001); the loss of IPCs and IFN-a production has been associated with 
high HIV RNA levels and AIDS (Soumelis et al., 2002). The type I IFNs also 
produce enzymes that collectively interfere with viral replication.
The pattern of proviral DNA loads was similar to those described in other studies, 
where persistently infected cats demonstrated two peaks in proviral DNA load, at 
weeks 4-7 and again at weeks 10-16 (Hofmann-Lehmann et al., 2001; Flynn et al., 
2002b). These peaks in proviral DNA loads were temporally associated with the 
peaks in s:p values determined using the p27 ELISA. However, no statistically 
significant correlation between these two results was found in either group of cats at 
either time points (weeks 4-7 or weeks 10-16).
Although proviral DNA was detected in latently infected cat E12 from weeks 7-13, 
p27 antigenaemia was not detected at any sample date over the study. A group of 
PCR-positive, p27-negative recovered cats was identified in FeLV experimentally 
infected cats, that became PCR positive one week following FeLV exposure in the 
absence of p27 antigenaemia, and remained PCR-positive, p27-negative (Hofmann- 
Lehmann et al., 2001). The mean proviral copy numbers for cat E12 (0.0093 ± 
0.0099 copies per cell) was less than those recorded for the p27 ELISA-negative, 
PCR-positive cats (0.08 ± 0.07 copies per cell) (Hofmann-Lehmann et al., 2001). 
However, neither the infection route nor the infection dose was comparable to those
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used in cats E7-E12. Persistently viraemic cats E1-E6 that received an equivalent 
exposure dose of FeLV to cats in Hofmaim-Lehmann’s study, had higher mean levels 
of proviral DNA (4.5 ± 1 . 2  copies per cell), than were detected in persistently 
infected cats from Hofmaim-Lehmann’s study (1.4 ± 2.7 copies per cell). Much 
higher mean proviral copy numbers were detected in naturally infected viraemic cats 
in the same study (10 ± 47 copies per cell), although the duration of infection, age at 
time of exposure and challenge dose in these cats was unknown.
Quantitative RT-PCR was the most sensitive method used to detect FeLV infection 
in this study; proviral DNA was detected in all cats, except cats E7 and E12, one 
week following FeLV exposure, whereas neither the p27 ELISA nor VI detected 
FeLV CA protein p27 or infectious virus in those cats until at least week 4. 
Furthermore, although all negative qRT-PCR samples were negative by ELISA 
(n=28) and VI (n=28), and all positive ELISA (n=55) and VI samples (n=56) were 
positive by qRT-PCR; some positive qRT-PCR samples were negative by ELISA 
(n=13) and by VI (n=12). These results highlight incongruities between results 
obtained using the p27 ELISA, VI and the qRT-PCR assays in this study. Each assay 
detects different aspects of the FeLV life cycle: p27 antigenaemia, FeLV viraemia 
and FeLV integration respectively; the presence of either proviral DNA or the FeLV 
CA protein p27 does not signify the presence of an active infection. Discrepancies 
between qRT-PCR and the other assays used in this study also reflect the exquisite 
sensitivity of the qRT-PCR assay, which detected between 0.36 and 3.6 copies of the 
standard DNA template (Section 3.3.1.3) (Hofmann-Lehmann et al., 2001). Despite 
these differences, an extremely significant correlation was identified between the p27 
ELISA and PCR results obtained over the entire study in both groups of cats, E1-E6 
and E7-E12.
In another study, no samples negative by both p27 ELISA and VI were positive by 
nested PCR (Miyazawa and Jarrett, 1997). This was clearly not the case in this 
study; all cats E1-E12 in the early stages of infection were PCR-positive and both 
Vl-negative and p27-ELISA negative, as was cat E12 throughout the course of the 
study. Our findings concur with those reported by Hoffman-Lehmann et al. (2001), 
where 10% of naturally infected cats were found to be positive using PCR and 
negative using ELISA. The authors suggest that these cats either had recovered from
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FeLV infection, or were in the early stages of infection.
Although neither p27 antigenaemia nor viraemia were detected in the peripheral 
blood from E12 at any sample date throughout the study, proviral DNA detected in 
buffy coat and lymphoid tissue samples suggests that E12 experienced a transient 
cell-associated viraemia following exposure to FeLV. Furthermore, it was possible 
to isolate infectious FeLV from post mortem bone marrow samples following a short 
in vitro culture on QNIOS cells. These data indicate that E12 failed to wholly clear 
FeLV following exposure, allowing FeLV to migrate to lymphatic tissues and bone 
marrow, and establish a latent infection as integrated provirus. However, cell-free 
virus was not detected in the blood of cat E12 at any time over the study, suggesting 
that the immune response was sufficient to prevent widespread bone marrow 
replication and active infection. Virus neutralising antibodies were not detected in 
the plasma from persistently viraemic cats E l-E ll at any time during the study but 
were detected in the plasma from latently infected cat E12 at week 13. Although 
VNA in cat E12 appeared later than expected for recovered cats, and the titre was 
lower (Lutz et a i, 1980b; Hofmann-Lehmann et al., 2001; Flynn et al., 2002b), these 
data may be consistent with reports where transiently viraemic cats produced levels 
of antibody that overlapped with those produced by aviraemic and persistently 
viraemic cats (Lutz et al., 1980b). The early delay in FeLV integration, and the 
persistent absence of viraemia and antigenaemia throughout the study, suggest that 
antiviral immune responses were actively suppressing FeLV activity in cat E12. 
Recovery from FeLV infection began before the appearance of plasma VNA, 
indicating that these phenomena were mediated by mechanisms other than VNA. 
Early FeLV Gag/Pro-specific CD8^ CTL effector responses are known to be 
associated with recovery from experimental FeLV infection (Flynn et al., 2002b).
FeLV isolate, dose, host susceptibility, age at time of exposure and route of exposure
all interact to influence the outcome following exposure to FeLV (Hoover et al.,
1976). Specific pathogen free cats E1-E6 were exposed to FeLV at an age, dose and
route normally expected to result in approximately fifty per cent recovery, fifty per
cent persistent viraemia (Hoover et a l, 1976; Jarrett et a l, 1982a; Flynn et a l,
2002b). Nonetheless, all six exposed cats became persistently viraemic. With FeLV
isolate and dose, age and route of exposure consistent with previous studies; host
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susceptibility remains the unknown variable in this group. Cats E7-E12 were 
exposed to a lower dose of FeLV-A under the same conditions as cats E1-E6, and 
one cat, E12, cleared infectious virus from the peripheral blood. Together, these data 
suggest a greater inherent susceptibility of all cats to the molecular clone of FeLV- 
A/Glagow-1, which was somewhat improved by reducing FeLV exposure dose by a 
factor of one log.
3.5 Summary and Conclusions
Out of twelve cats exposed to FeLV, eleven cats became persistently infected, while 
cat E12, having cleared infectious virus from the peripheral blood, retained a latent 
proviral DNA infection in the bone marrow and lymphoid tissues.
Infectious virus was isolated from all persistently infected cats from week 4 until the 
end of the study. Furthermore, p27 antigenaemia was detected in these cats from 
weeks 4-7, until the termination of the study. Proviral DNA was detected in the 
peripheral blood from ten cats as early as week 1 following oronasal exposure to 
FeLV, and by week 7 from all cats, and continued to be detected until the termination 
of the study. In addition, proviral DNA was detected in the lymphoid tissues 
harvested from all cats post mortem.
Each of the assays used, p27 ELISA, VI and qRT-PCR, all detect different aspects of 
the FeLV lifecycle, which accounts for some discrepancies between results; only the 
VI technique detects an active infection.
I l l
CHAPTER 4
LONGITUDINAL IMMUNOPATHOGENESIS STUDY
II IMMUNOLOGY
4.1 Introduction
The previous chapter described the virological parameters measured in the peripheral 
blood and lymphoid tissues following the oronasal exposure of cats E1-E12 to FeLV. 
In this chapter, FeLV-specific cell-mediated immune responses elicited in the 
peripheral blood and lymphoid tissues are described, with particular emphasis on 
virus-specific CD4^ T cell responses.
The immune mechanisms that determine the fate of FeLV-exposed cats are not fully 
understood. Early studies showed that the presence of VNA correlated with recovery 
(Hardy et al., 1976; Hoover et al., 1976; Russell and Jarrett, 1978a; Lutz et al., 
1980b), and demonstrated that VNA passively protected kittens against FeLV 
challenge (Jarrett et aL, 1977). In field situations, this passive transfer of VNA from 
an immune queen to suckling kittens may be critical in the protection of kittens at an 
age of greatest immuno-incompetence (Hoover et aL, 1976; Jarrett et aL, 1977).
However, more recent experimental studies have shown that FeLV is cleared from 
the blood prior to, or concurrent with, the appearance of VNA (Flynn et al., 2000a; 
Flynn et al., 2002b). Early FeLV Gag/Pro-specific CD8^ CTL responses are known 
to be associated with recovery from experimental FeLV infection (Flynn et aL, 
2002b), and are implicated in protective immune responses following inoculation of 
cats with an experimental FeLV DNA vaccine (Flynn et aL, 2000a; Hanlon et al., 
2001).
These studies illustrate that both VNA and virus-specific CTL are associated with 
recovery and protection following exposure to FeLV. We know that virus-specific 
CD4^ T cells are important in the initiation and regulation of specific cellular and 
humoral immune responses (Battegay et al., 1994; Matloubian et al., 1994; 
Rosenberg et al., 1997); therefore, the capacity of FeLV-specific CD4^ T cells to 
activate and maintain virus-specific CD8^ T cells and virus-specific B cells, may be a 
critical component in the immune mechanisms contributing to the control of FeLV 
viraemia.
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Following the oronasal exposure of cats E1-E12 to FeLV, the virus-specific cell- 
mediated response elicited in the peripheral blood and lymphoid tissues was 
determined using two different techniques, the LPA, and ICS analysed using flow 
cytometry. Virus-specific responses in the peripheral blood were evaluated one 
week following exposure and at three-week intervals thereafter, while virus-specific 
responses in the lymphoid tissues were investigated post mortem.
The specificity of the immune response was determined using recombinant p27 and 
p45 proteins, and inactivated FeLV particles. The genes encoding FeLV CA protein 
p27, and SU protein gp70, were expressed by Escherischia coli {E. coli) as fusion 
proteins; the recombinant p27 and p45 proteins were then purified using affinity 
chromatography under denaturing conditions. Feline leukaemia virus was purified 
from F422 cell culture supernatants, and heat-inactivated. The purity of the 
recombinant p27 and p45 proteins, and inactivated FeLV particles, was assessed 
using SDS-PAGE and Western blots.
The LPA was used to assess the ability of mononuclear cells in the peripheral blood 
and lymphoid tissues to proliferate in response to mitogenic and virus-specific 
stimulation ex vivo. Mononuclear cells were stimulated for three days with Con A, 
and either recombinant p27 or p45 proteins, or inactivated FeLV particles. 
Proliferative responses were measured using a liquid scintillation spectrophotometer 
to calculate the uptake of ^H-thymidine (methyl-^H-thymidine, Amersham 
Biosciences, U.K.) by cellular DNA. Concurrent phenotypic analysis was conducted 
using flow cytometry to enumerate the proportion of CD4^ and CD8^ T cells, and 
either CD21^ B cells or CD45R^ white blood cells (WBC), in significant virus- 
specific proliferative responses in the peripheral blood.
Intracellular cytokine staining techniques evaluated the ability of mononuclear cells 
in the peripheral blood and lymphoid tissues to upregulate flFN-y in response to 
virus-specific stimulation ex vivo. Mononuclear cells were stimulated with either 
recombinant p27 or p45 proteins, or inactivated FeLV particles, for four hours; 
intracellular flFN-y expressed in recognition of cognate antigen was detected using 
an anti-flFN-y mAb, generated in this thesis, and analysed using flow cytometry.
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Concurrent phenotypic analysis was conducted to enumerate the proportion of CD4^ 
and CD8^ T cells that expressed flFN-y.
4.2 Materials and Methods
4.2.1 Preparation of Recombinant p27 and p45 Proteins
4.2.1.1 Expression o f FeLV Genes
The genes encoding FeLV CA protein p27, and SU protein gp70, were cloned by Drs 
Norman Spibey and Julie McDonald within the Department of Veterinary Pathology 
at the University of Glasgow, then inserted into gene fusion vectors containing six 
tandem histidine (6 x his) residues in the N-terminal peptide (Invitrogen Ltd., U.K.), 
and expressed in E. coli bacterial cells. The FeLV SU protein gp70 is glycosylated 
in vivo, with a molecular weight (mw) of 70 kDa; the recombinant protein expressed 
by E. coli is non-glycosylated, and has a mw of 45 kDa (p45). The polyhistidine tag 
has a strong affinity for the divalent nickel chloride (NiCla) cations immobilised on 
TroBond™’ resin (Invitrogen Ltd., U.K.) used to purify the recombinant p27 and 
p45 proteins. Denaturing buffers containing 6 M urea were used in all stages of the 
purification process. The purification method used was based on the manufacturer’s 
protocol (Invitrogen Ltd., U.K.) with some minor amendments: additional astringent 
washes were required to enhance the purity of the recombinant p45 protein.
4.2.1.2 Preparation o f Denatured E. coli Lysate
The bacterial expression vectors were prepared in a similar way to the vectors 
described in Section 2.2.1.2. Following centrifugation of the induced cultures, the 
cell pellets were resuspended in 10 ml guanidinium lysis buffer^^, preheated to 37°C. 
The cells were subsequently agitated for ten minutes at RT to ensure thorough 
bacterial cell lysis, and then sonicated on ice using three five-second pulses. To 
remove the insoluble debris, the bacterial lysate was transferred to a JA-21 rotor and
Guanidinium lysis buffer, pH 7,8: 6 M (w/v) guanidine hydrochloride; 20 mM (w/v) sodium 
phosphate; 500 mM (w/v) sodium chloride
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centrifuged at 5000rpm for fifteen minutes; the supernatant containing the sheared 
lysate was stored at -20°C until further use.
4.2.1.3 Purification o f Recombinant Proteins using Affinity Chromatography
Four ml 50% ‘ProBond™’ resin was added to an empty polypropylene column 
(Gibco, Invitrogen Ltd., U.K.). The column was placed in a centrifuge tube (Falcon 
2070, Becton Dickinson, France) and centrifuged in a swinging bucket rotor within a 
bench-top centrifuge for two minutes at lOOOrpm to sediment the resin. The ethanol 
preservative was decanted from the column and the resin resuspended by gentle 
agitation. The resin was washed twice with 7 ml sterile water using centrifugation as 
described above, followed by two washes with denaturing binding buffer^^ to 
equilibrate the resin. Once equilibrated, 5 ml denatured bacterial lysate was added to 
the resin. The column was then agitated at RT for ten minutes to allow the his- 
tagged proteins to bind the nickel cations. The resin was sedimented as described 
above and a further 5 ml denatured bacterial lysate applied to the column.
Non-specific bacterial proteins were stripped from the column using progressively 
astringent washes. For each wash, 4 ml denaturing wash buffer^^ was added to the 
resuspended resin, which was agitated at RT for two minutes before sedimentation 
by centrifugation at SOOrpm for two minutes. Initially, the column was washed with 
denaturing binding buffer, followed by denaturing wash buffer pH 6.0, and finally 
denaturing wash buffer pH 5.3. Each wash was repeated once. For purification of 
the recombinant p45 protein, two additional washes using denaturing wash buffer pH 
4.5 were conducted in order to remove contaminant bacterial cell proteins. The 
proteins were eluted from the column by applying 5 ml elution buffer^^ to the top of 
the column, and allowing the eluted proteins to run through the column where they 
were collected.
Denaturing binding buffer, pH 7.8: 8 M (w/v) urea; 20 mM (w/v) sodium phosphate; 500 mM (w/v) 
sodium chloride
Denaturing wash buffer, pH 4.5-6.0: 8 M (w/v) urea; 20 mM (w/v) sodium phosphate; 500 mM 
(w/v) sodium chloride
Denaturing elution buffer, pH 4.0: 8 M (w/v) urea; 20 mM (w/v) sodium phosphate; 500 mM (w/v) 
sodium chloride
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To remove the urea used in the denaturing buffers, the proteins were placed into 
dialysis tubing and dialysed overnight at 4°C into 0.01 M tris buffer, pH 8.0. 
Removal of the urea rendered the proteins insoluble; therefore, 2-5 drops 5 M 
sodium hydroxide (NaOH, Fisher Scientific U.K. Ltd, Loughborough, Leicestershire, 
U.K.) were added using a 22 guage needle to resolubilise the proteins. The purified 
recombinant p27 and p45 proteins were quantified using a spectrophotometer; a 
proportion was electrophoresed on a 12% polyacrylamide gel (Section 2.2.1.4), then 
blotted onto nitrocellulose (Section 2.2.2.6). The remainder was aliquoted and stored 
at -20°C.
The basic protocol used for Western blots was similar to that described in Section
2.2.2.Ô. The blotted recombinant p27 protein and FeLV particles was probed for two 
hours with a sheep anti-p27 pAb (Dr A. Pacitti, University of Glasgow), diluted in 
20% NRS in TBS-T, followed by a one-hour incubation using a biotinylated rabbit 
anti-sheep Ig pAb, diluted 1:2000 in 20% NRS in TBS-T. A further one-hour 
incubation with strepatavidin-peroxidase, diluted 1:500 in TBS-T, preceded the 
development of colour using DAB. Blots were probed with either 20% NRS or 20% 
NGS in TBS-T, diluted as the primary antibody, as negative controls. In addition, 
recombinant p27 and p45 proteins, and FeLV particles, prior to heat inactivation, 
were probed with serum from FeLV recovered cats, diluted 1:4 in 20% NGS, 
followed by a one-hour incubation with biotinylated protein A (ICN Biomedicals, 
Hampshire, U.K.), diluted 1:500 in TBS-T. A second one-hour incubation with 
peroxidase-conjugated streptavidin preceded the development of colour using DAB. 
Blots were probed with either 20% NGS, or 20% NRS, diluted as the primary 
antibody, as negative controls.
4.2.2 Preparation of Inactivated FeLV Particles
4,2,2.1 Culture ofF422 Cells
F422 cells are derived from a naturally occurring feline lymphosarcoma (Rickard et 
aL, 1969), and express FeLV proteins. F422 cells were cultured in a 
compaitmentalised flask, ‘CL-1000’, at 37°C with 5% CO2 . Two x 10  ^ cells were 
seeded into the 15 ml cell compartment, and nourished through a semi-permeable
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membrane by 1 litre of complete R PM I1640 medium. At three to four day inteiwals, 
the cells were removed from the cell compartment and pelleted by centrifugation in a 
bench-top centrifuge at lOOOrpm for ten minutes. The supernatant was decanted, and 
stored at 4°C in 0.1% sodium azide.
42.2.2 Sucrose Gradient Purification o f FeLV
In 1967, Kawakami et al. isolated mature virus particles from the plasma of cats 
suffering from feline leukaemia, using linear sucrose-density gradients. A modified 
method of this original work was used to purify FeLV from plasma and tissue culture 
supernatants. A gradient comprising 5 ml 20% sucrose (Fisher Scientific, U.K.) 
layered over 5 ml 50% sucrose, was made in SW28 inner tubes (Beckman-Coulter, 
U.S.). The F422 cell culture supernatants were gently applied over the sucrose layers 
to fill the tubes, which were balanced using a Sartorius balance (European 
Instruments, Oxford, U.K.). The tubes were inserted into a SW28 rotor (Beckman- 
Coulter, U.S.), and centrifuged at 4°C in an ultracentrifuge (Beckman L8-70M, 
Beckman-Coulter, U.S.) for two hours at 25,000rpm. Purified virus was removed 
from the interface using a 23 guage needle and syringe and subsequently layered 
over a second gradient comprising 1.5 ml 50% sucrose, 1.5 ml 30% sucrose and 1.5 
ml 20% sucrose, in chilled SW41 inner tubes (Beckman-Coulter, U.S.). The tubes 
were balanced and spun using a SW41 rotor (Beckman-Coulter, U.S.) at 4°C for one 
hour at 40,000rpm in an ultracentrifuge. The purified virus was removed from the 
interface between 50% and 30% sucrose layers as before, and dialysed overnight at 
4°C in 0.01 M tris, pH 8.0.
4.2.2.3 Inactivation of Purified FeLV
Purified FeLV virus was inactivated by boiling for 2.5 minutes in a boiling bath. The 
inactivated virus was passed through a 0.22 pm filter (‘Minisart’, Sartorius Ltd., 
U.K.) and quantified using a spectrophotometer. A proportion was electrophoresed 
on a 12% polyacrylamide gel (Section 2.2.1.4), and then blotted onto nitrocellulose 
(Section 2.2.2.6). The remainder was aliquoted and stored at -20°C. Inactivated 
FeLV particles did not contain any infectious virus as determined using VI 
techniques on QNIOS cells (Section 3.2.3.1).
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4.2.3 FeLV-Specific Cell-Mediated Immune Responses
4.2.3.1 Lymphocyte Proliferation Assay
The ability of mononuclear cells in the peripheral blood and lymphoid tissues to 
proliferate in response to mitogenic and virus-specific stimulation was determined in 
the LPA.
Serial dilutions of recombinant p27 and p45 proteins, and inactivated FeLV particles, 
were prepared in complete RPMI 1640 medium. One hundred p.1 of each dilution 
was added in triplicate to the wells of a 96-well U-bottom tissue-culture plate (Falcon 
3077, Becton Dickinson, France). To detect background proliferation, control wells 
were coated in 100 [xl complete RPMI 1640 medium, devoid of viral antigen and 
mitogen. The plate was incubated overnight at 37°C in a humidified atmosphere 
containing 5% CO2 to ensure that the medium was at the correct pH and temperature 
before the addition of cells. Mononuclear cells were prepared from the peripheral 
blood by centrifugation of whole blood over Ficoll-Paque. Additionally, 
mononuclear cells were prepared from post mortem PLN, MLN and spleen tissues as 
described in Section 3.2.4.1, and layered over Ficoll-Paque. Peripheral blood and 
tissue mononuclear cells were resuspended in complete RPMI 1640 medium (2 x 10  ^
cells/ml); 100 fxl of which was added to each well, to give final viral protein 
concentrations of 25 p,g/10  ^ cells; 12.5 p.g/10^ cells; 6.25 trg/10^ cells and 3.125 
p-g/10  ^cells. The mitogen Con A was added in triplicate at 5 trg/10^ cells, 0.5 p-g/lO  ^
cells and 0.1 p.g/10^ cells, and used as a positive control. The plates were sealed in 
plastic bags and incubated for three days, as before. On the third day of culture, 
methyl-^H-thymidine was added to each well (0.5 p,Ci/well) for the final five hours 
of incubation. The cells were subsequently harvested (‘Filtermate 196 Cell 
Harvester’, Packard, Netherlands) onto filter plates (‘UniFilter-96 GF/C’, Packard 
Bio science BV, Groningen, Netherlands). The filter plates were dried at 37°C; 25 p,l 
scintillation fluid (‘MicroScint’, Packard, Netherlands) was then added to each well, 
and the plates were sealed. Radioactivity was read on a liquid scintillation counter as 
counts per minute (cpm) (‘TopCount Microplate Scintillation Counter’, Packard, 
Netherlands). The stimulation index (S.l.) for virus-specific and mitogenic
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proliferative responses was calculated as follows:
Mean test wells (cpm)
Mean background wells (cpm)
4,23,2 Immunophenotyping o f Proliferating Cells
Additional 96-well plates were prepared to determine the phenotype of the 
proliferating cells. This was achieved using flow cytometry to detect surface CD4 
and CD8, and either CD45R or CD21, molecules, stained using anti-feline CD4-PE; 
anti-feline CD8-PE (10 (tl/lO'* cells, Serotec, U.K.), anti-rat CD45R-PE (10 pd/lO"^  
cells, Serotec, U.K.) and anti-canine CD21-PE (2.5 trl/10^ cells, Dr. P.P. Moore, 
University of Davis, California) mAbs.
The CD45R molecule comprises high and low molecular weight isoforms of the 
leukocyte common antigen CD45: CD45R* ‘^ and CD45R*°. The anti-rat CD45R mAb 
reacts predominately with mature and precursor B cells in the rat, in addition to 
marginal zone B cells and a small subset of T cells. In cats, this mAb is routinely 
used to enumerate B cells in fresh peripheral blood samples (Flynn, J.N., personal 
communication). However, after three days of culture in the LPA, it became 
apparent that other cell types upregulated expression on the CD45R molecule; 
therefore, this mAb was not a suitable marker for the enumeration of B cells in the 
LPA.
Single concentrations of either recombinant p27 or p45 proteins, or inactivated FeLV 
particles, were used as virus-specific stimulation (25 fxg/10  ^cells). The mitogen Con 
A (5 \k,gjl(f cells) was present as a positive control; wells containing neither viral 
antigen nor mitogen were included as negative controls. After three days, the cells 
were harvested into polypropylene tubes (2 x 10  ^ cells/tube), pelleted and washed in 
PBS by centrifugation for five minutes at lOOOrpm using a bench-top centrifuge. 
The cells were then incubated with the mAbs described above for thirty minutes at 
RT. The cells were subsequently washed in PBS as before, fixed in 2% 
formaldehyde and resuspended in fluorescence buffer as previously described
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(Section 2.2.2.S).
4.2.3.3 Intracellular Cytokine Staining Analysed Using Flow Cytometry
The production of intracellular flFN-y by mononuclear cells in the peripheral blood 
and lymphoid tissues in response to virus-specific stimulation was determined 
following a short four-hour culture ex vivo. The protocol followed was similar to 
that described in Section 2.2.2.8, except that virus-specific responses were now also 
measured. Tissue culture plates were pre-incubated with inactivated FeLV particles, 
as well as recombinant p27 and p45 proteins; mononuclear cells were then added to 
give a final viral protein concentration of 25 jig/10*^  cells.
For each sample, 10,000 events were recorded. The small lymphocyte and the 
lymphoblast populations were gated based on cell size and granularity, and the 
percentage of flFN-y-expressing CD4^ T cells within the lymphoblast population was 
enumerated. The gates for flFN-y expression were determined by the reactivity of 
the FITC-conjugated isotype matched control mAb.
4.2.4 Statistics
Statistical analysis was conducted using ‘GraphPad InStat’. Non-parametric tests 
were used throughout. The Mann-Whitney test was applied to compare results from 
two groups, using a two-tail P  value. The Spearman r-Test was performed to 
correlate FeLV proviral DNA loads and cell-mediated immune responses in 
peripheral blood and lymphoid tissues, following virus-specific and mitogenic 
stimulation.
4.3 Results
4.3.1 Production of Recombinant p27 and p45 Proteins, and Inactivated FeLV 
Particles
The genes encoding FeLV CA protein p27, and SU protein p45, were expressed by
E. coll as fusion proteins containing polyhistidine N-terminal tags. The recombinant
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p27 and p45 proteins were released following guanidinium bacterial cell lysis and 
sonication, then purified over NiCL resin under denaturing conditions. Feline 
leukaemia virus particles were purified from F422 cell culture supernatants using 
sucrose density gradients, and heat-inactivated. The yield of recombinant p27 and 
p45 proteins following purification and dialysis was approximately 2.5-5 mg and 3-5 
mg respectively, from 400 ml bacterial cultures. Aliquots of each recombinant 
protein, and inactivated FeLV particles, were electrophoresed on a 12% 
polyacrylamide gel using SDS-PAGE, and probed in Western blots, to ensure purity 
of the reagents. Recombinant p27 and p45 proteins and inactivated FeLV particles 
were stored in aliquots at -70°C. The same batch of recombinant p27 protein was 
used throughout the study to ensure consistent results. Two batches of recombinant 
p45 protein were produced, using the original glycerol preparation, and used for cats 
E1-E6 or cats E7-E12, respectively. Each batch of recombinant p45 protein was 
consistently pure, according to Coomasssie-stained SDS-PAGE, and reactivity in 
Western blots.
Prior to heat-inactivation, purified FeLV displayed three prominent bands in the 
Coomassie Brilliant Blue-stained gel, approximately 70 kDa, 27 kDa and 15 kDa in 
size, which corresponded to the FeLV SU protein gp70, CA protein p27 and TM 
protein pl5E, respectively (Fig. 4.1.1). However, these proteins became disrupted 
following heat-inactivation, and an additional two bands, between 37 kDa and 75 
kDa in size, were evident on the Coomassie Brilliant Blue-stained gel (Fig. 4.1.1). 
Feline leukaemia virus CA protein p27 has a molecular weight of approximately 27 
kDa. A single dense band of this approximate size was evident on the Coomassie 
Brilliant Blue-stained gel, confirming the successful purification of the recombinant 
p27 protein (Fig. 4.1.1). The FeLV SU protein gp70 expressed by E. coli is non­
glycosylated and only 45 kDa in size. A single band of this size was evident on the 
Coomassie Brilliant Blue-stained gel (Fig. 4.1.IV), which corresponded to the 
recombinant p45 protein.
Western blots were used to verify that the purified recombinant p27 and p45 proteins 
were the reagents of interest, and that each contained antigenic determinants that 
were immunologically relevant in FeLV-exposed cats; antibodies in sera from FeLV 
recovered cats recognised and bound to proteins of approximately 27 kDa (Fig.
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4.1.II) and 45 kDa (Fig. 4.1.V) in size, which corresponded to the recombinant p27 
and p45 proteins, respectively. Furthermore, the sheep anti-p27 pAb recognised 
antigenic determinants shared by the recombinant p27 protein and the FeLV CA 
protein p27 (Figs. 4.1.II and 4.1.III).
4.3.2 FeLV-Specific Cell-Mediated Immune Responses
Following oronasal exposure of cats E1-E12 to FeLV, virus-specific cell-mediated 
immune responses elicited in the blood and lymphoid tissues were compared using 
two different techniques, the LPA, and ICS analysed using flow cytometry. These 
assays were conducted using mononuclear cells prepared from peripheral blood 
sampled throughout the study, and from lymphoid tissues harvested post mortem. 
The specificity of the immune response was determined by measuring the ability of 
these mononuclear cells to proliferate, and to upregulate flFN-y, in response to 
stimulation with recombinant p27 or p45 proteins, or inactivated FeLV particles 
(Section 4.2.3). Mononuclear cells in the peripheral blood and lymphoid tissues 
were also assessed for their ability to respond to mitogenic stimulation in the LPA. 
Concurrent phenotypic analysis was conducted using flow cytometry to identify the 
virus-specific cells in each assay. Statistical analysis of the results was performed 
using the methods described in Section 4.2.4.
4.3.2.1 Lymphocyte Proliferation Assay
The virus-specific and mitogenic proliferative responses of mononuclear cells in the 
peripheral blood and lymphoid tissues are shown in Figs. 4.2-4.7. The net counts 
(cpm) recorded in the unstimulated wells are included in the figure legends. These 
background counts were used to calculate the S.L Virus-specific proliferation was 
considered significant when the S.l. was equal to, or greater than, 2. Prior to FeLV 
exposure, no significant virus-specific proliferation was observed in the peripheral 
blood from any cat (Figs. 4.2-4.3). Unless otherwise stated, S.L or statistical 
analyses are recorded as (cats that received an exposure dose of 5 x 10  ^ ffu FeLV-A; 
cats that received an exposure dose of 5 x 10"^  ffu FeLV-A, respectively).
1 2 2
4.3.2.L I Proliferative Responses in Peripheral Blood
(i) Proliferative Responses to Inactivated FeL V Particles
Over the course of the study, S.L equal to, or greater than, 2 were not detected in any 
cat in response to stimulation with inactivated FeLV particles (Figs. 4.2.A and 
4.3.A). Overall, mean proliferative responses to inactivated FeLV particles were 
similar in cats that were exposed to a higher dose of infectious FeLV by a factor of 
one log, compared to cats that received a lower exposure dose (S.L 1.05 ± 0.10; S.L
1.04 ± 0.07, respectively).
(ii) p27-Specific Proliferative Responses
Two distinct patterns of p27-specific proliferative responses were identified in the 
peripheral blood over the study, which appeared to be influenced by the FeLV 
exposure dose (Figs. 4.2.B and 4.3.B). Thus, cats that were exposed to a higher dose 
of FeLV-A by a factor of one log, displayed peaks in mean p27-specific proliferative 
responses at weeks 4 and 10 (S.L 2.09 ± 1.11; S.L 2.6 ± 0.9, respectively); whereas 
cats that received a lower exposure dose peaked in mean p27-specific proliferative 
responses at weeks 7 and 13 (S.L 2.2 ± 1.2; S.L 1.76 ± 0.32, respectively). Statistical 
analysis revealed that the peaks in proliferative responses at weeks 7, 10 and 13 were 
significant (Mann-Whitney Statistic, P=0.0260; F=0.0022; F=0.0411, respectively), 
compared to week 0. Although the temporal shift in peaks of p27-specific 
proliferative responses appeared to be related to the exposure dose, mean p27- 
specific proliferative responses recorded over the study were similar in both groups 
of cats (S.L 1.56 ± 0.46; S.L 1.48 ± 0.36, respectively).
Stimulation indices equal to, or greater than, 2, were detected in the peripheral blood 
from seven cats in response to p27-specific stimulation (cats E l; E3; E4; E6; E9; ElO 
and E ll) , on at least one sample date during the study. In cats E4 and E9, the mean
S.L over the study, exceeded 2 (S.L 2.27 ± 1.05; S.L 2.15 ± 1.23, respectively).
Statistical analysis showed that mean p27-specific proliferative responses in the 
peripheral blood from cats E4 and E9 were significantly greater than such responses 
in the peripheral blood from cats E2, E3, E5 and E12, when compared with cats that
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received a comparable exposure dose of FeLV (Mann-Whitney Statistic, P=0.0104; 
P=0.0499; F=0.0070; F=0.0411, respectively).
For each peripheral blood sample that showed a significant level of proliferation, i.e. 
S.l. equal to, or greater than, 2, the proportion of CD4^and CD8^ T cells, and either 
CD21+ B cells or CD45R+ WBC, was calculated (Figs. 4.4.A and 4.5.A). An 
increased proportion of CD4^ T cells proliferating in response to stimulation with the 
recombinant p27 protein, compared to medium alone, was detected in the peripheral 
blood from five cats (E4; E6; E9; ElO and E ll) , signifying the presence of p27- 
specific CD4^ T cells in the peripheral blood from these cats. In three cats (E4, E9 
and ElO), p27-specific CD4^ T cells were not detected during the earliest significant 
proliferative response, but were detected in each sample thereafter. p27-specific 
CD4^ T cells were detected early in two cats, E4 and E6; cat E4 maintained these 
cells over weeks 4-10. Cat E l l  developed p27-specific CD4^ T cells by week 7, 
while cats E9 and E l l  failed to generate p27-specific CD4^ T cells until week 13.
The presence of p27-specific CD4^ T cells among the proliferating cell population 
was not always accompanied by an increased proportion of either CD8^ T cells or 
CD21^ B cells. A concomitant increase in the percentage of CD8^ T cells was 
detected in the peripheral blood from cat E4 only (weeks 4, 7 and 19), while 
concurrent increases in the percentage of CD21^ B cells were detected in cats E4 
(weeks 13 and 19), E6, E9 (week 13) and E l l  (week 7). Where p27-specific 
proliferative responses were not associated with detectable p27-specific CD4^ T 
cells, an increased proportion of CD8^ T cells, CD21^ B cells or CD45R^ WBC, 
were enumerated among the proliferating cells. Thus, in cats E l and E3, p27- 
specific proliferative responses were associated with an increased proportion of 
CD45R^ WBC (weeks 10 and 4, respectively), while in cats E3, E4 and E9, such 
responses were associated with increased numbers of CD8^ T cells, and either 
CD45R^ WBC or CD21^ B cells (weeks 10, 4 and 7, respectively).
(Hi) p45-Specific Proliferative Responses
The mean peaks and patterns in p45-specific proliferative responses in the peripheral 
blood occurred at time points similar to those previously described for p27-specific
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proliferative responses (Figs. 4.2.C and 4.3.C). Thus, p45-specific proliferative 
responses in cats that received the highest FeLV exposure dose peaked at weeks 4 
and 10, with an additional peak at week 19 (S.l. 1.67 ± 0.85; S.L 1.71 ± 0.52; S.L 
1.67 ± 0.39, respectively). Such responses peaked later in cats that received a lower 
exposure dose, at weeks 7 and 13 (S.L 1.61 ± 0.63; S.L 1.89 ± 0.56, respectively).
Despite the disparate patterns of p45-specific proliferative responses in cats that 
received different exposure doses, mean responses recorded in each group over the 
study were similar (S.L 1.38 ± 0.25; S.L 1.39 ± 0.26, respectively). The mean S.L 
recorded in response to stimulation with the recombinant p45 protein were lower in 
both groups of cats, than those recorded in response to stimulation with the 
recombinant p27 protein. The difference was not statistically significant (Mann- 
Whitney Statistic, P=0.5512).
At various sample dates over the study, eight cats recorded S.l in excess of 2 in 
response stimulation with the recombinant p45 protein (El; E4; E6; E7-E11). An 
increased proportion of CD4^ T cells proliferating to stimulation with the 
recombinant p45 protein, compared to medium alone, was detected in the peripheral 
blood from five of these cats (E l; E8; E9; ElO and E ll) , indicating the presence of 
p45-specific CD4^ T cells (Figs. 4.4.B and 4.5.B). p45-specific CD4^ T cells were 
not detected in any cat until week 7 (cats E9 and E ll) . Cats E l, E8 and ElO 
developed p45-specific CD4^ T cells by week 13. The presence of such cells was 
accompanied by a corresponding increase in CD21^ B cells in cat E9 at week 13, 
while a concomitant increase in CD8^ T cells, and either CD45R^ WBC or CD21^ B 
cells, was detected in each of the remaining samples. In the absence of detectable 
p45-specific CD4^ T cells, increased proportions of CD8^ T cells, and either CD45R"  ^
or CD21^ B cells, were enumerated among the proliferating cells (cats E l, E4 and E6 
at weeks 19, 4 and 10, respectively).
(iv) Mitogenic Proliferative Responses
At each sample date, marked differences in the ability of mononuclear cells in the
peripheral blood from cats E1-E12 to respond to mitogenic stimulation were
observed (Fig. 4.6). The highest mean mitogenic proliferative responses over the
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study were recorded in the peripheral blood from cats E9 and ElO (S.L 53.5 ± 23.3 
and S.L 44.1 ±31.4, respectively), while cats E2 and E12 recorded the lowest mean 
values (S.L 10.9 ± 8.5; S.L 12.2 ± 6.5, respectively).
Over the study, greater mean mitogenic proliferative responses were detected in the 
peripheral blood from cats that were exposed to a lower dose of infectious FeLV by a 
factor of one log (S. I. 37.37 ± 13.81), compared to cats that received the higher 
exposure dose (S.L 22.62 ± 11.2); these differences were not quite statistically 
significant (Mann-Whitney Statistic, f =0.0931).
4.3.2.1.2 Proliferative Responses in the Lymphoid Tissues
(i) Proliferative Responses to Inactivated FeLV Particles
Over the course of the study, S.L equal to, or greater than, 2 were not detected in the
PLN tissues from any cat in response to stimulation with inactivated FeLV particles
(Fig. 4.7.A). Nonetheless, using statistical analysis, significantly greater proliferative 
responses to inactivated FeLV particles were demonstrated in the PLN tissues from 
cats that received a lower exposure dose of FeLV (Mann-Whitney Statistic, 
P=0.0152), compared to cats that received a higher exposure dose. Significantly 
lower proviral DNA levels were also recorded in the PLN tissues from cats that 
received a lower exposure dose of FeLV (Section 3.3.1.3).
Stimulation indices equal to, or greater than, 2 were not detected in the MLN or 
splenic tissues from any cat tested in response to stimulation with inactivated FeLV 
particles (Figs. 4.7.B and 4.7.C).
(ii) p27-Specific Proliferative Responses
No S.L greater than, or equal to, 2 was recorded in the PLN tissues from any cat in 
response to stimulation with the recombinant p27 protein (Fig. 4.7.A). Nonetheless, 
statistical analysis showed that significantly greater p27-specific proliferative 
responses were detected in the PLN tissues from cats that received a lower FeLV 
exposure dose (Mann-Whitney Statistic, P=0.0043), compared to cats that received a 
higher exposure dose. Cats exposed to a lower dose of infectious FeLV also
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recorded significantly lower proviral DNA levels in the PLN tissues (Section 
3.3.1.3).
Out of ten cats tested, p27-specific proliferative responses were detected in the MLN 
tissues from only one cat, E12 (S.l. 2,1) (Fig. 4.7.B). Viral protein concentrations of 
25 |Lig/10^ cells were generally optimal; occasionally, lower concentrations resulted 
in S.l in excess of 2, e.g. mononuclear cells in the MLN tissues from cat E7 
proliferated optimally at 12.5 gg p27/10^ cells.
Mononuclear cells in the splenic tissues from six cats (E2; E4; E7; E9; ElO and E12) 
were tested for their ability to respond to specific stimulation with the recombinant 
p27 protein; however, no S.l. greater than, or equal to, 2 were detected (Fig. 4.7.C).
(Hi) p45-Specific Proliferative Responses
Mononuclear cells in the PLN tissues from all cats were examined for p45-specific 
proliferative responses; however, only cat E9 recorded an S.L equal to, or greater 
than, 2 (S.L 2.38) (Fig. 4.7.A).
The MLN tissues from cats E7 and E12 alone recorded an S.L equal to, or greater 
than, 2 in response to stimulation with the recombinant p45 protein (S.L 2.03; S.L 
2.6, respectively) (Fig. 4.7.B). p45-specific proliferative responses were also
detected in the PLN tissues from cat E8 when the viral protein concentration was 
reduced to 12.5 gg /lO^ cells. Significantly greater p45-specific proliferative 
responses were recorded in the MLN tissues from cats that received a lower exposure 
dose of FeLV (Mann-Whitney Statistic, P=0.0381), compared to cats that received a 
higher exposure dose. Lower proviral DNA levels were also quantified in the MLN 
tissues from cats exposed to a lower dose of infectious FeLV (Section 3.3.1.3).
Mononuclear cells in the splenic tissues from six cats (E2; E4; E7; E9; ElO and E12) 
were tested for their ability to respond to specific stimulation with the recombinant 
p45 protein; however, no S.L greater than, or equal to, 2 were detected (Fig. 4.7.C).
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(iv) Mitogenic Proliferative Responses
In each lymphoid tissue examined, marked differences were detected in the ability of 
mononuclear cells to respond to mitogenic stimulation (Fig. 4.7.D). Thus, the S.L 
recorded in response to the mitogenic stimulation of mononuclear cells in the MLN 
tissues ranged from 6.3-63.0 (cats E3 and E12, respectively), while in the PLN 
tissues, the S.L ranged from 6.7-48.0 (cats E4 and E6, respectively). Finally, in the 
splenic tissues, the S.l varied between 17.62-87.28, (cats E2 and E9, respectively).
Greater mean proliferative responses to Con A were detected in the MLN tissues 
from cats that received a lower exposure dose of FeLV (S.L 37.37 ± 21.18), 
compared to cats that received a higher exposure dose (S.L 13.39 ± 7.64); the 
difference was statistically significant (Mann-Whitney Statistic, P=0.0381). 
Differences in the mean proliferative responses in the PLN tissues were less affected 
by the exposure dose (S.L 25.3 ± 6.17; S.L 21.57 ± 15.1, respectively); this also 
applied to the splenic tissues (S.L 50.37 ± 26.65; S.L 44.22 ± 37.62, respectively).
43.2.2 Intracellular Cytokine Staining Analysed using Flow Cytometry
Intracellular cytokine staining analysed using flow cytometry, was used to evaluate 
the ability of mononuclear cells in the peripheral blood and the PLN tissues from cats 
E1-E12 to upregulate intracellular flFN-y in response to a four-hour virus-specific 
stimulation. The results are shown in Figs. 4.8-4.11.
The percentage of fIFN-y-expressing CD4^ and CD8^ T cells within the gated 
lymphoblast population was recorded. These data were corrected by deducting the 
percentage of any CD4^ and CD8  ^ T cells that expressed fIFN-y in the absence of 
virus-specific stimulation, in order to calculate the percentage of virus-specific CD4^ 
and CD8^ T cells (Figs. 4.8, 4.9 and 4.11). The percentage of lymphoblast cells that 
expressed flFN-y in the absence of virus-specific stimulation is tabulated in the 
figure legends (Figs. 4.8, 4.9 and 4.11).
Since a larger area of cells, which included some non-lymphoblast cells, was gated
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for cats that received a higher exposure dose of FeLV by a factor of one log, 
compared to cats that received the lower exposure dose; the percentage of CD4^ T 
cells and CD8^ T cells that co-expressed flFN-y was automatically lower in each 
sample from those cats. Therefore, direct comparisons between the results from 
these two groups of cats could not be made.
4.3.2.2.1 Virus-specific Responses in the Peripheral Blood
(i) CD4^ T cell Responses to Inactivated FeL VParticles
Specific CD4^ T cell responses to inactivated FeLV particles were detected in the 
peripheral blood from all cats, except E7 (Figs. 4.8.A and 4.9.A). However, the 
timing of the appearance of such cells varied between individual animals; thus, in 
five cats, E2, E3, E6, E l l  and E12, a specific CD4^ T cell response to inactivated 
FeLV particles was detected as early as one week following exposure to infectious 
virus. In three of these cats, such responses were transient; however, a second wave 
of specific CD4^ T cells was observed in the peripheral blood from each of these cats 
later in the study. Cat E3 maintained specific CD4^ T cells to inactivated FeLV 
particles until at least week 10, while latently infected cat E l2 maintained such cells 
throughout the study (weeks 0-13).
At week 4, specific CD4^ T cell responses to inactivated FeLV particles were 
detected in the peripheral blood from two cats, E l and E8. Cat E8 maintained these 
responses until the termination of the study at week 13, while additional specific 
CD4^ T cells were not detected in the peripheral blood from cat E l until week 19. 
By week 7, specific CD4^ T cell responses to inactivated FeLV particles were 
detected in the peripheral blood from a further three cats, E5, E9 and ElO. The 
frequencies of these cells were particularly high in cat ElO (2.15%). Specific CD4^ 
T cell responses to inactivated FeLV particles did not appear in the peripheral blood 
from cat E4 until week 16.
It was difficult to discern a consistent pattern in the development of CD4^ T cell 
responses to inactivated FeLV particles over the study. Nonetheless, if the mean 
responses were compared among cats that received a comparable exposure dose, two
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distinct patterns could be identified. Thus, in cats that received a higher exposure 
dose of FeLV by a factor of one log, an early peak of CD4^ T cell responses to 
inactivated FeLV particles was observed at week 4 (0.20% ± 0.23%) followed by a 
lower peak at week 16 (0.14% ± 0.16%) (Fig. 4.8.A). In cats that received a lower 
exposure dose of FeLV, specific CD4’*’ T cells to inactivated FeLV particles peaked 
only at week 10 (1.01% ± 1.7%) (Fig. 4.9.A). Over the entire study, the mean 
percentage of specific CD4^ T cells to inactivated FeLV particles from this latter 
group of cats was 0.42% ± 0.36%; while specific responses from cats that received a 
higher FeLV exposure dose averaged 0.075% ± 0.075%.
Statistical analysis showed that the correlation between CD4^ T cell responses to 
inactivated FeLV, and proviral DNA loads, was not significant, irrespective of the 
exposure dose (Spearman r-Test, r=-0.6, P=0.2417; r=-0.7143, P=0.1361, 
respectively).
(ii) CD8^ T cell Responses to Inactivated FeLV Particles
Specific CDS’*' T cell responses to inactivated FeLV particles were detected in the 
peripheral blood from all twelve cats (Figs. 4.8.D and 4.9.D). Six cats, E3, E4, E7, 
E8, E l l  and E12, developed specific CD8^ T cell responses to inactivated FeLV 
particles one week following oronasal exposure to FeLV; these were particularly 
numerous in cats E4 and E12 (0.49%; 2.22%, respectively). Cat E4 maintained these 
specific responses over weeks 1-7, with an additional high peak at week 16. 
Although these early responses were transient in the remaining cats, each developed 
a second wave of specific CD8^ T cell responses to inactivated FeLV particles; such 
responses were particularly high in cat E12 over weeks 7-10, and in cat E7 at week 
10. Moderately high frequencies of specific CD8^ T cells to inactivated FeLV 
particles were detected in the peripheral blood from cat ElO over weeks 4-10, and at 
lower levels in cat E2 over weeks 7-10. The remaining cats failed to develop any 
specific CD8^ T cell responses to inactivated FeLV particles until late in the study, at 
weeks 10 (E5 and E9), 13 (E l) and 16 (E6).
The mean specific CD8’*' T cell responses to inactivated FeLV particles recorded in 
the peripheral blood from cats E1-E6 peaked at weeks 1 (0.11% ± 0.12%) and 16
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(0.18% ± 0.12%), while the mean responses from cats E7-E12 peaked at weeks 1 
(0.61% ± 0.86%) and 10 (1.35% ± 1.03%). The mean values of specific CD8^ T cell 
responses to inactivated FeLV particles were comparable to those recorded for 
specific CD4^ T cell responses. Thus, cats that received a higher exposure dose 
demonstrated mean specific CDS'*' T cell responses of 0.075% ± 0.043%; cats that 
received a lower exposure dose of FeLV demonstrated mean specific CDS'*' T cell 
responses 0.45% ± 0.38%.
Using statistical analysis, a significant correlation was not detected between CD8^ T 
cell responses to inactivated FeLV, and proviral DNA loads, irrespective of the 
exposure dose (Spearman r-Test, r=-0.5429, P=0.2972; r=-0.6, jP=0.2417, 
respectively).
(Hi) p27-Specific CD4^ T cell Responses
Eleven cats developed p27-specific CD4^ T cell responses in the peripheral blood 
following oronasal exposure to FeLV (Figs. 4.8.B and 4.9.B). Two cats, E6 and E8, 
developed such responses by week 1; however, p27-specific CD4’*' T cells were not 
detected in the peripheral blood from cat E8 at any further time point. Fluctuating 
frequencies of p27-specific CD4^ T cells were apparent in the peripheral blood from 
cat E6, reappearing over weeks 7-10 and at week 16.
p27-specific CD4^ T cells were detected in the peripheral blood from cats E3 and 
E12 over weeks 4-10. At week 4, the proportion of p27-specific CD4^ T cells in the 
peripheral blood from cat E12 was initially very high (0.88%), and had increased 
further by week 10 (2.13%). However, such responses were undetectable by week 
13 (Figs. 4.9.A and 4.10). Cats E2, E9 and ElO developed p27-specific CD4+ T cell 
responses by week 10; these were particularly high in cat ElO (3.59%). Three cats, 
E l, E5 and E7 developed p27-specific CD4^ T cell responses in the peripheral blood 
by week 13. Cat E4 developed moderately high frequencies of p27-specific CD4'*' T 
cells in the peripheral blood by week 16 (0.35%).
In cats that received a higher exposure dose of FeLV, mean p27-specific CD4'*' T cell 
responses did not vary greatly over the course of this study. However, an early low
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peak in p27-specific CD4'*' T cell frequency could be discerned at week 4 (0.06% ± 
0.14%), which was followed by a slightly higher peak at week 16 (0.08 ± 0.14). Cats 
that were exposed to a lower dose of FeLV peaked in mean p27-specific CD4^ T cell 
responses at weeks 4 (0.15% ± 0.36%) and 10 (0.96% ± 1.54%). These latter cats 
recorded 0.23% ± 0.3% in mean p27-specific CD4^ T cells over the course of the 
study, while cats that received a higher exposure dose recorded a mean value of 
0.055% ± 0.028%. Thus, the mean levels of p27-specific CD4'*' T cell responses 
were lower than recorded to specific CD4^ T cell responses to inactivated FeLV 
particles, irrespective of the exposure dose.
Statistical analysis showed that the correlation between p27-specific CD4^ T cell 
responses, and proviral DNA loads, was not significant, irrespective of the exposure 
dose (Spearman r-Test, r=-0.3143, P=0.5639; r=-0.3143, P=0.5639 respectively).
(iv) p27-Specific CD8^ T cell Responses
All twelve cats developed p27-specific CD8^ T cell responses in the peripheral blood 
following oronasal exposure to FeLV (Figs. 4.8.E and 4.9.E). Eight cats, E2, E4, E5, 
E6, E7, E8, E l l  and E12, developed p27-specific CD8^ T cell responses in the 
peripheral blood as early as week 1 post exposure to FeLV. In two of these cats, E4 
and E8, such responses were maintained over weeks 1-4, before disappearing. Cat 
E l l  maintained these levels for a further three weeks; in addition, a large peak in 
p27-specific CD8^ T cell numbers was observed in this cat at week 13 (3.23%). Cats 
E l, E3 and E9 had all developed transient levels of p27-specific CD8^ T cells by 
week 7, while cat ElO generated a high peak of p27-specific CDS’* T cell responses 
at week 10 (3.92%).
The patterns of mean p27-specific CDS^ T cell responses in the peripheral blood over
the study were similar to those observed for p27-specific CD4^ T cell responses and
CD4^ and CD8^ T cell responses to inactivated FeLV particles. Cats that received a
higher dose of infectious virus peaked in mean p27-specific CD8'*' T cell responses at
weeks 4 (0.23% ± 0.49%) and 16 (0.12% ± 0.14%), while in cats that received a
lower exposure dose of FeLV, mean responses peaked at weeks 1 (0.44% ± 0.47%)
and 10 (1.02% ±1.7%). In the latter group of cats, mean responses were comparable
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to specific CD4^ and CDS’*" T cell responses to inactivated FeLV particles (0.41% ± 
0.32%). However, in cats that were exposed to a higher infectious dose of FeLV, 
p27-specific CDS’*" T cell responses were much higher than p27-specific CD4^ 
responses and both specific CD4^ and CDS'*' T cell responses to inactivated FeLV 
(0.12% ± 0.088%).
The correlation between p27-specific CD8^ T cell responses and proviral DNA loads 
was not statistically significant, irrespective of the exposure dose (Spearman r-Test, 
r=0.7827, F=0.1028; r=~0.5429, P=0.2417, respectively).
(v) p45-Specific CD4^ T cell Responses
Ten cats developed p45-specific CD4^ T cells in the peripheral blood following 
oronasal exposure to FeLV; such responses were not detected in the peripheral blood 
from cats E7 and ElO (Figs. 4.8.C and 4.9.C). Five cats, E6, E8, E9, E l l  and E12 
developed p45-specific CD4^ T cell responses in the peripheral blood one week 
following exposure to FeLV. All such responses had disappeared by week 4; 
however, additional p45-specific CD4'*' T cell responses in the peripheral blood were 
detected later in the study for all of these cats except E6; a particularly high peak was 
recorded in the peripheral blood from cat E12 at week 10. By week 4, a further two 
cats, E l and E3, had developed transient low levels of p45-specific CD4^ T cell 
responses. Low numbers of p45-specific CD4^ T cells were detected in the 
peripheral blood from cats E4 and E5 for the first time at week 7. Cat E2 failed to 
develop p45-specific CD4^ T cell responses in the peripheral blood until week 13.
In cats exposed to a higher infectious dose of FeLV, the patterns of mean p45-
specific CD4'*' T cell responses observed over the course of the study were dissimilar
from those detected in response to both the recombinant p27 protein and inactivated
FeLV particles, peaking only at week 7 (0.07% ± 0.08%). The mean p45-specific
CD4^ T cell responses in the peripheral blood from cats exposed to a lower exposure
dose of FeLV peaked at weeks 1 (0.17% ± 0.21%) and 10 (0.25% ± 0.61%). The
values of the mean responses were much lower than previously recorded for specific
CD4 + Y cell responses to p27 and inactivated FeLV particles, irrespective of the
exposure dose. Thus, cats that were exposed to a higher infectious dose averaged
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0.033% ± 0.017% p27-specific CD4^ T cells, much lower than the specific CD4'*' T 
cell responses to either the recombinant p27 protein or inactivated FeLV particles. 
Cats that received a lower exposure dose by a factor of one log, demonstrated 0.14% 
± 0.16% mean p27-specific CD4^ T cells over the course of the study, which was 
also much lower than the mean specific CD4’*' T cell responses to either the 
recombinant p27 protein or inactivated FeLV particles.
Using statistical analysis, a significant correlation was not observed between p45- 
specific CD4^ T cell responses, and proviral DNA loads, irrespective of the exposure 
dose (Spearman r-Test, r=-0.02857, P>0.9999; r=-0.2319, P=0.6583, respectively).
(vi) p45-Specific CD8^ T cell Responses
Ten cats generated p45-specific CD8^ T cell responses in the peripheral blood 
following oronasal exposure to FeLV; such responses were not detected in the 
peripheral blood from cats E8 and E l l  (Figs. 4.8.F and 4.9.F). p45-specific CD8'*' T 
cell responses were detected in the peripheral blood from one cat, E7, at week 1 post 
exposure. However, four cats, E4, E5, E6 and ElO, all developed p45-specific CD8^ 
T cell responses by week 4, which were particularly high in cat E4 (0.7%). Each of 
these early peaks in p45-specific CDS'*’ T cell responses was followed by a second, at 
weeks 10 (E5 and ElO) and 13 (E4 and E6), which was particularly high in cat ElO 
(1.74%). By week 7, three cats, E2, E3 and E9 had developed low levels of p45- 
specific CD8^ T cell responses in the peripheral blood; these were transient in cats 
E2 and E9. However, cat E3 maintained these cells until at least week 16. Cats E12 
and E l did not generate p45-specific CDS'*' T cells until weeks 10 and 13, 
respectively.
The pattern of p45-specific CD8'*' T cell responses recorded over the course of the
study differed among cats exposed to a different dose of infectious FeLV. Thus, the
mean responses from cats that received a higher exposure dose peaked at weeks 4
(0.15 ± 0.27) and 13 (0.12 ± 0.16) while p45-specific CDS'*' T cell responses from
cats that received a lower exposure dose peaked at weeks 4 (0.06 ± 0.14) and 10
(0.64% ± 0.76%). These latter cats generated mean p45-specific CDS'*' T cell
responses of 0.126% ± 0.146% over the course of the study, while cats that received
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a higher exposure dose averaged 0.05% ± 0.051%. Thus, mean specific CD8^ T cell 
responses to the recombinant p45 protein in the peripheral blood from cats E7-E12 
over the course of the study were much lower than to either the recombinant p27 
protein or inactivated FeLV particles. However, mean p45-specific CDS*" T cell 
responses in the peripheral blood from cats E7-E12 were greater than p27-specific 
CDS'*' T cell responses and p45-specific CD4'*' T cell responses.
Using statistical analysis, a significant correlation was not detected between p45- 
specific CDS’*' T cell responses, and proviral DNA loads, irrespective of the exposure 
dose (Spearman r-Test, r=0.1429, P=0.8028; r=-0.4348, P=0.4194, respectively).
43.2.2.2 Virus-specific Responses in the PLN Tissues
Specific CD4^ T cell responses to either the recombinant p27 or p45 proteins, or 
inactivated FeLV particles, were examined in the PLN tissues from cats E4-E12 post 
mortem. Similarly, virus-specific CDS'*" T cell responses were investigated in the 
PLN tissues from cats E4-E7, and cat E12 (Fig. 4.11).
(i) Specific T cell Responses to Inactivated FeLV Particles
Moderate numbers of specific CD4^ T cells to inactivated FeLV particles were 
enumerated in the PLN tissues from cats E4, E5, E6 and E9 (Fig. 4.11). A low 
percentage of concurrent specific CD8^ T cells were detected in the PLN tissues 
from cat E5 (0.06%). Corresponding data was not available for cats E8-E11.
(ii) p27-Specific T cell Responses
Moderate numbers of p27-specific CD4^ T cells were recorded in the PLN tissues 
from cats E4, E5, and E9, while the PLN tissues from cat E6 demonstrated strong 
p27-specific CD4^ T cell responses (1.81%) (Fig. 4.11). Low numbers of p27- 
specific CD8^ T cells were detected in the PLN tissues from cats E5 and E12 
(0.12%; 0.3%, respectively). No data was available for cats E8-E11.
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(in) p45-Specific T cell Responses
The PLN tissues from cats E5, E8, E9 and ElO all contained moderately low 
numbers of p45-specific CD4^ T cells, while the PLN tissues from cat E6 contained 
much higher numbers of p45-specific CD4^ T cells (2.05%) (Fig. 4.11). Peripheral 
lymph node tissues from cats E4 and E5 all contained high frequencies of p45- 
specific CD8'*‘ T cells, whereas lower frequencies were detected in cat E12 (0.74%, 
1.18% and 0.26%, respectively); similar data was unavailable for cats E8-E11.
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Fig. 4.2 Virus-specific proliferative responses in the peripheral blood 
from cats E1-E6
Proliferative responses of mononuclear cells in the peripheral blood from cats E1-E6 
to stimulation with either inactivated FeLV particles (25 pg/10^ cells) (A), or 
recombinant p27 (25 pg/10^ cells) (B), or p45 proteins (25 |xg/10^ cells) (C). 
Mononuclear cells were prepared from peripheral blood sampled at regular intervals 
from weeks 0-19 following oronasal exposure to FeLV. Cells were cultured for 3 
days ex vivo\ ^H-thymidine was added for the final 5 h of incubation. The net counts 
(cpm) recorded by unstimulated cells are displayed in the table below; these data 
were used to calculate the S.L In addition, the range of the lowest and highest net 
counts (cpm) recorded by antigen-stimulated cells is displayed in bold.
Cat No. WkO W k l W k4 W k7 Wk 10 W k l3 Wk 16 Wk 19
E l 388.40 492.33 416.12 368.11 383.90 173.03 482.61 362.42
E2 169.53 594.83 588.47 630.83 403.60 863.50 475.80 437.77
E3 217.47 498.57 291.31 460.41 395.78 510.49 496.84 476.00
E4 335.13 359.50 168.73 318.73 367.74 431.64 428.21 326.10
E5 473.47 535.87 582.46 436.20 446.14 493.37 653.26 482.44
E6 519.20 399.47 384.66 449.70 527.52 405.85 620.92 386.81
Range 145.00- 219.67- 208.50- 329.80- 294.57- 122.17- 252.10- 273.50-520.60 750.80 1046.20 1023.03 2069.43 1100.30 1170.07 972.30
Bweek I wvek 4 week 7 week 10 week 13
W eeks P ost E xposure
week 4 week 7 week 10 week 13 week 16 week IV
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Fig. 4.3 Virus-specific proliferative responses in the peripheral blood 
from cats E7-E12
Proliferative responses of mononuclear cells in the peripheral blood from cats E7- 
E12 to stimulation with either inactivated FeLV particles (25 p-g/10  ^ cells) (A), or 
recombinant p27 (25 pig/10  ^ cells) (B) or p45 proteins (25 p,g/10  ^ cells) (C). 
Mononuclear cells were prepared from peripheral blood sampled at regular intervals 
from weeks 0-13 following oronasal exposure to FeLV. Cells were cultured for 3 
days ex vivo; ^H-thymidine was added to the cultures for the final 5 h of incubation. 
The background net counts (cpm) recorded in the unstimulated wells from each cat 
E7-E12 are displayed below; these data were used to calculate the S.l. In addition, 
the range of the lowest and highest net counts (cpm) recorded by antigen-stimulated 
cells is displayed in bold.
Cat No. WkO W k l W k4 W k? Wk 10 Wk 13
E7 463.41 208.70 165.83 482.53 602.44 271.42
E8 398.37 203.67 278.07 404.82 473.94 504.99
E9 499.57 271.67 385.71 424.97 590.41 622.36
ElO 388.43 276.73 309.99 646.86 825.21 194.77
E ll 995.33 596.73 332.80 414.78 673.56 456.35
E12 558.46 626.03 199.39 412.57 993.49 638.70
Range 253.73-1171.73 131.03-764.17 144.70-672.20 211.33-1687.43 439.40-1036.20 227.63-1291.90
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Fig. 4.4 Phenotypic analysis of virus-specific T and B cells in the 
peripheral blood from cats E1-E6
Percentage increase in CD4^ and CD8^ T cells, and either CD45R'*" WBC or CD21^ B 
cells, in the peripheral blood from cats E1-E6 following virus-specific stimulation 
with recombinant p27 (25 pg/10^ cells) (A) or p45 proteins (25 pg/10^ cells) (B), or 
mitogenic stimulation with Con A (5 pg/10^ cells) (C) in the LPA, compared to 
unstimulated cells. Only data from cats that recorded an S.I. greater than, or equal 
to, 2 at any time point is shown.
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Fig. 4.5 Phenotypic analysis of virus-specific T and B cells in the 
peripheral blood from cats E7-E12
Percentage increase in CD4^ or CD8^ T cells, or CD21^ B cells, in the peripheral 
blood from cats E7-E12 following virus-specific stimulation with recombinant p27 
(25 pg/lO^ cells) (A) or p45 proteins (25 pg/10^ cells) (B), or mitogenic stimulation 
with Con A (5 pg/10^ cells) (C) in the LPA, compared to unstimulated cells. Only 
data from cats that recorded an S.I. greater than, or equal to, 2 at any time point is 
shown.
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Fig. 4.6 Mitogenic proliferative responses in the peripheral blood 
from cats E1-E12
The ability of mononuclear cells in the peripheral blood from cats E1-E6 (A) and 
cats E7-E12 (B) to proliferate to the mitogen Con A (5 pg/10^ cells) over weeks 0-19 
(E1-E6) and weeks 0-13 (E7-E12) is illustrated. Mononuclear cells were prepared 
from the peripheral blood at regular intervals following oronasal exposure to FeLV. 
Cells were cultured for three days ex vivo; ^H-thymidine was added to the cultures 
for the final 5 h incubation. The background net counts recorded by the unstimulated 
cells were used to calculate the S.I. These are the same data used to calculate the 
virus-specific proliferative responses for cats E1-E6 over weeks 0-19 (Fig. 4.2), and 
cats E7-E12 over weeks 0-13 (Fig. 4.3).
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Fig. 4.7 Virus-specific and mitogenic proliferative responses in the 
lymphoid tissues from cats E1-E12
Proliferative responses in the PLN tissues from cats E l-E l 2 (A), MEN tissues from 
cats E1-E7, E9, ElO and E12 (B), and splenic tissues from cats E2; E4; E7; E9; ElO 
and E l2 (C), were recorded following stimulation with either recombinant p27 (25 
pg /lO^ cells) or p45 proteins (25 pg /lO^ cells), or inactivated FeLV particles (25 pg 
/lO^ cells). Proliferative responses to Con A (5 pg/10^ cells) in the MLN, PLN and 
splenic tissues from cats E l-E l2 are illustrated in chart D. Mononuclear cells were 
prepared from the lymphoid tissues post mortem and stimulated ex vivo for 3 days; 
^H-thymidine was added for the final 5 h of culture. The background net counts 
(cpm) recorded by the unstimulated cells from each tissue are displayed below; these 
data were used to calculate the S.I. in response to both virus specific and mitogenic 
stimulation. The data are presented as ‘not done' (n.d.) when samples were not 
analysed.
Cat No. PLN MLN Spleen
E l 363.00 375.01 n.d
E2 623.02 420.24 446.33
E3 342.13 358.65 n.d
E4 509.47 285.77 186.02
E5 404.63 346.03 n.d
E6 280.60 302.86 n.d
E7 731.11 176.66 536.89
E8 967.22 n.d n.d
E9 828.32 319.87 530.52
ElO 700.26 236.81 365.11
E l l 527.75 n.d n.d
E12 807.53 265.97 270.62
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Fig. 4.8 Virus-specific CD4^ and CD8  ^T cells in the peripheral blood
from cats E1-E6, detected using ICS
Graphs depicting the expression of flFN-y by CD4^ T cells (A-C) and CD8^ T cells 
(D-F) in the peripheral blood from cats E1-E6 following a 4 h stimulation with either 
inactivated FeLV particles (A, D), or recombinant p27 (B, E) or p45 proteins (C, F), 
in the presence of BFA. The gates that determined flFN-y expression were set 
according to the reactivity of the isotype-matched control-FITC mAb. In total,
10,000 events were counted. Feline IFN-y expressing CD4^ and CD8^ T cells within 
the lymphoblast population were enumerated at regular intervals following 
experimental exposure to FeLV at week 0. These data were corrected by deducting 
the percentage of any CD4^ and CD8^ T cells that expressed flFN-y in the absence of 
virus-specific stimulation, in order to calculate the percentage of virus-specific CD4^ 
and CD8^ T cells. The data recorded for unstimulated CD4^ and CD8^ T cells are 
shown in tables (i) and (ii), respectively. On each sample date, the mean percentage 
of virus-specific CD4^ and CD8^ T cells was calculated (Mean E1-E6).
(i)
Cat No. WkO W k l W k4 W k ? W k 10 W k 13 W k 16 W k 19
E l 0.68 Lo.07 0.15 0.00 0.16 0.28 0.16 0.13
E2 0.17 0.03 0.00 0.13 0.00 0.00 0.14 0.02
E3 0.14 0.06 0.00 0.00 0.07 0.35 0.32 0.08
E4 0.28 0.51 0.53 0.21 0.25 0.45 0.39 0.20
E5 2.53 0.05 0.41 0.00 0.17 0.00 0.24 0.01
E6 0.61 0.00 0.54 0.06 0.08 0.00 0.06 0.03
(ii)
Cat No. WkO W k l W k4 W k ? W k 10 W k 13 W k l6 W k 19
E l 0.72 0.07 0.58 0.00 0.18 0.10 0.16 0.04
E2 0.69 0.04 0.22 0.00 0.00 0.00 0.10 0.00
E3 0.57 0.00 0.53 0.09 0.07 0.18 0.22 0.22
E4 0.43 0.00 0.00 0.00 0.34 0.34 0.09 0.33
E5 1.33 0.05 0.34 0.00 0.00 0.10 0.17 0.05
E6 0.50 0.00 0.50 0.16 0.29 0.00 0.06 0.02
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Fig. 4.9 Virus-specific CD4^ and CD8^ T cells in the peripheral blood
from cats E7-E12, detected using ICS
Graphs depicting the expression of flFN-y by CD4^ T cells (A-C) and CD8^ T cells 
(D-F) in the peripheral blood following a 4 h stimulation with either inactivated 
FeLV particles (A, D), or recombinant p27 (B, E) or p45 proteins (C, F). The gates 
that determined flFN-y expression were set according to the reactivity of the isotype- 
matched control-FITC mAb. In total, 10, 000 events were counted. Feline IFN-y 
expressing CD4^ and CD8^ T cells within the lymphoblast population were 
enumerated from cats E7-E12 at regular intervals following experimental exposure to 
FeLV at week 0. These data were corrected by deducting the percentage of any 
CD4^ and CD8^ T cells that expressed fIFN-y, either in the absence of virus-specific 
stimulation, or prior to FeLV exposure, in order to calculate the percentage of virus- 
specific CD4^ and CD8^ T cells. The data recorded for unstimulated CD4^ and 
CD8^ T cells are shown in tables (i) and (ii), respectively. On each sample date, the 
mean percentage of virus-specific CD4^ and CD8^ T cells was calculated (Mean E7- 
E12). The data are presented as ‘not done’ (n.d) when samples were not analysed.
(i)
Cat No. WkO W k l W k4 W k7 Wk 10 Wk 13
E7 1.68 0.51 0.66 0.00 0.66 0.93
E8 0.62 0.09 0.00 0.19 0.00 0.40
E9 0.68 0.27 0.71 0.00 0.16 0.00
ElO 0.61 0.74 0.65 0.00 0.78 0.52
E l l 0.68 0.00 0.30 0.00 4.23 0.56
E12 1.75 0.52 0.19 0.00 0.34 1.67
(ii)
Cat No. WkO W k l W k4 W k7 WklO Wk 13
E7 1.28 0.30 0.55 0.19 0.53 0.23
E8 2.61 0.19 0.52 0.29 n.d 2.62
E9 0.75 0.16 0.00 0.00 0.36 0.00
ElO 0.70 0.28 0.00 0.00 0.56 1.39
E l l 1.36 0.13 0.00 0.00 4.66 0.58
E12 0.82 0.33 0.45 ^ n.d 0.56 1.26
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Fig. 4,10 p27-specific CD4^ and CD8^ T cells in the peripheral blood 
from cat E12, detected using ICS
Two-colour dot plots A-D displaying the percentage of CD4^ (A-B) and CD8^ T 
lymphoblasts (C-D) in the peripheral blood from cat E12 that expressed flFN-y 
(quadrants C2 and D2) following a 4 h stimulation with the recombinant p27 protein 
(B, D) in the presence of BFA. The gates that determined flFN-y expression were set 
according to the reactivity of the isotype-matched control-FITC mAb. In total,
10,000 events were counted. Feline IFN-y-expressing CD4^ and CD8^ T cells within 
the lymphoblast population are illustrated from weeks 0-13 following experimental 
exposure to FeLV. Unstimulated CD4^ (A) and CD8^ T cells (C) were used as 
controls.
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Fig. 4.11 Virus-specific CD4  ^T cells in the PLN tissues from cats E4-
E12, detected using ICS
Graphs depicting the expression of fIFN-y by virus-specific CD4^ T cells in the PLN 
tissues from cats E4-E6 (A) and cats E7-E12 (B) following a 4 h stimulation with 
either recombinant p27 or p45 proteins, or inactivated FeLV particles, in the 
presence of BFA. Feline IFN-y expressing CD4^ T cells within the lymphoblast 
population were enumerated in the PLN tissues post mortem, 13 (cats E4-E6) and 19 
weeks (cats E7-E12) following oronasal exposure to FeLV. The gates that 
determined fIFN-y expression were set according to the reactivity of the isotype- 
matched control-FITC mAb. In total, 10,000 events were counted. The percentage 
of virus-specific CD4^ T cells was calculated by deducting the percentage of fIFN-y 
expressing cells detected within unstimulated cells; the data from unstimulated cells 
are displayed in the table below. The data were presented as ‘not done’ (n.d.) when 
samples were not analysed.
Cat No. CD4+
E4 0.25
E5 0.28
E6 0.00
E7 0.00
E8 0.52
E9 0.30
ElO n.d
E ll 1.35
E12 0.45
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4.4 Discussion
The primary aim of the longitudinal study was to correlate immune responses with 
viral burden, and in so doing, establish the role of host immunity in disease outcome. 
As previously mentioned, there are three possible outcomes following exposure of 
cats to FeLV, namely persistence, recovery and latency. However, the results 
presented in Chapter 3 clearly demonstrate that eleven out of twelve cats in this study 
became persistently viraemic and one cat became latently infected. This occurred in 
spite of the fact that around fifty per cent of the cats were expected to recover, given 
their age at exposure and the exposure dose of virulent FeLV (Hoover et al., 1976; 
Jarrett et a l, 1982a; Flynn et al., 2002b). It is not clear why no cats spontaneously 
recovered. Indeed, other studies in our laboratory conducted at the same time as this 
study did show recovery, despite using higher challenge doses (Donovan, L., PhD 
thesis. University of Glasgow). Thus, in this chapter the FeLV-specific immune 
responses in peripheral blood were compared with the levels of proviral DNA in the 
blood throughout infection, and proviral DNA loads in lymph nodes and spleen were 
compared with the FeLV-specific cellular immune responses present in those 
lymphoid tissues post mortem.
The recombinant p27 protein expressed in E. coli is identical in size to the FeLV CA 
protein p27, as indicated in a Coomassie Brilliant Blue-stained SDS-PAGE gel (Fig.
4.1.1). Serum from an FeLV recovered cat, which was shown to harbour VNA, and 
is likely to contain additional anti-FeLV antibodies (Lutz et al., 1980b; Charreyre 
and Pedersen, 1991; Hawks et al., 1991; Flynn et al., 2002b), recognised and bound 
to antigenic determinants within the recombinant p27 protein in a Western blot. 
These results demonstrate that the recombinant p27 protein shared antigenic 
determinants with FeLV; therefore, this recombinant protein has the potential to 
elicit antigen-specific responses in any cat exposed to this protein (Fig. 4.1.II). The 
FeLV SU protein gp70 expressed in E. coli is non-glycosylated, and is approximately 
45 kDa in size. The recombinant p45 protein contained antigenic determinants 
recognised by sera from FeLV-recovered cats in a Western blot, indicating that the 
recombinant p45 protein also has the potential to be antigenic, and is therefore useful 
in this study (Fig. 4.1.V). Furthermore, a recombinant p45 protein forms the basis of 
a vaccine commercially available in the U.K. (‘Leucogen’, Virbac S.A, France),
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which is known to elicit protective immunity against FeLV (Marciani et al,, 1991; 
Jarrett and Ganière, 1996).
The recombinant FeLV proteins generated in this thesis were not tested for the 
presence of endotoxin. An endotoxin is a microbial protein that acts as a 
superantigen, Le. a potent non-specific polyclonal activator of CD4^ T cells; in 
addition, endotoxin-primed CD4^ T cells may enhance antigen-specific responses 
(Torres et al., 2002). Thus, any endotoxin present in the recombinant protein 
preparations would be expected to exert a mitogenic effect on the CD4^ T cells 
present in the LPA cultures. However, the data generated using these recombinant 
proteins in the proliferation assays were consistently low, suggesting the absence of 
endotoxic activity (Figs. 4.2-4.S and 4.7).
Data from the LPA can be expressed in two principal forms, as S.I., or as the net 
count (cpm). The data generated from the proliferation assays in this thesis were 
presented as S.I. There are advantages associated with both forms of data 
presentation. Significant inter-laboratory variation in net cpm can occur due to the 
variations in the efficiency of liquid scintillation counters; therefore, for comparative 
purposes, the S.I. is a more useful unit. Furthermore, variations in cell preparation 
and culture conditions are minimised by calculating the S.I., as both the unstimulated 
and stimulated cells should be similarly affected. However, under certain 
circumstances, the S.I. may obscure important information. Since the S.I. is a ratio, 
it is particularly vulnerable to changes in the background data. High levels of 
background proliferation may cause misleadingly low S.I. results. Such high counts 
may indicate that cultured cells were activated in vivo prior to sampling, or that APC 
within the mononuclear cell preparation were loaded with viral antigen in vivo and 
therefore were capable of activating CD4"^  and CD8^ T cells ex vivo. These 
phenomena are particularly relevant in this thesis, where the majority of cats were 
persistently viraemic. However, the S.I. are calculated from the raw cpm data; thus, 
aberrant background counts should be readily detectable and reported in the analyses. 
In this thesis, background cpm levels were generally very low (Figs. 4.2-4.S and 4.7). 
At week 10, cats ElO and E12 generated higher levels of background cpm than 
previously recorded. However, the antigen-specific responses in these cats were also 
proportionately higher, which suggests that the cells were subject to between-week
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laboratory variations. Because of the low background counts recorded over the 
course of the study, it was considered that the S.I. was an appropriate means of data 
presentation in this thesis.
Lymphocyte proliferation assays were conducted to monitor the development of 
virus-specific cell-mediated immunity, particularly CD4^ T cell responses, in the 
peripheral blood and lymphoid tissues from cats E1-E12, following oronasal 
exposure to FeLV. In addition, the general immune competence of these cats was 
evaluated by assessing the ability of mononuclear cells to proliferate in response to 
Con A stimulation (Torten et al., 1991; Lawrence et al., 1992). When feline 
mononuclear cells are cultured with Con A in vitro, the proportion of CD4^ and 
CD8^ T cells within the proliferating population increases, compared to unstimulated 
cells, whereas CD21^ B cell numbers decline (Figs. 4.4.C and 4.5.C). Thus, Con A- 
induced proliferation is a good indicator of T cell function in the cat.
Marked variations were observed in the ability of mononuclear cells in the peripheral 
blood and lymphoid tissues to proliferate in response to Con A (Figs. 4.6 and 4.7.D). 
Differences were detected in between-week samples, as well as between-cat samples. 
Several reasons are proposed in explanation; first, periodic discrepancies may be 
accounted for by the occasional use of frozen mononuclear cells, i.e. in the peripheral 
blood from cats E1-E6 (weeks 0-1), cat E2 (weeks 0-19) and cat E6 (week 19); and 
in the PLN tissues from cats E1-E6. However, on occasions where only fresh 
mononuclear cells were used, proliferative responses to Con A were still distinctly 
diverse, e.g. the S.I. recorded using PBMC from cats E7-E12 at week 1 ranged from
S.I. 16.24 (E12) to S.I. 93.5 (E9); moreover, a four-fold increase in proliferative 
responses were detected in PBMC from cat E7 over weeks 1 (S.I. 17.8) to 4 (S.I. 
79.33).
Second, PBMC from FeLV-infected cats have been shown to be immunologically 
compromised in vivo (Olsen et at., 1977; Mathes et a l, 1979; Trainin et a l, 1983), 
with a reduced ability to respond to Con A stimulation in the LBT in vitro (Cockerell 
et a l, 1976). These findings suggest that the FeLV-infected cats in the present study 
may also be subject to FeLV-induced immunosuppression in vivo, which could 
compromise the ability of mononuclear cells to proliferate in response to mitogenic 
stimulation ex vivo. Variations in the level of mitogen-induced proliferation among
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cats E l-E l 2 in this study may reflect viral burdens, and therefore the degree of 
immunosuppression within each cat. Mitogenic proliferative responses in the 
peripheral blood and lymphoid tissues were greater in cats that also recorded the 
lowest proviral DNA loads in each of those tissues (Section 3.3.1.3). However, such 
proliferative responses did not significantly correlate with proviral DNA loads using 
the Spearman r-Test.
Third, inactivated FeLV particles, particularly the pl5E constituent, have been 
shown to have an immunosuppressive effect on the proliferative and secretory 
function of normal feline and human cells in vitro (Hebebrand et al., 1977; Mathes et 
al., 1978; Hebebrand et al., 1979; Copelan et al., 1983; Stiff and Olsen, 1983; 
Engelman et al., 1984; Orosz et al., 1985; Lafrado et al., 1987). Therefore, any virus 
present within cell cultures prepared from viraemic cats in this study may have 
interfered with normal mitogenic responses.
Fourth, it is well known that proliferation assays are subject to great variability as a 
result of normal biological variation within and between individual humans (Froebel 
et al., 1999; Picker and Maino, 2000). Mononuclear cells in the peripheral blood and 
lymphoid tissues from normal cats also demonstrate a wide range of proliferative 
responses to Con A in the LPA (Flynn, J.N., personal communication). Indeed, 
variation among individual cats was observed in this study; prior to FeLV exposure,
S.I. recorded using fresh PBMC ranged from S.I. 3.19 (cat E12) to S.I. 43.88 (cat E8) 
(Figs. 4.2 and 4.3). Poor mitogenic responses in some cats might render virus- 
specific proliferative responses more significant; cats such as E4 and E6 that 
recorded high levels of mean mitogenic proliferative responses in the peripheral 
blood tended to demonstrate strong virus-specific responses, whereas cat E12 
demonstrated both poor mitogenic and virus-specific proliferative responses (Figs. 
4.3 and 4.4.B).
The magnitude of p27-specific and p45-specific proliferative responses in the 
peripheral blood was similar in groups of cats exposed to different doses of 
infectious FeLV. However, a temporal shift in the peaks of mean specific 
proliferative responses to both recombinant p27 and p45 proteins was observed, 
which was related to the exposure dose. Thus, cats that received a higher exposure 
dose of FeLV by a factor of one log, recorded mean peaks in proliferative responses
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at weeks 4 and 10, while cats that received a lower exposure dose peaked at weeks 7 
and 13. Since proviral DNA loads were significantly higher at weeks 1 and 4 in 
peripheral blood from cats that received the higher exposure dose (Section 3.3.1.3), 
these cats might be expected to develop virus-specific responses earlier. In another 
study, cats that developed an early peak in antigenaemia recovered from FeLV, 
whereas cats that failed to develop an early peak in antigenaemia became persistently 
viraemic; the authors suggested that the early antigenaemia may have primed the 
immune response (Flynn et al., 2002b). In this study, early virus-specific 
proliferative responses were not a good predictor of recovery, in that all five cats that 
generated significant p27-specific proliferative responses at week 4 became 
persistently viraemic. Overall, the magnitude of mean p45-specific proliferative 
response in the peripheral blood was less than that observed for mean p27-specific 
proliferative responses, irrespective of the exposure dose; however, the difference 
was not statistically significant (Section 4.3.2.1.1).
The inability of inactivated FeLV particles to induce a S.I. greater than 2 in any cat
over the course of the study was surprising, given that the principal viral constituents,
p27 and p45 respectively, were able to induce specific proliferative responses in most
cats. A number of explanations can be offered. First, immunosuppressive factors
may have been present within the inactivated FeLV particles. pl5E, a recognised
immunosuppressive element (Mathes et a i, 1979; Copelan et al., 1983; Lafrado et
al., 1987), was visible on the Coomassie-stained SDS-PAGE gel, indicating that this
protein was retained within the inactivated FeLV particles used in these studies (Fig.
4.1.1). To ascertain whether inactivated FeLV particles were in fact
immunosuppressive, the degree to which these particles inhibited the mitogen-
induced proliferation of normal feline cells in the LPA could be evaluated. Second,
virus-specific proliferative responses would be subject to the same
immunosuppressive factors as described for mitogenic proliferative responses.
Third, key antigenic determinants may have been denatured by heat inactivation.
The protein structure of the virus is severely disrupted by the boiling process; and
important antigenic determinants may not have been preserved. It may have been
more prudent to inactivate FeLV using UV light. Nucleic acids are the most
important absorbers of UV light; therefore, such treatment causes photochemical
damage to viral RNA, which inhibits viral replication. Since the protein structure of
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the virus is preserved, the antigenic determinants should remain intact. Nonetheless, 
using ICS, specific CD4^ and CD8^ T cell responses to inactivated FeLV particles 
were detected in the majority of cats, suggesting that antigenic epitopes were retained 
within the inactivated FeLV particles. Fourth, inactivated FeLV particles were used 
at the same concentration (25 p.g/10^ cells) as both recombinant p27 and p45 
proteins; thus, the relative amounts of viral core protein and envelope glycoprotein 
corresponding to recombinant p27 and p45 proteins, respectively, would be much 
lower. However, titration studies conducted using the inactivated FeLV particles 
demonstrated that increased viral concentrations did not elicit greater proliferative 
responses.
It has previously been shown that FeLV recovered cats generate high levels of 
Gag/Pro-specific CTL in the peripheral blood shortly after oronasal exposure to 
FeLV, whereas persistently viraemic cats develop delayed and reduced levels of 
Gag/Pro-specific CTL (Flynn et al., 2002b). On this evidence, we proposed that 
Gag-specific CD4"^  T cells might be important in eliciting protective immune 
responses following oronasal exposure to FeLV. To investigate this, we evaluated 
the ability of CD4^ T cells in the peripheral blood from cats E1-E12 to proliferate, 
and to express flFN-y, in response to stimulation with the recombinant p27 protein. 
Concurrent virus-specific CD8^ T cell responses were analysed using ICS, while the 
numbers of proliferating CD8^ T cells, and either CD21^ B cells or CD45R^ WBC, 
were recorded in the LPA.
Using ICS, high frequencies of p27-specific CD4^ T cells were detected in the 
peripheral blood from latently infected cat E12 four weeks following exposure to 
FeLV, which were maintained until week 13. Moderately high numbers of p27- 
specific CD8^ T cell responses were detected in the peripheral blood from this cat at 
weeks 1 and 7-10. Conversely, in the LPA, p27-specific CD4^ or CD8^ T cells were 
not detected in the peripheral blood from latently infected cat E l2 at any time 
throughout the study. p27-specific CD4^ T cell responses were detected in ten 
persistently infected cats following oronasal exposure to FeLV using ICS; three of 
which, E3, E6 and E8, had developed such responses by week 4. However, these 
responses either rapidly declined, or disappeared altogether. The remaining 
persistently infected cats generated transient levels of p27-specific CD4'*' T cell
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responses after week 10. All persistently infected cats generated p27-specific CD8'*' 
T cells in the peripheral blood; seven of which had generated such responses by 
week 1. Cat E l l  maintained p27-specific CD8^ T cells responses over weeks 1-7; 
however, such early responses were transient in each of the remaining cats. 
Stimulation indices greater than, or in excess of, 2 were recorded in sixteen 
peripheral blood samples from seven persistently infected cats throughout the study 
in response to p27-specific stimulation. In ten of these samples, from cats E4, E6, 
E9, ElO and E l l ,  such responses were associated with p27-specific CD4^ T cells. 
These cells were detected early following exposure in just two cats, E4 and E6.
In a previous study, differences in Env-specific CTL in the peripheral blood between 
recovered and persistently viraemic cats were not significant (Flynn et a i, 2002b). 
In this study, Env-specific CD4^ T cell responses in the peripheral blood were 
investigated by assessing the ability of mononuclear cells from cats E1-E12 to 
proliferate, and to express flFN-y, in response to stimulation with recombinant p45 
protein.
Moderate frequencies of p45-specific CD4^ T cells were detected in the peripheral 
blood from latently infected cat E12 shortly after exposure and over weeks 7-10, 
using ICS. Concurrent CD8^ T cell responses were not detected in the peripheral 
blood from this cat until week 10. However, in the LPA, neither p45-specific CD4^ 
nor CD8^ T cells were detected in the peripheral blood from cat E l2 at any time 
throughout the study. Using ICS, p45-specific CD4^ T cells were detected in the 
peripheral blood from nine persistently infected cats; four of which had developed 
such responses by week 1. However, no persistently infected cat generated high 
levels of p45-specific CD4^ T cells. Nine persistently infected cats developed p45- 
specific CD8^ T cell responses in the peripheral blood. High frequencies of such 
cells were detected in the peripheral blood from cats E4 (weeks 4 and 13), ElO 
(weeks 10-13) and E l l  (week 13). Stimulation indices greater than, or in excess of, 
2 were recorded in ten peripheral blood samples from eight persistently viraemic cats 
in response to p45-specific stimulation. These were associated with p45-specific 
CD4^ T cells in six samples, from cats E l, E8, E9, ElO, E l l .  However, in this assay, 
p45-specific CD4^ T cells were not detected in any cat until week 7 (cats E9 and 
E ll) .
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Although S.I. greater than, or in excess of 2, were not recorded in the peripheral 
blood from any cat in the LPA in response to stimulation with inactivated FeLV 
particles, such responses were identified using ICS. Overall, specific CD4^ T cell 
responses to inactivated FeLV particles were higher than to the recombinant p45 
protein, irrespective of the exposure dose (Section 4.3.2.2.1). Specific CD4^ T cell 
responses to inactivated FeLV particles were detected throughout the course of the 
study in the peripheral blood from latently infected cat E12 with high levels of 
concurrent specific CD8^ T cell responses to inactivated FeLV particles at weeks 1 
and 7-10. Four persistently infected cats developed early peaks in specific CD4^ T 
cell responses to inactivated FeLV particles; cat E3 maintained these responses over 
weeks 1-10. Cat ElO developed high frequencies of specific CD4^ T cell responses 
to inactivated FeLV particles at week 7, with concurrent high levels of CD8^ T cell 
responses.
FeLV-recovered cats developed higher levels of Gag-specific CTL in lymphoid 
tissues, compared to persistently viraemic cats (Flynn et a l, 2000a). In this study, 
virus-specific responses were examined in the lymphoid tissues from cats E1-E12 
post mortem in the LPA and using ICS. p27-specific proliferative responses were 
detected in the MLN tissues from cat E12. In addition, p27-specific CD8^ T cell 
responses were detected in the PLN tissues from latently infected cat E l2 and from 
persistently infected cats E4, E5, E6 and E9, using ICS. p45-specific proliferative 
responses and p45-specific CD8^ T cells were detected in the MLN tissues from 
latently infected cat E12. Persistently infected cats E7 and E9 recorded S.I. greater 
then, or equal to 2, in response to p45-specific stimulation. Using ICS, p45-specific 
CD4^ T cells were detected in the PLN tissues from persistently infected cats E5, E6, 
E8, E9 and ElO, which were particularly high in cat E6.
The virus-specific CD4^ T cell responses presented for recovery and latent infection 
were based on the data generated by a single cat, E12. As we have seen, a wide 
range of virus-specific CD4^ T cell responses were recorded for persistently infected 
cats; thus, it is important that virus-specific CD4^ T cell responses are compared 
among a significant number of recovered cats. In addition, no results were presented 
for spontaneously recovered cats.
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The data generated in the present study indicated that there was a poor correlation 
between results obtained using the LPA and ICS in the detection of virus-specific 
CD4^ T cells. Intracellular cytokine staining is a highly sensitive assay, which 
facilitates the enumeration of individual virus-specific cells. Mononuclear cells are 
stimulated for a mere four hours ex vivo; therefore, CD4^ T cells detected using this 
assay are in the early stages of a virus-specific response when flFN-y expression and 
secretion is optimal. Effector T cells rapidly produce high levels of cytokines upon 
activation, particularly IFN-y (Fitzpatrick et al., 1998). A four-hour period of 
restimulation was used in this thesis to generate these data. However, as discussed in 
Chapter 2, this may have been insufficient time to elicit optimal flFN-y expression. 
Thus, levels of flFN-y expresssion recorded by cats in this thesis may not reflect 
optimal flFN-y production by CD4^ and CD8^ T cells.
Results from the LPA are acquired after three days of culture. In the interim, flFN-y 
expression by virus-specific effector cells has ceased, and other cytokines 
characterised by different secretion profiles predominate, such as IL-2 (Swain, 1999). 
Therefore, the profile of the virus-specific cells detected using each of these 
techniques is fundamentally different. Second, results from the LPA reflect both the 
absolute numbers of responsive cells plated out and the ability of these cells to 
exponentially expand in vitro, which may be altered by factors such as the presence 
of inhibitory viral elements, viral destruction of responding cells and apoptosis of 
responding cells. The relevant antigen-specific CD4^ T cells may be present but 
dysfunctional, reflecting either an inability to proliferate in vivo, or a novel 
dysfunction acquired in vitro (Palmer et al., 2002). As we have seen in the present 
study, idiosyncratic variation among individual cats may affect the results. Third, the 
processing and presentation of Gag and Env soluble antigens with MHC class I 
molecules in vitro may be distinct from pathways that express the same proteins in 
vivo during natural infection. Fourth, virus-specific CD4^ T cell precursors may be 
present but difficult to expand in vitro, or present at such low frequencies that they 
are not detected in LPA (Musey et al., 1999). The LPA may underestimate the 
frequencies of virus-specific cells, particularly when the starting proportion of CD4^ 
T cells in the mononuclear preparation is low, thereby decreasing the absolute 
numbers of responding cells in each well (Picker and Maino, 2000). Fifth, LPA 
require multiple days of culture in vitro, and are susceptible to factors that
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differentially influence cell viability during these long incubations (Pitcher et al., 
1999).
Although both assays are vulnerable to the immunosuppressive factors previously 
outlined, the enhanced sensitivity of ICS used in conjunction with flow cytometry in 
the detection of individual antigen-specific cells means that low frequencies of virus- 
specific cells consequent to inadequate antigen concentration or immunosuppression 
can be identified and enumerated.
Moderate levels of flFN-y secretion were recorded for the unstimulated mononuclear 
cells in the peripheral blood and lymphoid tissues from cats E1-E12 over the course 
of the study (Figs. 4.8-4.11). Common causes of background staining were 
discussed in Chapter 2. In addition, flFN-y expression was detected at week 0 in 
many cats E1-E12. In cats E1-E6, good separation of the cell populations was not 
achieved at week 0; thus, it was difficult to gate solely on the lymphoblast 
population. In cats E7-E12, a different batch of D9-FITC mAb was used compared 
to the rest of the study, and appeared to detect much higher levels of flFN-y in both 
the unstimulated and the stimulated cells than the subsequent batch of mAb, 
suggesting the presence of high levels of non-specific staining. Therefore, it is 
highly probable that the data recorded at week 0 from either group of cats were 
inaccurate.
In the dot plots presented for cat E12, the majority of fIFN-y expressing cells in the 
antigen-stimulated populations were not CD4^ T cells (Fig. 4.10). Similar results for 
mitogen-activated cells were reported and discussed in Chapter 2. Natural killer cells 
are a population of large granular lymphocytes, which constitute important effectors 
and regulators of the innate immune response, particularly against intracellular 
pathogens. Thus, these cells are particularly relevant to FeLV infection. Natural 
killer cells are readily activated via specialised surface receptors, and can only be 
inactivated through the detection of MHC class I molecules by cell surface inhibitory 
receptors (Moretta. et al., 2002a; Moretta. et al., 2002a). In humans, two subsets of 
NK cells with diverse effector functions have been identified based on expression of 
the CD56 molecule. CD56'^“®'*‘ NK cells are major producers of IFN-y and other 
cytokines, whereas CD56^™ NK cells can lyse target cells in the absence of prior
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activation. CD56^"^^  ^NK cells constitutively express multiple monokine receptors, 
and can produce IFN-y and other cytokines rapidly in response to stimulation by 
monokines, such as IL-12, IL-18 and IL-15 (Cooper et al., 2001). Natural killer-like 
cells with cytotoxic function have been described in the spleen and peripheral blood 
from normal cats (Tompkins and Tompkins, 1985). Thus, these cells, which may be 
incorporated into the gated lymphoblast population, may be partly responsible for the 
high levels of fIFN-y expression detected using these reagents.
Some significant differences in virus-specific proliferative responses were observed 
between groups of cats that were exposed to different doses of infectious FeLV. Cats 
exposed to a lower exposure dose of FeLV by a factor of one log, developed 
significantly greater p27-specific and p45-specific proliferative responses in the PLN 
and MLN tissues respectively, than cats exposed to a higher exposure dose; these 
cats also generated significantly greater mitogenic responses in the MLN tissues. In 
addition, cats that were exposed to the lowest FeLV exposure dose also recorded the 
lowest proviral DNA loads in the peripheral blood over much of the study (weeks 1, 
4,10 and 13), and in all the lymphoid tissues examined post mortem.
4.5 Summary and Conclusions
All twelve cats developed p27-specific and/or p45-specific CD4^ T cell responses in 
the peripheral blood following oronasal exposure to FeLV. In persistently infected 
cats, early virus-specific CD4^ and CD8^ T cell responses were frequently transient 
or low, whereas higher frequencies of p27-specific and p45-specific responses were 
often detected later in the study. Only persistently infected cats generated virus- 
specific proliferative responses in the peripheral blood. Four persistently infected 
cats generated p27-specific responses in the PLN and MLN tissues, while seven cats 
generated p45-specific responses in those tissues.
Latently infected cat E12 developed high frequencies of p27-specific CD4^ T cells in 
the peripheral blood over weeks 4-10; p27-specific CD8^ T cells were detected at 
weeks 1 and 7-10. Furthermore, p45-specific CD4^ T cell responses were detected in 
the peripheral blood from this cat at weeks 1 and 7-10, with concurrent p45-specific
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Cp)8+ T cells at week 10. This cat maintained specific CD4^ T cell responses to 
inactivated FeLV particles over the course of the study (weeks 1-13), with concurrent 
CD8 responses at weeks 1 and 7-10. Low numbers of p27-specific and p45-specific 
CDB^ T cells were detected in the PLN tissues from latently infected cat E12 post 
mortem. In addition, p27~specific and p45-specific proliferative responses were 
detected in the MLN tissues from this cat.
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CHAPTER 5
LONGITUDINAL IMMUNOPATHOGENESIS STUDY
III FeLV EXPRESSION IN THE BONE MARROW
AND PLN
5.1 Introduction
The bone marrow and lymphoid tissues are critical sites of FeLV integration, 
replication and expression. Following oronasal exposure, FeLV initially replicates in 
tonsillar lymphocytes and macrophages, before being conveyed to the draining 
lymph nodes of the head and neck (Rojko et a l, 1979). Exposed cats may recover at 
this point, indicating that virus-specific immune responses have successfully 
eliminated virus within the lymph nodes. Conversely, failure to purge the lymph 
nodes of virus precipitates a cell-associated viraemia, which disseminates FeLV to 
the bone marrow, gut and other lymphoid organs (Rojko and Kociba, 1991). In the 
absence of antiviral immunity, extensive replication in these tissues precedes the 
dispersal of virus to epithelial and glandular tissues throughout the host; these events 
can occur as early as 3 weeks following exposure (Jarrett, 2001).
Virus replicates easily in the actively dividing precursor cells within the bone 
marrow. Using the IFA test on bone marrow smears prepared from FeLV-infected 
cats, FeLV CA protein p27 was detected in neutrophil and erythrocyte precursor cells 
(Hoover et aL, 1977b); in addition, immunohistochemical studies identified the 
FeLV CA protein p27, and SU protein gp70, chiefly in association with 
megakaryocytes (Kovacevic et ah, 1997). In lymphoid tissues, FeLV has a 
predilection for the follicular B cell (Rojko et aL, 1979; Rojko et aL, 1981). In 
lymph node sections from FeLV-infected cats, expression of the FeLV CA protein 
p27 was mainly restricted to the lymph node follicles, in close association with the 
FDC network, while the FeLV SU protein gp70 was demonstrated in the follicles, 
paracortex and medulla (Kovacevic et aL, 1997; Kipar et aL, 2000).
Many degenerative and proliferative diseases arise because of FeLV activity in the 
bone marrow and lymphoid tissues. Bone marrow haematopoiesis is impaired; in 
addition to the direct cytopathic effect of replicating virus on infected cells, some 
FeLV-infected cats experience a maturation arrest at the myelocyte and 
metamyelocyte stage in granulocytic haematopoiesis (Shelton and Linenberger, 
1995). Thus, neutropenia is a common symptom of persistent infection (Latimer, 
1995), and may be accompanied by neutrophil dysfunction (Lewis et aL, 1986).
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Furthermore, FeLV-C greatly impairs the differentiation of early erythroid progenitor 
cells within the bone marrow, inhibiting erythrocyte production and causing a 
primary non-regenerative anaemia (Onions et aL, 1982; Hoover and Mullins, 1991). 
Moreover, bone marrow and lymphoid tissues are important sites of FeLV-associated 
oncogenesis. Myeloid and lymphoid tumours can originate in either tissue; however, 
90% of the tumours characterised in the U.S. were lymphoid, or LSA (Hardy, 
1981b).
These pathogenesis studies illustrate that the outcome of infection is influenced by 
early encounters between FeLV and the antiviral immune response in the bone 
marrow and lymphoid tissues. Furthermore, they demonstrate that virus integration, 
replication and expression in the bone marrow and lymphoid tissues have important 
disease consequences. Impaired haematopoiesis may interfere with the capacity of 
infected cats to overcome active FeLV infection and combat secondary infection; 
moreover, virus activity in these tissues may trigger the development of a fatal 
FeLV-associated disease, such as non-regenerative anaemia, or LSA.
Following oronasal exposure to FeLV, eleven cats in this study became persistently 
infected, and one cat retained a latent infection in the bone marrow and lymphoid 
tissues (Chapter 3). In this chapter, we investigated whether the expression of FeLV 
CA protein p27 in the bone marrow and PLN tissues correlated with the disease 
outcome or the antiviral immune response characterised in Chapters 3 and 4. In 
addition, we attempted to identify the cells that were associated with viral proteins in 
the bone marrow and PLN tissues, to determine whether this was relevant to the 
immunopathogenesis of FeLV-associated disease.
Bone marrow, lymphoid tissues and peripheral blood were sampled post mortem,
thirteen (cats E7-E12) and nineteen (cats E1-E6) weeks following oronasal exposure
to FeLV. To detect virus expression in the bone marrow and PLN tissues, cytospin
preparations of bone marrow, and cryostat sections of PLN tissues, were probed with
a sheep anti-p27 pAb in an immunofluorescent, and an immunohistochemical,
technique, respectively. The impact of virus expression on haematopoiesis was
determined through concurrent cytological and haematological analyses of bone
marrow and peripheral blood smears, respectively. Bone marrow cytospin
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preparations were stained with May-Griinwald-Giemsa for cytological assessment; 
peripheral blood smears were similarly stained to calculate the WBC differential 
count.
An abnormally large population of mature lymphoid cells was identified within the 
bone marrow cytospin preparations from nine cats. To characterise these cells, 
paraffin-embedded sections were prepared from formalin-fixed bone marrow tissue, 
and stained with anti-T and anti-B cell mAbs, in an immunoperoxidase technique.
5.2 Materials and Methods
5.2.1 Bone Marrow and Peripheral Blood
Bone marrow tissue was harvested from the femoral bones of cats E1-E12 post 
mortem (Section 3.2.4). The tissue was distributed among sterile containers 
containing 5% BSA in PBS, 10% formalin, or BMTM, for cytological and 
immunofluorescent analysis, immunohistochemistry, and VI, respectively. A 
description of the VI techniques conducted on bone marrow tissues harvested in 
BMTM was given in Chapter 3; the remaining techniques will be described below.
While under deep terminal anaesthesia, a 1 ml sample of peripheral blood was 
collected from cats E1-E12 in EDTA blood tubes, for haematological analysis.
5.2.1.1 Immunofluorescence
The expression of the FeLV CA protein p27 in the bone marrow from FeLV exposed 
cats E1-E12, was determined using a sheep anti-p27 pAb in an immunofluorescent 
technique on bone marrow cytospin preparations.
Bone marrow harvested into bijoux containing 5% BSA in PBS was transported on 
ice to the Clinical Diagnostics Laboratory. Bone marrow spicules were gently 
washed from the tissue in a test tube using a 1 ml syringe. The suspended marrow 
was then pelleted, and resuspended in approximately 50 [il 5% BSA in PBS.
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Conventional wedge smears were prepared from the marrow pellet using a 
cytocentrifuge, and air-dried; a proportion of which were retained for cytological 
analysis (Section 5.2.1.2). The remainder were air-dried overnight, and then fixed in 
ice-cold acetone for ten minutes. Slides were wrapped in ‘Parafilm’ and aluminium 
foil, and stored at -20°C until use.
Immediately before staining, frozen slides were brought to RT while still wrapped in 
‘Parafilm’. A small area of cells was encircled with the ‘Pap pen’ to minimise 
reagent wastage, then hydrated in wash buffer (PBS-T), for five minutes. The slides 
were subsequently incubated with 50 pi sheep anti-p27 pAb, diluted 1:500 in wash 
buffer, in a humidified chamber for one hour at 37^C. Following two, five-minute 
washes in PBS-T, the slides were incubated with a FITC-conjugated anti-sheep Ig 
pAb (Diagnostics Scotland, U.K.), diluted 1:1000 in PBS-T, for one hour at 37°C. 
The slides were washed twice over ten minutes in PBS-T and rinsed in deionised 
water. The slides were then stained in 0.02% Evans Blue for seven minutes to 
eliminate autofluorescence. Slides were rinsed in running tap water, mounted under 
water, and examined for fluorescent staining using a UV microscope (Leica 
Instruments, Germany).
5.2.1.2 Cytology and Haematology
Cytospin preparations (Section 5.2.1.1) were stained with May-Griinwald-Giemsa for 
cytological assessment. A standard wedge smear was prepared from each peripheral 
blood sample, and stained with May-Griinwald-Giemsa to calculate the differential 
WBC count.
5.2.1.3. Immunohistochemistry
An unusually large population of mature lymphoid cells was observed within May- 
Griinwald-Giemsa stained cytospin preparations of bone marrow from nine 
persistently infected cats in this study (Section 5.3.1.2). These cells were further 
characterised using mAbs that recognise T and B cell antigens, in an 
immunoperoxidase technique.
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Formalin-fixed bone marrow tissue was submitted to the Histopathology Laboratory, 
for the preparation of paraffin-embedded tissue sections. Formalin-fixation 
preserves cellular morphology very well; however, it has a tendency to mask 
antigens due to the formation of methylene bridges between reactive sites in different 
areas of the same molecule, or on adjacent proteins (Mason and O'Leary, 1991). 
Superheating in denaturing solutions is effective in rupturing some of these cross­
links, re-exposing antigens masked by fixation (Cattoretti et aL, 1993). This 
technique is known as antigen retrieval, and is required for the detection of some cell 
surface antigens. It was known that the feline CD4 and CDS antigens recognised by 
the species-specific anti-CD4 and anti-CD8 mAbs (vpg34 and vpg9, respectively) are 
masked following formalin-fixation (J.J. Callanan, personal communication). In the 
absence of established antigen-retrieval methods that could be used to re-expose 
these particular antigens, alternative antibodies were used.
The anti-CD3 and anti-CD79a mAbs (Dako A/S, Glostrup, Denmark), which detect 
human T and B cells respectively, were used in these experiments. The CD3 and 
CD79a antigens recognised by these mAbs are also masked by formalin fixation; 
however, superheating in a 0.01 M sodium citrate buffer pH 6.0, is known to be 
effective in re-exposing these antigens (C. Nixon, personal communication). The 
anti-CD3 mAb recognises the human CD3 molecule, which is associated with the 
TCR, and is therefore highly specific for T cells (Campana et aL, 1987). The anti- 
CD3 mAb also cross-reacts with the CD3 molecule from other species (Jones et aL, 
1993), including canine CD3. CD79a represents the mb-1 polypeptide, which forms 
a disulphide-linked heterodimer with the B29 polypeptide. This heterodimer is non- 
covalently associated with membrane-bound Ig on B cells, forming the B cell antigen 
receptor complex (van Noesel et aL, 1991). The anti-CD79a mAb was raised to the 
human mb-1 polypeptide, but has been shown to stain B cells in a number of 
mammalian species, including cattle, horses, monkeys, rats and mice (Mason et aL, 
1991), as well as dogs.
Bone marrow tissue sections from cats El-7, E9 and E12 were deparaffinised by 
immersing in ‘Histoclear’ for two minutes, then passed through graded alcohols and 
placed in water. Bone marrow tissue sections were also prepared from an SPF cat,
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TIO, which was not part of this FeLV immunopathogenesis study. Cat TIO was a 
control animal in another group of experimental cats; the bone marrow from this cat 
was used here to assess the normal distribution of B and T cells in an age-matched 
SPF cat. Endogenous peroxidase activity was blocked by immersing the slides in 
0.5% H2 O2 in methanol for thirty minutes, before returning to water. The sections 
were subsequently pressure cooked in 0.01 M sodium citrate buffer, pH 6.0, at 15 lb 
of pressure for seventy-five seconds, followed by three, five-minute washes in TBS- 
T. All subsequent incubations were conducted in a humidified chamber at RT, and 
were followed by three, five-minute washes in TBS-T. The tissue sections were 
encircled using a ‘Pap pen’. Non-specific background staining was minimised by a 
thirty-minute incubation with 1% NRS or 1% normal swine serum (NSS), prior to a 
two-hour incubation with either anti-CD3 (diluted 1:500 in TBS-T) or anti-CD79a 
(diluted 1:1000 in TBS-T) mAbs, respectively. This was followed by a thirty-minute 
incubation with either biotinylated rabbit anti-mouse Ig pAb (Dako A/S, Denmark), 
or biotinylated swine anti-rabbit Ig pAb (Dako A/S, Denmark), to detect CD3 and 
CD79a, respectively; both pAbs were diluted 1:200 in TBS-T. Finally, all sections 
were incubated with streptavidin-peroxidase (Dako A/S, Denmark), diluted 1:1000 in 
TBS-T, for one hour, before developing colour with DAB. Slides were 
counterstained using Gills’ Haematoxylin; then dehydrated in graded alcohols, 
cleared and mounted using DPX. Control slides were incubated with either 1% NRS, 
or 1% NSS in TBS-T, in place of the primary antibody.
5.2.2 Peripheral Lymph Nodes
Peripheral lymph node tissues were harvested from cats E1-E12 post mortem. These 
tissues were snap frozen in liquid nitrogen and stored at -70°C for future 
immunohistochemical studies and qRT-PCR analysis, or placed into RPMI 1640 
medium for the preparation of single cell suspensions. The methods used to conduct 
qRT-PCR analysis and prepare single cell suspensions were described in Chapter 3.
5,2,2.1 Single Immunohistochemistry Staining
The expression of the FeLV CA protein p27 in PLN tissues was determined using a
sheep anti-p27 pAb in an immunoperoxidase technique on cryostat PLN tissue
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sections. In addition, the distribution of the FDC network in PLN tissues was 
determined using the Ki-M4 mAb (a kind gift from Prof. Parwaresch, University of 
Kiel), in an immunophosphatase technique. The FDC population resides within 
primary and secondary lymph node follicles; their cytoplasmic processes extend 
between neighbouring B cells, forming a complex meshwork (van Der Valk and 
Meijer, 1992). The FDC retains antigen-antibody complexes bound to Fc receptors, 
and antigen-antibody-complement complexes bound to complement receptors 
(Szakal et aL, 1983; Schriever and Nadler, 1992). The Ki-M4 mAb recognises the 
long isoform of the CD21 molecule (CD21L), which is selectively expressed on the 
FDC population in humans (Paiwaresch et aL, 1983; Liu et aL, 1997) and in felines 
(Bach et aL, 1994; Graham, E.M., MVM Thesis, University College Dublin).
The Histopathology Laboratory prepared cryostat sections of PLN tissues from four 
cats, E4, E5, E7 and E l2. Frozen PLN tissues were embedded in ‘O.C.T.% from 
which 5-8 p,m sections were cut using a cryotome and placed onto ‘sticky’ slides 
(‘SuperFrost slides’, Menzel Glaser, Braunscheig, Germany). Slides were fixed in 
ice-cold acetone for ten minutes, wrapped in ‘Parafilm’ and aluminium foil, and 
stored at -20°C until use. Immediately prior to staining, frozen slides were brought to 
RT while still wrapped in ‘Parafilm’. The tissue sections were encircled using a ‘Pap 
pen’ and gently agitated in TBS for five minutes. All incubations were carried out at 
RT in a humidified chamber, and were followed by two, five-minute washes in TBS 
to remove unbound reagents. The sections were initially incubated with 0.3% H2O2  
and 0.1% NaNs in TBS for twenty minutes, to block endogenous peroxidase activity. 
To minimise non-specific binding, sections were incubated for twenty minutes with 
10% NRS. Excess serum was shaken from the sections, which were subsequently 
incubated with the primary antibodies, sheep anti-p27 pAb or K1-M4 mAb, diluted 
1:1000 in 1% NRS in TBS, for two hours. This was followed by a one-hour 
incubation with the secondary reagents, biotinylated rabbit anti-sheep Ig pAb 
(Southern Biotechnology, U.S.) and AP-conjugated rabbit anti-mouse Ig pAb 
(Southern Biotechnology, U.S.), diluted 1:2000 and 1:1000 respectively, in 1% NRS 
in TBS.
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Alkaline phosphatase activity was developed using the chromogen Fast Blue BB^^ 
(FBBB, Sigma-Aldrich, U.K.). A final one-hour incubation with streptavidin- 
peroxidase, diluted 1:500 in TBS, preceded the development of peroxidase activity 
using a commercial kit based on the chromogen ABC (Vector Laboratories, U.S.). 
Sections were washed with tap water to halt colour development, and mounted using 
an aqueous permanent mounting medium (‘UltraMounF, Dako A/S, Denmark). 
Negative control slides were prepared to examine the specificity of the primary mAb; 
in these slides, the primary mAb was omitted and replaced with 10% NRS.
5.22.2 Simultaneous Double Immunoenzyme Staining
The association of the FeLV CA protein p27 with the FDC population in the PLN 
tissues was investigated using a double immunoenzyme technique. Two unlabelled 
primary antibodies of different animal host origin were used in an indirect/indirect 
simultaneous double immunoenzyme staining, based on the original concept 
described by Mason and Sammons (1978). The protocol used follows many of the 
procedures described in Section 5.2.2.I. Following the blocking of endogenous 
peroxidase and non-specific binding, tissue sections were incubated for two hours 
with a primary antibody cocktail comprising sheep anti-p27 pAb and Ki-M4 mAb, 
diluted 1:1000 and 1:500 respectively, in 1% NRS in TBS. Sections were further 
incubated for one hour with a cocktail of secondary pAbs, biotinylated rabbit anti­
sheep Ig and AP-conjugated rabbit anti-mouse Ig, diluted 1:2000, and 1:1000 
respectively, in 1% NRS in TBS. Streptavidin-peroxidase, diluted 1:500 in 1% NRS 
in TBS, was added for a further hour prior to the development of colour. Alkaline 
phosphatase activity was then developed using the chromogen FBBB. The sections 
were washed with TBS twice over ten minutes before peroxidase activity was 
developed using the chromogen AEG. Sections were washed with tap water to halt 
colour development, and mounted using ‘UltraMounF. Negative control slides were 
prepared by replacing the primary antibody cocktail with 10% NRS. The individual 
reactivity of each primary monoclonal antibody was assessed using single 
immunohistochemical stainings in the same experiment.
FBBB: 1 mg of FBBB was added to 5 ml of O.IM tris buffer containing 0.5 mM levamisole and 1% 
naphthol-AS-MX-phosphate in N N dimethylformamide; the solution was filtered and applied.
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5.3 Results
5.3.1 Bone Marrow and Peripheral Blood
53.1.1 Immunofluorescence
Immunofluorescent techniques were employed to identify the FeLV CA protein p27 
within bone marrow cytospin preparations. Slides were examined using a UV 
microscope and photographed; some images are shown in Fig. 5.1. Negative control 
slides did not show any positive staining. Red blood cells did not emit UV light 
when examined using the UV microscope but did appear red. The imaging system 
used displayed all objects in the field in a green light; therefore, green RBC are 
evident in some of the images shown. This is a technical limitation of the equipment 
used to photograph these images.
The FeLV CA protein p27 was expressed in bone marrow cytospin preparations from 
all persistently infected cats E l-E ll  (Fig. 5.1). The level of FeLV CA protein p27 
expression varied markedly, with distinctly greater numbers of positive cells detected 
in cats E1-E6 and cat E9. It was difficult to definitively identify each cell that 
expressed the FeLV CA protein p27 in the bone marrow; cells in the early stages of 
haematopoiesis cannot easily be distinguished. However, the majority of positive 
cells were large mononuclear cells, principally of the granulocytic lineage, such as 
promyelocytes, myelocytes and metamyelocytes. Polymorphonuclear (FMN) cells 
that expressed FeLV CA protein p27 were also evident in the bone marrow from 
several cats; these represent more differentiated cells of the same lineage (Fig. 5.1). 
Positive plasma cells were also frequently detected. A single large vacuolated cell 
that expressed FeLV CA protein p27 was also pictured, which may represent either a 
macrophage or a megakaryocyte (Fig. 5.1).
No fluorescence was detected in bone marrow preparations from latently infected cat 
E12, indicating that the FeLV CA protein p27 was not expressed in the bone marrow 
from this cat thirteen weeks post exposure (Fig. 5.1).
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5.3.1.2 Cytology and Haematology
Cytospin preparations of bone marrow tissues were stained with May-Griinwald- 
Giemsa post mortem. Images of the bone marrow preparations are displayed in Fig. 
5.2. The myeloidierythroid (M:E) ratios, the approximate percentage of lymphoid 
cells enumerated within the cytospin preparations, and summaries of the cytology 
reports are displayed in Table 5.1. The differential WBC count was calculated 
manually from blood smears prepared from post mortem peripheral blood samples; 
the results are shown in Table 5.2.
Preliminary naked eye examination revealed marked differences in the cellularity of 
bone marrow from persistently infected cats, compared to the latently infected cat, 
E12 (Fig. 5.3). This initial finding suggested that the bone marrow from persistently 
infected cats was subject to decreased haematopoiesis and/or increased cell death. 
Indeed, granulocytic hypoplasia was observed in five persistently infected cats, E l 
and E8-E11, associated with a depleted pool of mature segmented neutrophils (Table 
5.1). The haematological picture showed that four of these cats, E l and E9-E11, 
presented with a concurrent neutropenia; this was moderately severe in cat E9 and 
was accompanied by a leukopenia (Table 5.2). Cat E l l  also suffered a concurrent 
mild neutropenia and leukopenia. However, all cell lines were present at all stages of 
differentiation in six persistently infected cats, E2-E6 and E7, indicating 
normoplasia.
Under normal circumstances, the bone marrow lymphoid population chiefly 
comprises circulating lymphocytes and maturing B cells. Occasional lymphoblasts, 
prolymphocytes and plasmacytoid cells are also considered normal. In the literature, 
the reported proportion of lymphoid cells in normal bone marrow varies widely; 
ranging from 0.2-15% (Keller and Freudiger, 1983), or averaging either 11.2% 
(Latimer, 1995) or 16.13% ± 2.92 (Clinkenbeard and Meinkoth, 2000). The values 
from all cats, except E l, comply with the most stringent normal range, albeit at the 
upper extremes of normal. However, an increased proportion of small, mature 
lymphoid cells was observed in the bone marrow from nine persistently infected cats 
in this study (cats E1-E8 and ElO) (Table 5.1). These cells, 6 pm-9pim in diameter,
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were identified by the presence of round to slightly indented nuclei, surrounded by a 
thin rim of light blue cytoplasm (Tyler et aL, 1999; Steffans, 2000).
The M:E ratio, which is the ratio of cells in the myelopoietic line to those in the 
erythropoietic line, varied widely between cats, ranging from 0.51:1 in cat E9, to 
2.9:1 in cat E12 (Table 5.1). The normal reference range cited in the literature also 
varies widely, from 0.65-4.29:1 (Keller and Freudiger, 1983) or from 0.9-2.5 
(Latimer, 1995), or averaging 1.63 ± 0.35:1 (Clinkenbeard and Meinkoth, 2000). 
Using the broadest published criteria, three cats, E l, E4 and E9, recorded M:E ratios 
below the normal range. A low M:E ratio is associated with either decreased 
leukocyte precursor cells, or increased erythrocyte precursors. In the affected cats, a 
low M:E ratio could be attributed to a reduced numbers of leukocyte precursor cells; 
a granulocytic hypoplasia was identified in both cats E l and E9. Furthermore, there 
was no evidence of increased erythrocyte precursor cells in the bone marrow from 
any cat; in fact, a mild erythroid hypoplasia was detected in the bone marrow from 
cat E9.
Normal haematology reports were cited for cats E2, E3, E7, E8 and E12. A mild 
leukocytosis was demonstrated in the peripheral blood from cat E6, accompanied by 
a slight increase in the proportion of band neutrophils. These findings were reflected 
in a high M:E ratio. The numbers of mature neutrophils and lymphocytes in this cat 
were also high, but within the normal reference range (Table 5.2). Two cats, E l and 
E4, presented with lymphocytosis.
5 . 3 . i . 3  Immunohistochemistry
An increased number of small, mature lymphoid cells was detected in the bone 
marrow tissues from nine cats in this study (Table 5.1). These lymphoid cells were 
characterised using anti-human CD3 and CD79a mAbs on formalin-fixed bone 
marrow sections, in an immunoperoxidase technique. The anti-CD3 and anti-CD79ot 
mAbs are known to cross-react with the CD3 and CD79a molecules, respectively, 
expressed by many other species. No attempt was made to ascertain whether these 
mAbs definitively recognised the CD3 and CD79a molecules expressed by feline
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cells. However, each mAb identified a distinct homogenous cell population defined 
by disparate distribution and staining patterns (Fig. 5.4); thus, it was considered that 
the cell populations recognised by these mAbs corresponded to feline T and B cells, 
respectively. Bone marrow tissue sections were prepared from cats E1-E6, E7, E9, 
E12 and SPF cat TIO post mortem. Stained sections of bone marrow tissue from 
each cat were photographed; representative images are shown in Figs. 5.4 and 5.5. 
Megakaryocytes within the sections were susceptible to non-specific staining, 
particularly when the anti-CD79a mAb was used. No staining was detected on the 
negative control slides.
Few CDS’*” T cells were detected in the bone marrow sections from SPF cat, TIG 
(Fig. 5.4). However, bone marrow tissue sections from all FeLV-exposed cats 
demonstrated strong reactivity to the anti-CD3 mAb. In particular, large numbers of 
CD3^ T cells were apparent in the bone marrow sections from cats E l and E5. CD3^ 
T cells were often distributed at the periphery of the bone marrow sections. In 
addition, positive cells were occasionally clustered together; this was particularly 
evident in cat E2. Bone marrow sections from latently infected cat, E12, contained a 
greater number of CD3^ T cells, compared to SPF cat TIO (Fig. 5.4).
CD79a'*' B cells were distributed widely in bone marrow sections from SPF cat TIO 
(Fig. 5.4). In FeLV-exposed cats, reactivity to CD79a was less intense than to CD3, 
and fewer positive cells were detected; indeed, no positive cells were detected in the 
bone marrow from cat E3. Nonetheless, large numbers of positive cells were evident 
in bone marrow sections from cat E5. A distinct cluster of CD79(%  ^ B cells was 
evident within the bone marrow from cat E2 (Fig. 5.5.E); however, in cat E9, this 
effect was more dramatic. Large numbers of CD79a^ B cells had congregated, 
forming two large pools of positive cells (Fig. 5.5.C). Both lesions were associated 
with CD3^ T cells. In cat E2, a small number of CD3^ T cells were distributed 
throughout the pool of CD79a^ B cells, with a greater number congregated distally 
(Fig. 5.5.F). In cat E9, a large number of CD3^ T cells had infiltrated the pool of 
CD79oc^ B cells, forming an organised pattern. The lesion was also surrounded by 
considerable numbers of CD3^ T cells (Fig. 5.5.D).
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5.3.2 Peripheral Lymph Nodes
53.2.1 Single Immunohistochemistry Staining
The distribution of the FeLV CA protein p27 in the PLN tissues was investigated 
using a selection of cats in the present study. Cryostat sections were prepared from 
the PLN tissues from persistently infected cats, E4, E5 and E7, and latently infected 
cat E12 post mortem. No staining was detected on the negative control slides. 
Positively stained PLN sections were photographed; representative images are shown 
in Fig. 5.6.
The FeLV CA protein p27 was not detected in the PLN sections from latently 
infected cat E12, indicating that FeLV infection was not active in the PLN tissues 
from this cat thirteen weeks post exposure. However, this viral protein was detected 
in PLN sections from all the persistently infected cats examined (cats E4, E5, E7). In 
these cats, the positive cells were largely confined to the lymph node follicles (Fig.
5.6.B). Furthermore, the distribution of positive cells corresponded approximately to 
the distribution of the FDC network, demonstrated using the Ki-M4 mAb (Fig.
5.6.A). Therefore, it was considered likely that the FDC population might harbour 
the FeLV CA protein p27, as suggested in previous studies (Kovacevic et aL, 1997).
5.3.2.2 Simultaneous Double Immunoenzyme Staining
To investigate whether the FeLV CA protein p27 was retained by the FDC
population, the Ki-M4 mAb was used with the sheep anti-p27 pAb in a simultaneous
double immunoenzyme technique on PLN cryostat sections from persistently
infected cat E4. Peripheral lymph node sections from latently infected cat E12 were
also used in a double immunoenzyme technique to compare the findings. The results
are shown in Fig. 5.6. Single staining of either the FDC population, or the FeLV CA
protein p27, in the PLN tissue sections from cat E4, resulted in a homogenous blue or
red staining, respectively, developed with either FBBB or AEC (Fig. 5.6.A and B).
However, when the FeLV CA protein p27 and the CD21L antigen were probed
simultaneously, a purple staining arose, indicating antigen co-localisation (Fig. 5.6.C
and D). Cryostat PLN sections from cat E l2 were probed simultaneously with the
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same antibody cocktail; however, as cat E12 did not express the FeLV CA protein 
p27, no co-localisation was evident (Fig. 5.6.E and F).
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Fig. 5.2 May-Grünwald-Giemsa stained bone marrow cytospin 
preparations
Images of bone marrow cytospin preparations from cats E1-E12, stained with May- 
Griinwald-Giemsa, which illustrate some of the cells and cell series identified within 
the bone marrow.
(A) Neutrophil series, segmented mature neutrophil (arrow); mature 
lymphocytes; (xlOO)
(B) Basophil (arrow, xlOO)
(C) Erythroid series; mitotic figure (arrow, xlOO)
(D) Megakaryocyte (open arrow); osteoclast (closed arrow, x40)
(E) Eosinophil series; mature eosinophil (arrow, xlOO)
(F) Plasma cell (xlOO)
(G) Megakaryocyte; normoplasia, (x40)
(H) Megakaryocye erupting, dispersing platelets (xlOO)
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Fig. 5.3 Comparison of bone marrow results from cats E9 and E12
Bone marrow was harvested from persistently infected cat E9 and latently infected 
cat E12 post mortem. Cytospin preparations were stained with May-Grünwald- 
Giemsa and examined cytologically (x40). The distribution of T and B cells in the 
bone marrow was detected using anti-CD3 and anti-CD79a mAbs respectively, in an 
immunoperoxidase technique on formalin-fixed bone marrow tissue sections (CD3: 
E9, x2 and E12, x4; CD79a: E9, x4 and E12, xlO). Finally, expression of the FeLV 
CA protein p27 was detected using immunofluorescence on bone marrow cytospin 
preparations (x40).
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Fig. 5.5 CD3  ^ and CD79a^ cells in bone marrow from cats E2 and 
E9
Formalin-fixed sections of bone marrow from persistently infected cats E9 (A-D) and 
E2 (E and F). The sections were probed with anti-CD79a (C and E, xlO) or anti- 
CD3 (D and F, xlO) mAbs using an immunoperoxidase technique. Colour was 
developed using DAB, and the sections were counter-stained using Gills’ 
haematoxylin. Sections probed with normal serum, acted as negative controls (A, x4 
and B, xlO).
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Fig. 5.6 FeLV CA protein p27 and FDC network in cryostat PLN 
sections, detected using immunohistochemistry
Detection of the FDC network in cryostat section of PLN from persistently infected 
cat E4, using the Ki-M4 mAh in an immunophosphatase technique; colour was 
developed using FBBB (A, xlO). Detection of FeLV CA protein p27 in cryostat 
section of PLN from cat E4, using a sheep anti-p27 pAb in an immunoperoxidase 
technique; colour was developed using AEC (B, xlO). Two-colour staining was 
performed in PLN tissues from the same cat using an antibody cocktail comprising 
Ki-M4 mAb and sheep anti-p27 pAb; co-expression of FeLV CA protein p27 and the 
FDC population is illustrated with the colour purple (C, D, xlO). Staining of cryostat 
sections of PLN from cat E12 using the same antibody cocktail resulted in FDC 
staining only, indicating the absence of FeLV CA protein p27 expression (E, F, xlO).
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5.4 Discussion
Bone marrow and lymphoid tissues have an important role in the 
immunopathogenesis of FeLV infection. Virus may be rapidly eliminated in the 
PLN, prior to a cell-associated viraemia; however, uncontrolled viral replication in 
the bone marrow leads to the dissemination of virus throughout the infected host. In 
addition, virus integration, replication and expression in these tissues may impair 
normal cell function in these tissues and precipitate FeLV-associated disease.
Using immunofluorescence on bone marrow cytospin preparations, the FeLV CA 
protein p27 was detected in the bone marrow cells from each persistently infected 
cat. This technique, similar to the original IFA technique described by Hardy et al. 
(1973), detects cell-associated viral protein rather than free viral protein. Thus, this 
method provides an alternative means of diagnosing viraemia or active infection 
(Hardy et al., 1973; Jarrett et al., 1982b; Pedersen, 1988). The bone marrow from 
cats E1-E6, and cat E9, contained the greatest numbers of p27-positive cells. Cats 
that received the highest exposure dose of FeLV by a factor of one log (E1-E6) 
generated significantly greater proviral DNA loads in the peripheral blood post 
mortem, compared to cats that were exposed to a lower dose of infectious virus 
(Mann-Whitney, P=0.0043). Thus, we can speculate that these cats also expressed 
higher levels of infectious virus in the bone marrow. The FeLV CA protein p27 was 
predominately associated with granulocytic precursor cells. These findings are 
consistent with other reports where virus was principally associated with neutrophil 
precursor cells (Hoover et al., 1977b); the authors also reported virus expression in 
erythrocyte precursor cells. However, our findings did not concur with a second 
study, where the FeLV CA protein p27 and SU protein gp70 were identified chiefly 
in association with megakaryocytes (Kovacevic et aL, 1997).
Bone marrow studies have previously identified a maturation arrest in granulocytic 
precursor cells at the metamyelocyte stage in some FeLV-infected animals, 
suggesting a developmental blockade (Shelton and Linenberger, 1995). In this 
thesis, the majority of p27-positive cells in the bone marrow were granulocytic 
precursor cells; virus replication in neutrophil precursor cells would directly deplete
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the pool of mature neutrophils. These phenomena may account for the granulocytic 
hypoplasia evident in the bone marrow from five persistently infected cats in this 
study, cats E l and E8-E11, reflected in low M:E ratios in cats E l and E9. The 
concomitant haematology results revealed that four of these cats, E l, E9-E11, had 
low levels of circulating mature neutrophils. Neutropenia was particularly marked in 
cat E9, and was accompanied by a leukopenia; cat E l l  also suffered a concurrent 
leukopenia and neutropenia. Since neutrophils are the predominant circulating 
leukocyte in cats, neutropenia usually results in a leukopenia (Latimer, 1995). In 
most FeLV-infected cats, neutropenia is mild, and is associated with relatively 
normal granulopoiesis. However, in some cats, a moderate neutropenia is 
accompanied by a granulocytic hypoplasia. Finally, less frequently, FeLV infection 
may result in a severe persistent neutropenia associated with a severe granulocytic 
hypoplasia (Latimer, 1995). As neutrophils provide one of the first lines of defence 
against invading pathogens, particularly bacteria, neutropenia predisposes FeLV- 
infected cats to secondary opportunistic infections (Latimer, 1995).
It was not possible to detect FeLV CA protein p27 expression in the bone marrow 
cells from latently infected cat E12 (Fig. 5.1). Failure to detect virus expression in 
the bone marrow does not necessarily indicate either recovery or latency following 
exposure to FeLV. In one study, the FeLV CA protein p27 or SU protein gp70 were 
not consistently detected in the bone marrow from cats suffering from an FeLV- 
associated disease (Kovacevic et a i, 1997). Furthermore, the FeLV CA protein p27 
was not detected in the bone marrow from a cat suffering from an FeLV-associated 
disease, which had a localised infection in the spleen (Hayes et aL, 1989). The 
cytological analysis of the bone marrow from latently infected cat E l2 was normal, 
indicating normoplasia (Table 5.1). Furthermore, no abnormalities were detected 
following the haematological analysis of the peripheral blood (Table 5.2). These 
finding are consistent with the fact that bone marrow cells from this cat were not 
actively producing infectious virus.
An infiltrating population of small mature lymphoid cells was detected in the bone
marrow from nine persistently infected cats, while normal numbers of lymphoid cells
were detected in the bone marrow from two persistently infected cats, E9 and E l l .
Both cats suffered a concurrent leukopenia, in addition to a granulocytic hypoplasia
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and neutropenia; cat E9 also presented with erythroid hypoplasia. These findings 
may reflect a general impaired haematopoiesis in these cats; circulating lymphocyte 
numbers were also low but within the normal range. The infiltrating cells were 
particularly numerous in the bone marrow from cats E l and E5, which contained 
high numbers of p27-positive cells. In addition, these cats had the highest mean 
levels of proviral DNA in the peripheral blood over the course of the study (4.66 ± 
3.65 and 4.82 ± 7.78 copies per cell, respectively). The infiltrating lymphoid cells 
were characterised using anti-CD3 and anti-CD79a mAbs in an immunoperoxidase 
technique. It was observed that the SPF cat, TIO, harboured very low numbers of 
CD3'*' T cells in the bone marrow; however, CD79a^ B cells were distributed widely. 
Since the normal range of lymphoid cells within the bone marrow varies widely, 
according to the literature (Section 5.3.1.1), it might be important to compare the 
data recorded in the present study with data from a greater number of SPF cats.
Greater numbers of CD3^ T cells were detected within the bone marrow from all 
cats, compared to SPF cat TIO. However, only in cat E5 was it possible to detect 
markedly increased numbers of CD79a^ B cells in the bone marrow, compared to cat 
TIO (Fig. 5.4). Thus, for each cat, the majority of infiltrating lymphoid cells were 
CD3^ T cells. T cells are not normally found in large numbers within the bone 
marrow; in an early study, only 8% of the small mononuclear cells in the bone 
marrow classified morphologically as lymphocytes (5-10% of total cells), were 
erythrocyte-rosette forming cells (E-RFC), regarded as probable T cells (Rojko et aL, 
1982a). Therefore, the large numbers of CD3^ T cells detected in the bone marrow 
from cats in this present study exceeded the normal bone marrow T cell population. 
The bone marrow from all persistently infected cats was actively infected; the FeLV 
CA protein p27 was demonstrated in the bone marrow tissues from all such cats 
using immunofluorescence. Furthermore, we have detected virus-specific T cell 
responses in the peripheral blood from all persistently infected cats at some time over 
the study (Chapter 4). Therefore, it is likely that the infiltrating T cells chiefly 
comprised virus-specific effector T cells activated in the lymphoid tissues in 
response to virus-specific stimulation. To verify this, and further characterise these 
cells, sophisticated immunohistochemical staining experiments could be conducted. 
The antigen-specificity and cell phenotype of the infiltrating cells could be
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established using tetramer staining in situ in combination with cell surface staining. 
These data would also indicate whether the infiltrating cells retained the capacity to 
secrete flFN-y in response to antigenic stimulation. Finally, FeLV CA protein p27 
expression by these cells would indicate whether these cells were actively replicating 
virus; this could be achieved using double immunoenzyme techniques.
The conclusion that the infiltrating CD3^ T cells represent virus-specific effector T 
cells is consistent with the low number of CD3^ T cells observed in latently infected 
cat E12, and SPF cat TIO, neither of which were actively infected. Although latently 
infected cat E12 contained greater numbers of CD3^ T cells within the bone marrow 
compared to cat TIG (Fig. 5.4), these numbers were still considered normal (Table 
5.1). Furthermore, cat TIO was SPF, while cat E12 had been exposed to FeLV under 
experimental conditions; circulating virus-specific T cells were detected in the blood 
and lymphoid tissues from cat E12 following oronasal exposure to FeLV (Chapter 4). 
Therefore, we can speculate that, in the absence of an productive FeLV infection, 
these infiltrating T cells in cat E12 may comprise effector memory T cells, derived 
from early effector T cells activated in the lymphoid tissues in response to virus- 
specific stimulation. These effector memory T cells home to specific viral antigen in 
the bone marrow and other non-lymphoid tissues (Lefrançois and Masopust, 2002).
The distinctive pooling of B cells in cats E2 and E9 (Fig. 5.5) may represent the 
formation of germinal centre follicles in the bone marrow, which can occur in 
response to prolonged antigen stimulation (Valli and Jacobs, 2000). It is known that 
virus can reach the bone marrow within two days following exposure; therefore, 
virus may have been expressed in the bone marrow from these cats for up to thirteen 
and nineteen weeks, respectively. High numbers of p27-positive cells were detected 
in the bone marrow from both cats post mortem. Continual expression of viral 
proteins represents a persistent focus for the antiviral immune response.
Neither p27 antigenaemia nor viraemia were detected in cat E12 at any time
throughout the study. However, proviral DNA was detected in the PLN tissues and
in the buffy coat cells from cat E12 post mortem; in addition, infectious virus was
isolated from the bone marrow of this cat after a short in vitro culture. Thus, this cat
maintained at least three foci of latency, the peripheral blood cells, the bone marrow
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and the lymphoid tissues. However, virus was not expressed in the peripheral blood 
(Chapter 3) or bone marrow (Chapter 5) from this cat post mortem. Furthermore, 
expression of the FeLV CA protein p27 was not detected in the PLN tissues (Fig. 
5.6.E and F). These findings suggest that cat E12 may have a true latent infection, 
where provirus is quiescent, and not replicating. However, the sensitivity of the 
assays used to detect virus expression in these tissues may be inadequate. Virus- 
specific T cells recognise a much greater array of FeLV epitopes compared to the 
sheep anti-p27 pAb; therefore, the detection of such cells may reflect the current 
viral status more accurately. A greater number of CD3^ T cells were detected in the 
bone marrow from cat E12, compared to SPF cat TIO. Although we have speculated 
that these cells may be virus-specific effector memory T cells, further investigations 
would be necessary to verify their identity.
High levels of proviral DNA were quantified in the PLN tissues from persistently
infected cats post mortem (Chapter 3). Furthermore, the FeLV CA protein p27 was
identified in the PLN follicles from all persistently infected cats tested. This is in
agreement with previous reports where the FeLV CA protein p27 was identified in
the MLN follicles in sixteen out of eighteen cats diagnosed with an FeLV-associated
disease (Kovacevic et aL, 1997). The virus-specific immune responses in the PLN
tissues were investigated post mortem using LPA, and ICS analysed using flow
cytometry; the results were discussed in Chapter 4. The expression of the FeLV CA
protein p27 in the PLN tissues was not associated with the presence of virus-specific
immune responses. Virus-specific CD8^ T cell responses were detected in the PLN
tissues from latently infected cat E12, which did not express the FeLV CA protein in
these tissues. Furthermore, virus-specific CD4^ T cell responses were only detected
in cats E4 and E5, although the PLN tissues from cats E4, E5 and E7 all expressed
this viral protein. It was suggested in Kovacevic's study (1997) that the FeLV CA
protein p27 was associated with the FDC network in the germinal centre of lymph
node follicles; however, this was not proven. In the present study, double staining
immunoenzyme procedures were used to verify that the FeLV CA protein p27 was
associated with the FDC population. It is not known whether the FDC was actively
infected, or whether the FeLV CA protein p27 was bound in the form of an immune
complex. Antigen retained by the FDC is typically in the form of an immune
complex, bound to FcR (Szakal et aL, 1983). The FDC can retain the immune
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complexes for months or years, and are thought to have a central role in the 
maintenance of the B cell memory pool (Gray and Skarvall, 1988; Tew et al., 1997). 
Although speculation exists that the soluble glycosylated p27 protein may induce 
anergic CD4^ T cell responses, which impede the formation of anti-Gag antibodies, 
immune complex disease is a common consequence of persistent FeLV infection 
(Pedersen, 1988). Furthermore, anti-Gag antibodies are known to be produced by 
persistently infected cats (Lutz et al., 1980b; Charreyre and Pedersen, 1991; Hawks 
et aL, 1991). In studies of FIV infection, it was shown that FIV RNA was co­
localised with the FDC population in lymph nodes, using a combination of in situ 
hybridisation and immunohistochemistry; the FDC virus load appeared concurrently 
with antibodies and persisted for at least three years (Bach et aL, 1994).
The implications of the FDC population harbouring the FeLV CA protein p27 are not 
clear. In the present study, this phenomenon occurred only in persistently infected 
cats; the FeLV CA protein p27 was not detected in the PLN tissues from latently 
infected cat E12. Many cats recover following exposure to FeLV with minimal 
evidence of virus replication; therefore, these cats cannot express and retain 
significant quantities of the FeLV CA protein p27. Despite the absence of an FDC- 
p27 network, recovered cats appear to be immune to subsequent exposure to FeLV; 
however, this may be an age-related phenomenon (Hoover et aL, 1976).
5.5 Summary and Conclusions
All persistently infected cats expressed the FeLV CA protein p27 in bone marrow, 
which was chiefly associated with large mononuclear granulocytic precursor cells. 
Five persistently infected cats suffered a granulocytic hypoplasia, which was 
associated with a concurrent neutropenia in four cats. In addition, an infiltrating 
small, mature lymphoid population was identified in the bone marrow cytospin 
preparations from nine persistently infected cats. The mature small lymphoid 
population chiefly comprised T cells, in addition to B cells, defined by CD3 and 
CD79a molecules, respectively. These mature T cells were particularly numerous in 
cats E l and E5. Cats E2 and E9 demonstrated unusual focal congregations of B 
cells, which may represent follicles formed in response to chronic viral stimulation.
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All persistently infected cats examined expressed the FeLV CA protein p27 in PLN 
tissues; double immunoenzyme staining demonstrated that the FeLV protein p27 was 
associated with the FDC population in lymph node follicles. Cat E12 retained latent 
infections in the bone marrow and lymphoid tissues; however, this cat did not 
express the FeLV CA protein p27 in either tissue. Consequently, cytology and 
haematology reports were normal.
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CHAPTER 6
GENERAL DISCUSSION
Feline leukaemia virus is a naturally occurring y-retrovirus of domestic cats, 
predominately associated with proliferative and degenerative diseases of the 
haematopoietic system. Fortunately, the majority of exposed cats recover and 
develop lasting protective immunity; however, a number fail to control virus 
replication, and become persistently viraemic, dying within two-to-three years from 
an FeLV-associated disease. A large proportion of recovered cats retain FeLV as a 
latent proviral DNA infection for months or years before eliminating the virus or, 
more rarely, progressing to a state of persistent viraemia. Virus isolate, dose, host 
susceptibility, age at the time of exposure and route of exposure all interact to 
influence the outcome following exposure to FeLV (Hoover et aL, 1976). The 
immune mechanisms that influence host susceptibility have yet to be fully 
delineated.
The importance of humoral immunity in the control of retroviral disease is 
controversial, and may vary among individual viruses. Virus neutralising antibodies 
are a vital correlate of protection against FV; however, VNA alone cannot mediate 
protection (Hasenkrug and Chesebro, 1997; Dittmer et aL, 1999). Recent studies 
involving chimeric SHIV demonstrated passive protection conferred by anti-HIV 
Env neutralising antibodies alone in vivo (Shibata et aL, 1999). However, although 
high anti-Env antibody titres can be detected in the sera of most HIV-infected 
individuals, the key events of CD4 binding and fusion are not inhibited, indicating 
that humoral immune responses are not protective (Matthews et aL, 1986). Early 
FeLV studies showed that the elicitation of VNA correlated with recovery following 
exposure (Russell and Jarrett, 1978a; Lutz et aL, 1980b), and passively protected 
kittens against FeLV challenge (Jarrett et aL, 1977). Nonetheless, in more recent 
studies, virus was shown to be cleared from the blood prior to, or concurrent with, 
the appearance of VNA (Flynn et aL, 2000a; Flynn et aL, 2002b). Thus, in each of 
these retroviral infections, VNA alone are not sufficient to mediate recovery and/or 
elicit protective immune responses, implicating a role for cell-mediated immunity.
Indeed, we know that virus-specific CTL are important in the elimination of virus,
and in the elicitation of protective immune responses, in each of these retroviral
infections. The development of FV-specific CTL correlated with recovery from
splenomegaly in FV-infected mice (Robertson et aL, 1992); depletion of CD8^ T
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cells in vivo dramatically reduced the incidence of recovery in these mice. Cytotoxic 
T cells are important in the control of viraemia in the initial acute phase, and during 
the asymptomatic period, following infection with HIV and SIV (Koup et aL, 1994; 
Borrow et aL, 1997; Ogg et aL, 1998; Wilson et aL, 1998; Jin et aL, 1999). Early 
Gag/Pro-specific CTL responses in the blood and lymphoid tissues are associated 
with recovery from FeLV infection (Flynn et aL, 2002b); moreover, such responses 
are implicated in protective immune responses following inoculation of cats with an 
experimental FeLV DNA vaccine containing gag, pol and env genes (Flynn et aL, 
2000a; Hanlon et aL, 2001). The adoptive transfer of a single infusion of mixed 
virus-specific CD4^ and CD8^ T cells significantly reduced the proviral DNA 
burdens in persistently infected cats, indicating a direct role for virus-specific T cells 
in the control of FeLV viraemia (Flynn et aL, 2002b).
CD4^ T cells have a key role in regulating the humoral and cell-mediated arms of the 
immune response, through the activation of DC, and the elaboration of cytokines, 
particularly IFN-y. Failure of the CD4^ T cell response in HIV and FV infections has 
been shown to result in inadequate priming, maturation and maintenance of the CTL 
response; inadequate CTL function culminates in viral persistence. Therefore, the 
capacity of FeLV-specific CD4^ T cells to activate, prime and maintain virus- 
specific CTL, and virus-specific B cells, may be a critical component in the immune 
mechanisms contributing to the control of FeLV viraemia.
The purpose of this thesis was to investigate the role of virus-specific CD4^ T cells in 
the control of FeLV infection. It was intended to compare such responses among 
spontaneously recovered, latently infected and persistently infected cats, following 
oronasal exposure to FeLV. To this end, six sixteen-week old SPF cats were 
exposed oronasally to 5 x 10  ^ffu, FeLV-A/Glasgow-1 in the anticipation that each of 
these three well-defined outcomes would ensue. However, all six cats became 
persistently infected. A second group of six sixteen-week old SPF cats was exposed 
to a reduced dose of FeLV under identical conditions as the first group of cats. Five 
cats in this second group became persistently infected and one cat, E12, retained a 
latent proviral DNA infection in the bone marrow and lymphoid tissues.
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Novel anti-flFN-Y antibodies were generated and characterised to facilitate the 
detection of virus-specific CD4^ T cells. We have demonstrated the sensitivity of 
these novel reagents in the detection of both recombinant flFN-y using ELISA and 
Western blots, and the production of intracellular GFN-y in physiologically 
stimulated cells using flow cytometry; the results were presented and discussed in 
Chapter 2. These reagents have clear applications in the investigation of other viral 
and non-viral infections, as well as anti-tumour immune responses.
To define the outcome of infection, and relate virus-specific immune responses with 
proviral DNA loads, a series of virological parameters were evaluated throughout the 
study. Sensitive and sophisticated assays, such as the p27 ELISA, VI, and qRT- 
PCR, were used to detect antigenaemia, viraemia and proviral DNA, respectively, in 
the peripheral blood throughout the study, and in the lymphoid tissues post mortem; 
the results were presented and discussed in Chapter 3. In the present study, the qRT- 
PCR assay was identified as the most sensitive method used in the detection of 
FeLV. Proviral DNA was detected in the peripheral blood prior to the detection of 
plasma viraemia or antigenaemia, in ten cats. In addition, this technique identified a 
persistent proviral DNA infection in the peripheral blood and lymphoid tissues from 
cat E12, in the absence of detectable antigenaemia or viraemia.
The development of virus-specific cell-mediated immune responses, particularly 
virus-specific CD4^ T cells, was monitored in the peripheral blood one week 
following exposure and at regular intervals thereafter. Such responses were also 
measured in the lymphoid tissues post mortem. Cell-mediated immune responses 
were assessed using two techniques, the LPA, and ICS analysed using flow 
cytometry; the results were presented and discussed in Chapter 4. Lymphocyte 
proliferation assays are technically straightforward to conduct; however, as discussed 
earlier, these assays do not provide precise information on the frequencies of virus- 
specific CD4^ T cells, as they reflect both the absolute numbers of responsive cells, 
and the ability of those cells to expand in vitro. Conversely, ICS analysed using flow 
cytometry is a highly sensitive assay; intracellular IFN-y expression can be detected 
at the single cell level following a short four-hour stimulation ex vivo, permitting the 
enumeration and phenotypic analysis of individual virus-specific cells.
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The bone marrow and lymphoid tissues are important sites of viral replication and 
expression; consequently, these are important sources of FeLV-associated disease 
and act as foci for the antiviral immune response. The expression of FeLV CA 
protein p27 in the bone marrow and lymphoid tissues was determined using 
immunofluorescence and immunohistochemistry, respectively; the results were 
illustrated and discussed in Chapter 5. Where possible, the cells that were associated 
with the viral proteins were identified, and the consequences for the 
immunopathogenesis of FeLV disease discussed.
The specificity of the immune response was evaluated by measuring the ability of 
mononuclear cells in the peripheral blood and lymphoid tissues to proliferate, and to 
express flFN-y, in response to stimulation with FeLV recombinant p27 and p45 
proteins, and inactivated FeLV particles. The recombinant p27 and p45 proteins 
were expressed in E. coli bacterial vectors, and purified using affinity 
chromatography; FeLV particles were purified from F422 cell culture supernatants, 
and heat-inactivated. The purity, and immunological relevance of these reagents in 
FeLV infection, was determined using SDS-PAGE and Western blots. In the 
retroviridae, the principal Gag polypeptide is cleaved to mature forms, MA, CA and 
NC proteins, by viral PR during and/or immediately after budding (Luciw and 
Leung, 1992). The CA protein comprises the internal shell, which surrounds the 
nucleocapsid. The FeLV CA protein p27 has an important role in the 
immunopathogenesis of FeLV infection; we know that Gag-specific CTL are 
important in mediating recovery following exposure to FeLV (Flynn et a i, 2002b), 
and in eliciting protection following inoculation with an experimental FeLV DNA 
vaccine. Furthermore, it has been suggested that the large quantities of glycosylated 
FeLV CA protein p27 released from infected cells may induce anergic CD4^ T cell 
responses in infected cats (Jarrett, 1999). The env gene product is a polypeptide that 
is post-translationally modified by cleavage and glycosylation in the ER, resulting in 
SU and TM domains that form a heterodimer (Vogt, 1997b). The SU protein is 
dotted along the surface of the lipid envelope and has a crucial role in determining 
host range and patterns of pathogenesis (Luciw and Leung, 1992). Envelope proteins 
are important targets for antiviral immune responses, particularly antibodies; major 
neutralisation epitopes have been identified on the FeLV SU protein gp70, and the
FeLV TM protein pl5E (Russell and Jarrett, 1978b; Elder et aL, 1987).
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Neither viraemia nor antigenaemia were detected in the peripheral blood from cat 
E12 at any sample date throughout the study (Table 3.1). Furthermore, the FeLV CA 
protein p27 was not detected in the bone marrow, or in the PLN tissues, post mortem. 
Nonetheless, the appearance of VNA in the peripheral blood at week 13 confirmed 
that this cat had been exposed to FeLV. It is understood that transient viraemia may 
last only a few days following oronasal exposure to FeLV (Jarrett et aL, 1982a). In 
the present study, peripheral blood samples were tested for the presence of infectious 
virus and the FeLV CA protein p27 one week following oronasal exposure to FeLV, 
and at three-week intervals thereafter; thus, it is possible that viraemia and/or 
antigenaemia may have occurred in cat E12 between sample dates, and passed 
undetected. In previous studies using an identical exposure route, transient viraemia 
was most commonly detected at, or prior to, week 4 post exposure to FeLV (Jarrett et 
aL, 1982a; Flynn et aL, 2002b). However, it is unlikely that either antigenaemia or 
viraemia occurred in cat E12 by week 4, as proviral DNA was not detected in the 
peripheral blood until week 7. In addition, the proviral DNA loads in the peripheral 
blood from this cat were very low, compared to most viraemic cats (Fig. 3.2). 
However, the presence of proviral DNA in the bone marrow post mortem indicates 
that a viraemia must have occurred in this cat. Since VI and p27 ELISA assays are 
conducted using plasma samples, a cell-associated viraemia would not have been 
detected using these methods.
The detection of infectious virus in the bone marrow post mortem, following VI on
cultured bone marrow cells in vitro, and the detection of proviral DNA in the
lymphoid tissues and peripheral blood post mortem, using qRT-PCR, indicated that
cat E12 was latently infected at the termination of the study. Other studies have
reported the reactivation of FeLV from myelomonocytic precursor cells in the bone
marrow, and from certain T cell populations in the lymph nodes of FeLV-exposed
aviraemic cats, but not from blood (Rojko et aL, 1982b). A high proportion of
recovered cats harbour a latent FeLV infection (Rojko et aL, 1982b; Madewell and
Jarrett, 1983; Pacitti and Jarrett, 1985). It is highly probable that in the absence of
stress factors, such as concurrent disease or pregnancy, which are known to
precipitate a recrudescence in viraemia in vivo, that cat E12 would have totally
eradicated FeLV over time. The majority of latently infected cats eliminate infection
within thirty months of exposure to FeLV (Pacitti and Jarrett, 1985); therefore,
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infected cells within the bone marrow or lymphoid tissues must differentiate to 
extinction, as suggested by Madewell et ah (1983). The persistence of proviral DNA 
in a latent infection may be advantageous, in that it may aid in the maintenance of 
immunological memory (Klenerman et al., 1997). However, latently infected cats 
have been shown to suffer from a degree of immune dysfunction (Lafrado and Olsen, 
1986), and are reported to have a higher incidence of FeLV-associated disease 
(Francis et al., 1979; Rojko et al., 1982b). Cytological and haematological analyses 
of bone marrow and peripheral blood respectively, from latently infected cat E l2 in 
this study, were normal thirteen weeks post exposure.
In this study, eleven cats became persistently infected following oronasal exposure to 
FeLV. From weeks 1-7 until the termination of the study, viraemia, antigenaemia 
and proviral DNA were detected in the peripheral blood from all eleven cats. 
Furthermore, an active bone marrow infection was detected in each of these cats post 
mortem, using VI on cell-free bone marrow suspensions, and immunofluorescence 
on bone marrow cytospin preparations. Persistently infected cats die from an FeLV- 
associated disease within two-to-three years following exposure. In this study, 
evidence that normal bone marrow function was compromised after just thirteen or 
nineteen weeks following exposure to FeLV, was presented and discussed in Chapter 
5. Abnormal cytology and/or haematology reports were presented for all such cats 
post mortem. Infiltrating CD3^ T cells were detected in the bone marrow from nine 
cats; five presented with granulocytic hypoplasia, four of which developed a 
concurrent neutropenia. Concomitant abnormalities in the peripheral blood were 
evident in seven persistently infected cats. Thus, cells that contribute to the immune 
defence were compromised in these cats as early as thirteen weeks post exposure, 
enhancing host susceptibility to opportunistic secondary infections.
Virus isolate, dose, host susceptibility, age at the time of exposure and route of 
exposure all interact to influence the outcome following exposure to FeLV (Hoover 
et al., 1976). Specific pathogen free cats E1-E6 were exposed to FeLV at an age, 
dose and route normally expected to result in approximately fifty per cent recovery, 
fifty per cent persistent viraemia (Hoover et a l, 1976; Jarrett et a l, 1982a; Flynn et 
al., 2002b). Nonetheless, all six exposed cats became persistently viraemic. Cats 
E7-E12 were exposed to a lower dose of FeLV-A under the same conditions as cats
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E1-E6, and one cat, E12, retained a latent proviral DNA infection in the bone 
marrow and lymphoid tissues. These data suggest a greater inherent susceptibility of 
all cats to the molecular clone of FeLV -A/Glasgow-1, which was somewhat 
improved by reducing the exposure dose by a factor of one log. Indeed, cats that 
were exposed to a lower exposure dose of infectious FeLV harboured lower levels of 
proviral DNA in the peripheral blood throughout much of the study, and in the 
lymphoid tissues post mortem. These cats also generated significantly greater p27- 
specific and p45-specific proliferative responses in the PLN and MLN tissues 
respectively, in addition to significantly greater mitogenic responses in the MLN 
tissues. Nonetheless, these studies have demonstrated the difficulty in predicting the 
responses of individual cats following oronasal exposure to FeLV.
Gag/Pro-specific CTL have been identified as important mediators of recovery and 
protection following exposure to FeLV. Under experimental conditions, cats that 
recovered following exposure to FeLV developed an early high peak in Gag/Pro­
specific CTL responses, which coincided with a peak in proviral DNA loads; 
similarly, cats that were protected following inoculation with an experimental FeLV 
DNA vaccine, generated high levels of Gag/Pro-specific CTL responses shortly after 
challenge. The magnitude and timing of Env-specific CTL responses were similar in 
recovered, protected and in viraemic cats. Thus, in FeLV infection, the Gag/Pro 
proteins are important in the induction of early virus-specific CTL responses 
associated with recovery and protection.
Similarly, the Gag protein appears to be immunodominant in the induction of CTL
responses in HIV-1 infection; only Gag-specific CD4^ T cell responses correlated
with Gag-specific CTL responses, i.e. for a given level of help, Gag-specific CTL
were more frequently detected than CTL specific for other HIV-1 proteins (Kalams
et al., 1999). In addition, a highly significant inverse correlation between Gag-
specific CD8^ T cells and plasma viral RNA loads was identified in HIV-1 infected
patients at different stages of disease (Ogg et al., 1998). Gag-specific CD4^ T cells
are also associated with low plasma viral RNA loads in HIV-1 infection; in a cohort
of HIV-1 infected individuals with a wide range of viral RNA loads, an inverse
correlation was identified between Gag-specific CD4^ T cell proliferative responses
and plasma viral RNA loads (Rosenberg et a l, 1997). Further studies demonstrated
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that the magnitude of the Gag-specific CD4^ T cell proliferative response directly 
correlated with levels of Gag-specific CTL precursors (Kalams et al., 1999); high 
frequencies of Gag-specific CD4^ T cells and Gag-specific CTL precursor cells were 
associated with the control of viraemia. However, when HIV-1 Gag-specific CD4^ T 
cells were enumerated using ICS to detect IFN-y expression, Gag-specific CD4^ T 
cell frequencies did not correlate with either viral RNA loads (Pitcher et al., 1999; 
Betts et al., 2001; Boaz et al., 2002), the magnitude of the CD8^ T cell response 
(Betts et al., 2001), or to a good clinical outcome (Boaz et al., 2002).
These findings illustrate discordance between the frequencies of virus-specific CD4^ 
T cells detected in the LPA, and such responses detected using ICS, where IFN-y 
expression is measured. Multiple reasons have been cited which attempt to account 
for these discrepancies, many of which have been outlined in Chapter 4. In addition, 
the LPA measures the capacity of CD4'*' T cells to proliferate, which greatly reflects 
IL-2 production. In the peripheral blood, IL-2 secreting CD4^ T cells comprise naïve 
cells, effector memory cells and virus-specific cells that have returned to a resting 
state (Boaz et al., 2002). It has previously been reported that only effector memory 
T cells in the peripheral blood produce IFN-y upon restimulation with cognate 
antigen; therefore, ICS assays based on IFN-y expression alone measure only the 
effector memory T cell population (Sallusto et al., 1999); naïve CD4^ T cells take 
around three-four days to produce cytokines such as IFN-y (Swain, 1999).
When Gag-specific CD4^ T cell responses were defined by the expression of IL-2 
and IFN-y together, rather than IFN-y alone. Gag-specific CD4^ T cells were 
associated with a good clinical outcome in HIV infection (Boaz et a l, 2002). 
Moreover, frequencies of the IFN-y^ IL-2^ CD4^ T cell population correlated 
inversely with virus RNA load, and directly with Gag-specific IFN-y^ CD8^ T cell 
frequencies (Boaz et al., 2002). These results are comparable with the proliferation 
data; therefore, the populations under examination in each of these assays may be 
equivalent. So, in HIV-1 infection, while the numbers of virus-specific IFN-y'*' CD4^ 
T cells remain constant as disease progresses, the IFN-y'*' IL-2'* CD4'*' T cell 
population becomes disrupted; therefore, the IFN-yIL-2^ CD4'* T cell population is 
more relevant to HIV-1 research. It may also be important to establish whether
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flFN-y secretion alone is sufficient to establish the presence of functional FeLV- 
specific CD4^ T cells.
In the present study, the frequencies of virus-specific responses detected in the LPA 
did not significantly correlate with the frequencies of such responses enumerated 
using ICS and flow cytometry. However, results obtained using the ICS, rather than 
the LPA, appeared to more accurately reflect the final outcome following exposure. 
Greater mean p27-specific (S.I. 1.56) and p45-specific (S.I. 1.46) proliferative 
responses were detected in the peripheral blood from persistently infected cats, than 
from latently infected cat E12 (S.I. 1.11 and 1.04, respectively), when compared with 
cats that received a comparable exposure dose of FeLV-A. Using ICS, high 
frequencies of early p27-specific CD4'* T cell responses were detected in the 
peripheral blood from latently infected cat E12, which persisted over weeks 4-10. 
Conversely, persistently infected cats developed transient low levels of p27-specific 
CD4 + T cell responses; higher levels were detected in some cats later in the study, 
but did not persist. Nonetheless, neither virus-specific proliferative responses nor 
virus-specific CD4** and CDS'*" T cell responses significantly correlated with proviral 
DNA loads using the Spearman r-Test, irrespective of the exposure dose.
The qRT-PCR technique used in this study detects and quantifies cellular DNA; 
however, the data generated also includes any unintegrated viral DNA (UVD) within 
the infected cell, in addition to archival DNA (Hofmann-Lehmann et al., 2001). 
High concentrations of UVD have been detected in the bone marrow, gut and 
lymphoid tissues from cats infected with FeLV-FAIDS (Hoover et al., 1987); the 
appearance of UVD coincides with the onset of a clinical immunodeficiency 
syndrome. Although large concentrations of UVD have not been definitively 
associated with other FeLV strains, UVD may account for the high proviral DNA 
levels detected in some persistently infected cats (Hofmann-Lehmann et al., 2001). 
The RT-PCR method used in this study cannot distinguish between integrated and 
unintegrated DNA (Hofmann-Lehmann et al., 2001); thus, the presence of UVD 
would artificially raise proviral DNA loads quantified using this method.
Once integrated, proviral DNA persists in the cellular DNA of infected cells; HIV-1
proviral DNA loads decline much more slowly in response to antiretroviral therapy,
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compared to plasma RNA loads (Désiré et al., 2001; Anton et al., 2003). The qRT- 
PCR technique used in this study detects intracellular viral DNA, which may 
represent either an active productive infection or a latent infection. In addition, qRT- 
PCR will also detect archival DNA, indicative of an earlier productive infection. 
Unfortunately, qRT-PCR cannot distinguish between these forms of viral DNA; thus, 
the data generated using this method will include viral DNA derived from each of 
these sources. Furthermore, proviral DNA detected using qRT-PCR may be 
replication incompetent. In HIV-1 infection, the presence of PBMC-associated viral 
DNA sequences significantly correlated with replicating virus, detected using a co­
culture assay; thus, at least some DNA detected included replication competent virus. 
However, the number of DNA-containing cells was two-to-three orders of magnitude 
greater than the number of infectious virus-containing cells; therefore, 99.9 per cent 
of detectable HIV DNA had no replication potential (Anton et al., 2003). Together, 
these data suggest that since the proviral DNA loads, measured using qRT-PCR, do 
not accurately reflect the current viral status, these data may not correlate with the 
virus-specific immune responses. Viral RNA loads, which rapidly respond to host- 
virus interactions, may correlate more significantly with virus-specific immune 
responses. Samples have been submitted to the University of Zurich for analysis; we 
are currently awaiting the results.
It is recognised that both Gag/Pro-specific CTL, and VNA, are important in 
mediating recovery and protection following oronasal exposure to FeLV; therefore, it 
was considered that virus-specific CD4^ T cells, which regulate both arms of the 
specific immune response, might also be an important element in the control of 
FeLV infection. In this study, latently infected cat E12, generated VNA in the 
peripheral blood by week 13 following exposure to FeLV; furthermore, low levels of 
p45-specific CD4^ T cells were detected in the peripheral blood from this cat at 
weeks 1 and 10. In addition, high levels of p27-specific CD4^ T cells were detected, 
which persisted from weeks 4-10. Conversely, VNA were not detected in the 
peripheral blood from any persistently infected cat at any time throughout the study. 
In addition, transient low levels of p45-specific, and p27-specific, CD4^ T cells were 
detected by week 4 in the peripheral blood from six, and three, persistently infected 
cats, respectively. Higher levels of virus-specific CD4^ T cells were briefly detected 
in the remaining persistently infected cats after week 7.
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All cats in this study developed virus-specific CD4^ T cell responses following 
oronasal exposure to FeLV. However, in persistently infected cats, these responses 
were either rapidly deleted, blunted, or absent, in the critical early stages following 
exposure. Feline leukaemia virus can reach the bone marrow within two days 
following oronasal exposure. Failure to control virus replication in this site leads to 
widespread dissemination of the virus, and persistent viraemia within three-to-eight 
weeks. Thus, there is a window of just three weeks in which virus-specific immune 
responses can develop, eliminate virus and mediate recovery (Jarrett, 2001).
A quantitative and/or qualitative failure of virus-specific CD4^ T cell responses in 
the early weeks following exposure to FeLV was associated with the development of 
persistent viraemia. However, the exact nature of this failure is unclear; in addition, 
the underlying contributing mechanisms are not understood. Nonetheless, we can 
speculate on the causes of the failure of the virus-specific CD4^ T cell response. 
First, the activation of virus-specific CD4^ T cells in the absence of adequate 
costimulation triggers anergic responses; sufficient numbers of competent DC are 
required to fully activate the virus-specific CD4^ T cell response. The role of DC in 
the immunopathogenesis of FeLV infection has not been delineated. Following 
oronasal exposure to FeLV, DC will be important in conveying virus to the draining 
lymph node (Macatonia et al., 1987), and in the activation of naïve virus-specific 
CD4^ T cells (Inaba et al., 1990; Steinman et al., 1991; Swain et al., 1999). It is not 
known whether DC numbers, or function, are compromised in FeLV infection. 
Widespread replication of FeLV in bone marrow myeloid precursor cells may curb 
DC numbers; furthermore, infection of DC in the peripheral tissues may impede 
function, or directly reduce cell numbers.
Second, the large quantity of soluble glycosylated FeLV CA protein p27, released 
from FeLV-infected cells, may also have a role in the induction of anergic CD4^ T 
cell responses (Neil et al., 1980b; Jarrett, 1999). In the present study, persistently 
infected cats either failed to develop early virus-specific CD4‘*‘ T cell responses; or 
developed truncated or delayed responses. In addition, VNA were not detected in 
any of these cats throughout the study. Although these data illustrate impaired virus- 
specific CD4^ T cell responses, it was not clear whether the glycosylated FeLV CA 
protein p27 contributed to these phenomena in vivo.
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Third, many early studies demonstrated that cell-mediated and humoral immune 
responses were impaired in FeLV-infected cats. Feline leukaemia virus has been 
shown to have an immunosuppressive effect on normal cells in vitro; this effect was 
reported to be associated with the FeLV TM protein pl5E. Furthermore, mitogenic 
responses of cells from FeLV-infected cats were shown to be impaired. The ability 
of mononuclear cells from the lymphoid tissues and the peripheral blood from FeLV 
exposed cats in the present study to proliferate in response to mitogenic stimulation 
varied markedly; however, mitogenic proliferative responses in the peripheral blood 
and lymphoid tissues did not correlate with proviral DNA loads. Thus, it was 
considered that differences among cats might be idiosyncratic, rather than associated 
with FeLV-induced immunosuppression. The inactivated FeLV particles used in the 
present study retained the immunosuppressive TM protein pl5E. Mononuclear cells 
from all cats in the present study proliferated poorly to inactivated FeLV particles in 
vitro. However, using ICS, specific responses were detected in response to 
stimulation with the inactivated FeLV particles. Therefore, in this present study, 
these particles did not have an immunosuppressive effect in vitro.
Impairment of the quantitative and/or qualitative virus-specific CD4'* T cell 
responses will compromise the elicitation, priming and maintenance of the virus- 
specific CD8^ T cell and virus-specific B cell responses. Failure of the virus-specific 
immune response will permit unlimited virus replication in the critical early weeks 
following exposure, precipitating a state of persistent viraemia. Neither the 
quantitative nor the qualitative virus-specific CD4^ T cell responses, required to 
mediate recovery and protection following oronasal exposure to FeLV, have 
previously been defined. However, we know that virus-specific CD8^ T cells and B 
cell effector responses directed towards either the FeLV Gag/Pro or Env proteins are 
associated with recovery and protection. Now, these studies illustrate that failure to 
generate and maintain adequate numbers of virus-specific IFN-y"* CD4^ T cells in the 
early weeks following exposure is associated with the development of persistent 
viraemia.
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